Search this site

20 Future Belgian HealthTech and MedTech Leaders The Ascendance of the Belgian HealthTech and MedTech Ecosystem: Analysis of 20 Future Leaders The Belgian healthcare innovation landscape has undergone a tectonic shift over the last decade, evolving from a traditional pharmaceutical stronghold into a globally recognised "Health and Biotech Valley". This maturation is not merely a product of historical legacy but the result of a deliberate, multi-layered strategy involving institutional catalysts, regional specialisation and a robust venture capital framework that prioritises deeptech inter-d isciplinarity The convergence of biotechnology, medical devices (MedTech) and digital health solutions has created an environment where the boundaries between hardware, software and biology are increasingly porous. Institutional Foundations and the Spin-Off Paradigm The engine of Belgian innovation is rooted in its research institutions, most notably the Flanders Institute for Biotechnology (VIB) and imec. The VIB has established a formidable track record, launching 39 spin-offs and securing over €1.8 Billion in venture capital. This institutional success is measured not only in capital but in scientific impact; for every Euro of core funding from the Flemish government, the VIB generates approximately €12 for the regional economy. The institute’s holistic approach extends beyond basic research to include infrastructure development, such as the bio-incubators in Ghent, Leuven and Brussels, which provide the essential wet-lab space and mentorship required for early-stage scaling. Simultaneously, imec has leveraged its status as a world leader in nanoelectronics to address the "memory wall" and data processing bottlenecks inherent in modern medical AI. Through its venturing arm, imec.xpand and its accelerator program, imec.istart, the centre has become a primary architect of the Belgian MedTech sector, fostering startups that utilise semiconductor precision for biological monitoring and therapeutic intervention. The integration of these two giants, VIB’s biological mastery and imec’s electronic precision, defines the unique value proposition of the Belgian ecosystem. Institutional Impact Metrics (2023-2024) VIB (Biotech) imec (MedTech/Digital) Spin-offs Launched (Total) 39 Over 30 (Active in Health) Venture Capital Secured €1.8 Billion €941 Million (Annual Revenue) Gross Value Added (Annual) €1 Billion N/A (Global Entity) Employment Supported 11,000 Jobs >5,000 Employees Regional Specialisation and the Merger of Clusters Belgium’s geographic compacting facilitates a level of collaboration that is rare in larger jurisdictions. Wallonia has carved out a dominant position in Advanced Therapy Medicinal Products (ATMPs) and nuclear medicine. The BioWin cluster in Wallonia represents over 90% of the region’s health-biotechnology players, focusing on a "Health and Biotech Valley" vision that integrates vaccines, biomedicines, and cellular therapies. This specialisation is supported by the BioPark in Charleroi and the LégiaPark in Liège, which offer specialized infrastructure for radiopharmaceutical production and GMP cell-therapy operations. In Flanders, the recent merger of the industry organization flanders.bio and the spearhead cluster MEDVIA signals a strategic move toward a unified representation of the sector. By bringing together "red, green, and white" biotech with healthtech developers, hospitals, and academic institutes, the new organisation aims to address global challenges with a single, more efficient voice. This merger is expected to streamline the "Say Yes to the US" program, which facilitates the entry of Flemish companies into the North American market, recognising that international expansion is critical for the survival of high-growth MedTech firms. Analysis of the 20 Future Belgian Leaders in HealthTech and MedTech The following entities represent the vanguard of Belgian medical innovation, characterised by deep technical moats, significant capital backing, and leadership teams with proven expertise in navigating the complex regulatory landscapes of the EMA and FDA. 1. AgomAb Therapeutics: Mastering the Fibrotic Microenvironment AgomAb Therapeutics, situated in Ghent, has emerged as a powerhouse in the treatment of fibrotic and degenerative diseases. Founded in 2017 by Paolo Michieli, the company focuses on growth factor mimetics that modulate regenerative pathways. The master-stroke of AgomAb’s strategy was its recent $100 Million Series C funding round, which provides the runway necessary to move its lead candidates through late-stage clinical trials. By targeting the hepatocyte growth factor (HGF) and its receptor MET, AgomAb aims to achieve what was previously considered impossible: the reversal of established fibrosis in organs such as the liver and lungs. 2. AstriVax: A Paradigm Shift in Vaccine Deployment AstriVax is a prime example of the high-impact spin-offs emerging from the KU Leuven Rega Institute. Under the leadership of CEO and co-founder Hanne Callewaert, the company is commercializing a versatile vaccine platform based on the yellow fever 17D (YF17D) vaccine. This technology allows for the rapid engineering of vaccines against emerging infectious diseases and therapeutic targets in oncology. Having secured €30 Million in seed funding, a record for the region, AstriVax is advancing toward clinical Proof of Concept in 2024, with a scientific advisory board that includes global luminaries like Peter Piot. 3. Vertical Compute: The Infrastructure for On-Device Medical AI Founded in 2024 as an imec spin-off, Vertical Compute addresses the fundamental physical limitation of modern computing: the memory bottleneck. Led by CEO Sylvain Dubois and CTO Sebastien Couet, the company has raised a total of €57 Million in seed funding to develop a 3D memory architecture. By stacking memory directly on top of logic, the platform achieves 100x improvement in the execution of Large Language Models (LLMs) and reduces energy consumption by 80%. While a deep-tech company, the implications for MedTech are profound, enabling real-time, high-security processing of genomic data and physiological signals directly on portable medical devices without relying on vulnerable cloud infrastructure. Vertical Compute Funding Trajectory Seed Phase 1 (Jan 2025) Seed Extension (Mar 2026) Amount Raised €20 Million €37 Million Total Funding €20 Million €57 Million Lead Investor imec.xpand Quantonation Strategic Support Eurazeo, XAnge PMV, Wallonie Entreprendre 4. Axithra: Photonics-on-Chip for Point-of-Care Monitoring Axithra, a joint spin-off of imec and Ghent University, is revolutionising therapeutic drug monitoring (TDM). Led by CEO Leander Van Neste, the company utilises Raman-on-chip spectroscopy to measure drug concentrations in blood in real-time. Their primary application focuses on lactam antibiotics in intensive care units (ICUs). In critical care settings, the variation in patient metabolism is extreme; Axithra’s technology allows clinicians to adjust dosages every few minutes rather than waiting hours for a central lab report, directly impacting survival rates and preventing antibiotic resistance. 5. Novadip Biosciences: Regenerative Orthopedics from Stem Cells Novadip Biosciences, based in the BioPark Charleroi, represents the pinnacle of Walloon excellence in ATMPs. Founded by Denis Dufrane, the company utilises an adipose-derived stem cell platform to create 3D tissue implants for bone reconstruction. Their flagship product aims to heal complex bone defects that are currently untreatable. Having secured €22 Million in Series B funding, Novadip is entering late-stage clinical trials, positioning itself to capture a significant share of a potential €13.5 Billion market. 6. Minze Health: The Digitalisation of Urology and Pelvic Health Minze Health has established itself as a leader in home-based urological diagnostics and digital therapeutics. Under the leadership of newly appointed CEO Thomas Moore—a veteran of the US MedTech market, Minze is scaling its platform for Benign Prostatic Hyperplasia (BPH) and Overactive Bladder (OAB). Their products, which include automated bladder diaries and home-based uroflowmetry, enable continuous monitoring outside the clinic, improving both diagnostic accuracy and patient compliance. The company is currently preparing for a Series B fundraising round to support its US commercial expansion. 7. Mona Health: Retinal Analysis as a Diagnostic Window````` Mona Health, founded by Olivier Ménage, utilises artificial intelligence to analyse retinal images for the early detection of glaucoma and other systemic conditions. Based in Mol, the company operates on the principle that the retina is a non-invasive window into the body’s vascular and neurological health. By providing automated screening tools to optometrists and primary care physicians, Mona Health addresses the global shortage of ophthalmologists and facilitates early intervention for vision-threatening diseases. 8. Skinetix: Biomechanical Intelligence via Smart Sportswear Skinetix is an imec and VUB spin-off that has successfully integrated electromyogram (EMG) sensors directly into textile fibers. Led by Joris De Winter and Kevin Langlois, the company provides real-time, field-based measurement of muscle activity. While the initial market focus is on professional sports organizations like international soccer clubs, the long-term MedTech value lies in post-injury recovery and neuro-rehabilitation. By linking sensor data with personalised AI biomechanical models, Skinetix provides clinicians with quantitative data on muscle fatigue and movement quality that was previously only available in specialised gait labs. 9. Specifix: Automating the Preoperative Surgical Workflow Specifix, an Antwerp-based healthtech startup, focuses on the high-precision requirements of orthopaedic surgery. Founded by Dr. Alejandra Ortega, Dr. Soha Mahdi, and Prof. Dr. Matthias Vanhees, the company provides automated 3D planning software for wrist fracture fixation. The platform allows surgeons to upload CT scans and receive a fully automated preoperative plan, identifying the optimal personalised implants to stabilise the fracture. This reduction in operative time and increase in placement precision leads to faster patient recovery and fewer surgical complications. 10. FiriX Therapeutics: Inhibiting Ferroptosis in Organ Survival FiriX Therapeutics is a 2025 spin-off from the University of Antwerp focusing on ischemia-reperfusion injury (IRI). Their lead candidate, FXT-001, is a first-in-class ferroptosis inhibitor designed to treat tissue damage that occurs when blood supply returns to oxygen-deprived organs. This mechanism is critical in organ transplantation and the treatment of myocardial infarctions. FiriX has already demonstrated that FXT-001 is "organ-saving" in pig and human ex vivo transplant settings, representing a major advancement in transplant medicine. 20 Future Belgian HealthTech and MedTech Leaders 11. Sightera Biosciences: Generative Drug Design via Tumoroid Screening Sightera Biosciences utilises AI to revolutionise oncological drug discovery. Led by Hendrik Vercammen and Maxim Le Compte, the company integrates robotic high-throughput screening with generative AI to identify drug-response patterns in patient-derived "tumoroids". This approach ensures that drug development is patient-relevant from the earliest stages, significantly increasing the probability of clinical success and reducing the multi-billion-dollar cost of drug failure. 12. Stimalia: Bioelectronic Implants for PTSD Stimalia addresses the global crisis in mental health through neuromodulation. The company is developing a miniaturised, injectable bioelectronic implant that provides drug-free therapy for Post-Traumatic Stress Disorder (PTSD) via continuous nerve stimulation. Led by a team of veterans from the neuro-modulation industry, including Olivier Ménage and Pascal Doguet, Stimalia’s device represents the transition of psychiatry from purely chemical interventions to precise electronic modulation of the nervous system. 13. Precirix: Nanobody-Based Radiopharmaceuticals Precirix is a prominent player in the targeted radiation therapy sector, developing radiopharmaceuticals based on single-domain antibodies (nanobodies). These molecules are designed to deliver radioisotopes directly to tumor cells with high specificity, sparing healthy tissue. Operating within the robust nuclear medicine ecosystem of Wallonia, Precirix leverages the region’s specialised logistics and isotope production to advance its clinical pipeline for several solid tumour indications. 14. Univercells: The Democratisation of Bioprocessing Univercells is redefining the cost structure of vaccine and biologic production. Founded by Hugues Bultot and Jose Castillo, the company develops modular manufacturing platforms that allow for high-throughput production in a small footprint. This technology is critical for the "Health and Biotech Valley" initiative, as it enables the regional production of gene and cell therapies at a fraction of the cost of traditional cleanroom facilities. 15. Bioxodes: Redefining Haemorrhagic Stroke Treatment Bioxodes is a Walloon drug development firm focusing on Ir-CPI, a first-in-class drug designed to prevent thrombosis and neuro-inflammation in patients suffering from haemorrhagic stroke. Unlike existing treatments that increase the risk of re-bleeding, Bioxodes’ molecule offers a safer profile. The company is currently moving toward a pivotal Phase 2b trial, with a strategic goal of gaining market approval by 2030, addressing a massive unmet need in neurological emergency care. 16. ABSCINT: Next-Generation Molecular Imaging ABSCINT is a molecular imaging company with two lead programs in cardiovascular disease and oncology. Their technology utilises nano-bodies for the imaging of vulnerable atherosclerotic plaques and tumour-specific antigens. By providing clinicians with a more precise view of biological activity at the molecular level, ABSCINT enables personalised treatment adjustments that are not possible with traditional anatomical imaging like CT or MRI. The company aims to launch its first diagnostics in the EU and North America by 2028. 17. iTeos Therapeutics: Precision Cancer Immunotherapy iTeos Therapeutics, a BioWin member, has transitioned from a promising startup to a clinical leader in cancer immunotherapy. The company recently released encouraging clinical data regarding its lung cancer treatment, which focuses on modulating the immune microenvironment of tumors. Their success reinforces Belgium’s reputation as a centre for high-value oncology research and provides a model for other startups aiming for IPO or major acquisition. 18. Thameus (Baby Detect): Genomic Preventive Medicine Thameus is the spin-off responsible for the "Baby Detect" project, which has pioneered genomic newborn screening in Liège. While traditional screening focuses on a handful of diseases, Baby Detect uses targeted next-generation sequencing (NGS) to screen for over 160 treatable conditions from a single heel-prick sample. This project exemplifies the shift toward "predictive medicine," where intervention begins before symptoms appear, fundamentally altering the life-trajectory of children with rare genetic disorders. 19. Sequana Medical: Active Fluid Management in Chronic Disease Sequana Medical, based in Ghent, has developed the alfapump®, a fully implantable, wirelessly charged pump system.The device is designed to manage fluid balance in patients with liver cirrhosis and congestive heart failure by automatically moving excess fluid from the abdomen to the bladder for natural elimination. With over $52 Million in funding, Sequana is a leader in the medical engineering space, providing a significant quality-of-life improvement for patients who would otherwise require frequent, painful drainage procedures. 20. Brailsports: The AI Engine for Physiological Optimisation Brailsports is a joint spin-off from imec, the University of Antwerp, and Ghent University. Led by CEO Erika Lutin, the company has developed an AI platform that accurately estimates an individual’s fitness and fatigue by analyzing cardiac and power data. While initially focused on professional cycling teams, the platform’s core technology has broad medical applications in the prevention of overtraining syndrome and the monitoring of cardiac rehabilitation patients. Brailsports represents the vanguard of "digital coaching," where medical-grade insights are used to optimise human performance and prevent injury. Cross-Sectoral Analysis and Market Dynamics The Belgian HealthTech sector is characterised by an exceptionally high density of R&D and clinical development actors. This density creates a "cluster effect" where information and talent circulate rapidly. For example, the merger of MEDVIA and FlandersBio was driven by the recognition that biotech and medtech are no longer distinct silos. Modern therapies, such as the ATMPs developed by Novadip, require specialised medical devices for delivery, while digital platforms like Awell Health are needed to manage the complex care pathways associated with these advanced treatments. Core Pillars of Belgian HealthTech Specialisation Representative Leaders Strategic Hubs Advanced Therapies (ATMP) Novadip, AgomAb, Univercells BioPark Charleroi Nuclear Medicine Precirix, ABSCINT, Trasis Liège/LégiaPark AI & Digital Diagnostics Mona Health, Minze, Baby Detect imec (Leuven), Antwerp Precision MedTech Axithra, Specifix, Sequana Ghent/Leuven The Role of Venture Capital and Public Support Public-private partnerships are the lifeblood of the Belgian ecosystem. The Flemish investment company PMV and the Walloon equivalent Wallonie Entreprendre (WE) act as anchor investors, providing the stability necessary to attract international venture capital firms like V-Bio Ventures, Kurma Partners, and Earlybird Health. In 2024, BioWin members secured €12.5 Million in combined funding, while larger scale-ups like AgomAb have demonstrated the ability to attract $100 Million rounds from global investors. This capital is supported by government subsidies from VLAIO (Flanders) and the SPW (Wallonia), which often provide non-dilutive funding for early-stage R&D. Future Outlook: Challenges in Scaling and Internationalisation As Belgium moves toward 2030, the primary challenge remains the transition from "frontier research" to "meaningful industrial transformation". While the country excels at launching startups, scaling them into global market leaders requires access to even larger capital pools and a deep understanding of the US healthcare market. The "Health and Biotech Valley" initiative is designed to address this by fostering international alliances and providing specialised training for founders. Furthermore, the integration of innovation into the Belgian hospital system remains a hurdle. The "Health on Stage" symposium in 2026 addressed this by inviting hospitals to present their "real-world challenges" to the startup community, flipping the traditional sales-pitch model. Projects like SIM BLOOD, a serious game for transfusion training developed by Cliniques de l'Europe and PLAY IT, won Innovation Awards for demonstrating tangible hospital impact, suggesting that the future of Belgian HealthTech lies in co-creation between engineers and clinicians. Conclusion: The Convergence of Biology and Bits The Belgian HealthTech and MedTech ecosystem has entered a period of unprecedented convergence. The 20 leaders identified in this report are not merely developing better medical products; they are redefining the mechanisms of diagnosis, therapy and patient management through the integration of artificial intelligence, photonics, and regenerative biology. Supported by world-class institutions like VIB, imec and a regional strategy that emphasises specialised clusters and international proximity, Belgium is well-positioned to remain a global leader in health innovation for the foreseeable future. The continued success of these firms will depend on their ability to maintain technical excellence while navigating the commercial complexities of a globalized healthcare economy. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Norwegian HealthTech and MedTech Leaders The Strategic Evolution of Norwegian HealthTech and MedTech: Analysis of 20 Emerging Leaders and the National Innovation Ecosystem The Norwegian life sciences landscape is currently undergoing a systemic transition, evolving from a research-intensive academic environment into a globally integrated commercial powerhouse. This metamorphosis is facilitated by a unique confluence of high-trust public health data, a robust sovereign wealth environment and a maturing infrastructure of specialised clusters such as Norway Health Tech, the Oslo Cancer Cluster and Aleap. As the global healthcare market increasingly demands precision medicine, decentralised care models and AI-augmented diagnostics, Norway has positioned itself as a "forerunner" region. This status is characterised by a "human scale" that allows for rapid testing and validation of sophisticated technologies within a public healthcare system, often referred to under the regional identity of "HealthFjords". The following report provides an analysis of twenty future leaders within this sector, the technological breakthroughs they oversee and the second-order socio-economic impacts of their work on the global stage. The Vanguard of Radiopharmaceuticals and Targeted Oncology The most capital-intensive and scientifically rigorous segment of the Norwegian ecosystem is currently focused on targeted alpha therapies (TAT) and precision diagnostics. This sector leverages Norway’s historical expertise in nuclear science and oncology to address malignancies traditionally resistant to conventional treatments. 1. Jasper Kurth and Thor Medical: Scaling Alpha Emitter Production Thor Medical ASA, directed by CEO Jasper Kurth, represents a critical shift in the global supply chain for modern oncology. Kurth, who possesses over fifteen years of leadership experience in the pharmaceutical and med-tech industries, including a significant tenure as General Manager of Radiology Nordics at Bayer, is spearheading the development of the AlphaOne commercial-scale plant at Herøya Industrial Park. The company focuses on the production of alpha-emitters derived from naturally occurring thorium, providing a reliable and environmentally friendly alternative to traditional nuclear reactor-based production. The strategic significance of Thor Medical lies in its proprietary production process, AlphaCycle™, which requires no irradiation, thereby reducing regulatory hurdles and environmental impact. In early 2025, the company secured a NOK 90 Million loan facility from Innovation Norway, complementing a private placement and retail offering that raised approximately NOK 200 Million. This funding ensures that the AlphaOne facility is fully capitalised through its 2026 production ramp-up. Strategic Milestone Metric / Detail Timeline / Status Source Capital Raising Private Placement and Retail Offering (NOK 173M initially) December 2024 Various Debt Financing Innovation Norway Loan Facility (NOK 90M) January 2025 Various Operational Launch Final Investment Decision (FID) for AlphaOne March 2025 Various Projected Output 25,000 patient doses annually Within 5 years Various Market Valuation Market capitalisation of approximately NOK 737.7M December 31, 2024 Various Kurth’s leadership is defined by a transition from pilot-stage validation to industrial-scale execution. The ability to produce medical isotopes at Herøya, where the pilot facility was ceremonially opened by the Norwegian Minister of Trade, positions Norway as a primary exporter in the radiopharmaceutical sector. The high-quality production has already been verified by international customers, leading to multi-year sales agreements that secure nearly full capacity utilization for the AlphaOne plant before construction begins. 2. Esmaeil Dorraji and ImmunoQuest Therapeutics: Precision ADC Development In the biopharmaceutical domain, Esmaeil Dorraji, founder and Chief Scientific Officer of ImmunoQuest Therapeutics, is advancing a novel class of Antibody-Drug Conjugates (ADCs). The company’s lead candidate, NAZ-001, is designed to target the p95HER2 protein—a truncated form of the HER2 receptor found exclusively in tumor cells. This selectivity is vital, as p95HER2 is associated with high rates of metastasis and resistance to existing HER2-targeted therapies such as trastuzumab. Dorraji’s approach exemplifies the "precision" in precision medicine. By focusing on a biomarker absent in healthy tissue, ImmunoQuest reduces the systemic toxicity that often limits the efficacy of oncological drugs. The potential application of NAZ-001 extends beyond breast cancer to ovarian, lung, and colorectal cancers, indicating a broad total addressable market (TAM). The company recently joined the Oslo Cancer Cluster to leverage the ecosystem's connections with academic researchers and international investors. 3. Chee Yong and Elpis Biopharmaceuticals: Engineering Long-Lasting Cell Therapies Elpis Biopharmaceuticals, co-founded by Co-CEO Chee Yong, is a clinical-stage cell therapy company that recently joined the Oslo Cancer Cluster to establish its European presence. While based in Boston and Singapore, the company’s expansion into Norway reflects the country’s growing leadership in advanced therapeutics and clinical trial infrastructure. Under Yong’s leadership, Elpis is developing technologies that treat solid tumors by targeting multiple tumour pathways simultaneously. A core innovation in the Elpis pipeline is the ability to engineer immune cells that last longer in the patient's body without the harmful side effects typically associated with intensive cell therapies. The company's therapies are currently in clinical trials in China, with interim results anticipated by the end of 2025. 4. Anders M. Dale and Precision Health: Multimodal Clinical Decision Support The integration of artificial intelligence into clinical workflows is spearheaded by Anders M. Dale, founder and CEO of Precision Health. Dale, an internationally recognized researcher with deep ties to both Norwegian and American academic institutions, focuses on developing multimodal tools for neurology, psychiatry, and oncology. Precision Health addresses diagnostic challenges such as Alzheimer’s disease, severe mental disorders, and prostate cancer. Dale’s leadership emphasizes the necessity of being part of a collaborative ecosystem. By joining the Oslo Cancer Cluster, Precision Health has gained access to a network of university hospitals and global pharma partners, which Dale credits with helping the company avoid common developmental mistakes and fine-tuning its strategy. The company serves as a bridge between the clinical excellence of Norway and the commercial dynamism of the United States. Innovations in Respiratory and Critical Care Monitoring The Norwegian MedTech sector is dominated by hardware-software hybrids that automate vital sign monitoring, thereby reducing clinician fatigue and enhancing patient safety in acute settings. 5. Øystein Theodor Ødegaard-Olsen and Eupnea: Intelligent Respiratory Surveillance Eupnea AS, co-founded by CEO Øystein Theodor Ødegaard-Olsen and Andreas Tunset, has emerged as a leader in wireless respiratory monitoring. The company’s core technology is a small, wireless sensor that transmits respiratory data via 5G networks to a Norwegian cloud-based data centre. The clinical insight driving Eupnea is that respiratory rate is often the most reliable early indicator of physiological deterioration, yet it is the vital sign most frequently recorded manually or omitted during busy shifts. Ødegaard-Olsen, who has a background in interdisciplinary group rehabilitation and clinical research at the University of Bergen, has overseen the validation of the sensor in prospective clinical studies. In 2025, Eupnea was recognised as a finalist for the Health Startup of the Year award, highlighting its potential to improve outcomes at institutions like Haraldsplass Deaconess Hospital. Operational Feature Specification / Impact Source Transmission Protocol 5G Network to Norwegian Cloud (no Bluetooth required) Various Clinical Validation RespX accelerometer-based wireless sensor study Various Target Utility Early detection of cardiac arrest and emergency admission Various Staff Impact Reduces manual counting workload for nurses Various 6. Trude Tingvoll and Respinor: Diaphragm Ultrasound for Ventilation Weaning Respinor AS, led by CEO Trude Tingvoll, has reached significant international milestones with its RESPINOR DXT® technology. The device provides continuous, operator-independent ultrasound monitoring of the diaphragm to predict successful weaning from mechanical ventilation. This is critical for the 3.2 Million patients using respirators annually, as prolonged ventilation increases both costs and patient risk. Tingvoll’s leadership has been instrumental in securing the FDA’s "Breakthrough Device" designation in late 2024 and the CE Mark under the EU MDR in August 2025. Furthermore, she participated in the NOME (Nordic Mentor Network for Entrepreneurship) U.S. delegation, which provided concrete investor leads and regulatory insights crucial for the company's expansion into the American market. 7. Fridtjof Heyerdahl and EpiGuard: High-End Isolation Systems EpiGuard, founded in 2015 by Fridtjof Heyerdahl, MD, PhD, specialises in high-end medical isolation and transport systems. The company’s flagship product, the EpiShuttle, was developed to allow for the safe transport of patients with highly infectious diseases while protecting healthcare personnel. Heyerdahl’s expertise in product development and manufacturing has positioned EpiGuard as a key player in global health security. The company is a portfolio business of Inven2, the technology transfer office for the University of Oslo and Oslo University Hospital. EpiGuard’s success demonstrates how Norwegian clinical innovation can be rapidly scaled to meet international demand during pandemics and other public health crises. 8. Nicolas Elvemo and GlucoSet: Continuous Glucose Control in the ICU Nicolas Elvemo, co-founder of GlucoSet, focuses on metabolic monitoring in the Intensive Care Unit (ICU). GlucoSet develops tools for accurate continuous glucose control to reduce patient mortality and hospital costs associated with improper glucose management in critical care settings. The company, which emerged as a spin-off from NTNU, utilizes advanced sensor technology to provide real-time data to clinicians. Elvemo’s leadership has been characterised by a commitment to rigorous technical validation, ensuring that the sensor can operate reliably in the high-stakes environment of an ICU. Leadership in Women's Health and Reproductive Technology FemTech is a burgeoning sub-sector in Norway, where entrepreneurs are addressing long-overlooked conditions such as maternal safety, endometriosis and fertility. 9. Hege Hansen and Induvita: Elevating Gynecological and Maternal Standards Induvita AS, led by CEO Hege Hansen, was named the "Health Startup of the Year" (Årets helsegründer) for 2025. The company develops medical devices and training simulators designed to make vaginal examinations and gynaecological procedures more comfortable and safer for women. Hansen’s strategy involves a comprehensive portfolio, including the Runa and Ayla training simulators, the Vega speculum (launching in 2026), and the Iola induction catheter. The Iola device is a balloon catheter designed to make labor induction more predictable and safer for both the clinician and the mother. Hansen’s leadership is notable for its advocacy; she views the award not just as a business success, but as a signal that women's health is finally receiving the clinical and commercial attention it deserves. 10. Dilip K. Prasad and Spermotile: AI-Enhanced Male Fertility Solutions Professor Dilip K. Prasad from UiT The Arctic University of Norway is the founder of Spermotile, a deep-tech MedTech company revolutionizing assisted reproduction technology (ART). Spermotile utilises AI-powered sperm selection technology to improve the success rates of In-Vitro Fertilisation (IVF). Prasad has successfully raised $4 Million from high-profile sources, including the European Research Council (ERC) and the Research Council of Norway. The company is currently navigating the stringent regulatory pathways for CE marking and FDA clearance, a process required for deep-tech medical devices before commercial scaling. Prasad’s leadership is characterised by an interdisciplinary approach, combining advanced microscopy, fluid mechanics and bio-AI. 11. Kristian Larsen and Diagnostrix: Non-Invasive Diagnostics for Endometriosis Diagnostrix is a joint venture between the Biolink Group (Norway) and Oratel Diagnostics (USA), directed by CEO Kristian Larsen. Larsen, a serial entrepreneur with over twenty years of experience in business development, has positioned Diagnostrix to solve the long-standing challenge of diagnosing endometriosis, which currently often requires invasive surgery. The Diagnostrix solution uses color-detection technology for saliva testing, providing a low-cost and non-invasive alternative to traditional diagnostics. The team, which includes R&D Director Mariana T. Eiane, MD, and synthetic chemist Einar Bakstad, PhD, aims to make women's health diagnostics radically more accessible on a global scale. 20 Future Norwegian HealthTech and MedTech Leaders Digital Health, AI and Remote Patient Management Norway’s mature digital infrastructure provides a testing ground for AI-native startups that aim to automate clinical documentation and decentralise care follow-up. 12. Jorunn Thaulow and Medbric: Transforming Clinical Documentation with AI Dr. Jorunn Thaulow, a physician and researcher, founded Medbric in late 2024 to address the dual challenges of antibiotic overuse and the administrative burden of clinical notes. Medbric’s ambient scribe solution, Aila, uses speech-to-note technology to generate personalised clinical documentation, allowing doctors to focus on patient interaction rather than their computer screens. Within fifteen months of its launch, Medbric captured a market share of approximately 25-30% of all general practitioners in Norway and expanded into ten hospitals across the Helse Vest and Helse Midt-Norge regions. Thaulow’s leadership is defined by her "research-first" mentality, collaborating closely with the NorWAI research centre to ensure the AI agents are tailored to the Norwegian language and clinical requirements. 13. Anders Eikenes and Oivi: AI-Powered Diabetic Retinopathy Screening Anders Eikenes, co-founder of Oivi and a former co-founder of Huddly, has pioneered an accessible AI-camera system for the early detection of diabetic eye disease. Eikenes’ vision is to provide an affordable, automated screening solution that can be deployed in primary care settings or community clinics, rather than requiring patients to visit specialised eye centres. Eikenes brings a strong commercial and product-design background to the company. His leadership has focused on creating a "human-centred" device that is intuitive for non-specialist healthcare workers to operate, thereby democratising access to complex diagnostic imaging. 14. Espen Riskedal and AgeLabs: Predictive Models for Early Disease Detection AgeLabs, founded by Espen Riskedal and Karl Trygve Kalleberg in 2017, utilizes machine learning to identify biological markers for early disease detection. Riskedal has led the company through various R&D projects with public institutions, focusing initially on age-related diseases and later expanding into the predictive modeling of COVID-19 severity. Under Riskedal’s guidance, AgeLabs has secured nearly $1 Million in funding and earned nominations for Best Health Tech Startup at the Nordic Startup Awards. The company’s work represents the transition from reactive medicine to proactive, data-driven health interventions. 15. Marius Mathisen and Pletly: Harmonising Care for Vulnerable Populations Marius Mathisen is the CEO of Pletly, a Norwegian-American healthtech firm that provides a connected care platform for individuals with cognitive challenges, such as dementia or autism. The platform bridges the communication gap between family members and professional caregivers, ensuring a single, accurate source of information for the "circle of care". Mathisen’s leadership highlights the importance of empathy in HealthTech design. Founded by individuals with personal caregiving experience, Pletly has signed strategic agreements with special education academies and senior care providers like NewCourtland in Philadelphia, demonstrating the international scalability of the Norwegian "connected care" model. Company Focus Area Key Leadership Core Technology Source Medbric Clinical AI Jorunn Thaulow Ambient Scribe (Aila) Various Oivi Ophthalmology Anders Eikenes AI-integrated Camera Various AgeLabs Predictive Health Espen Riskedal ML for Biomarkers Various Pletly Connected Care Marius Mathisen Coordination Platform Various Neurotechnology and Robotic Rehabilitation Advances in cybernetics and biofeedback are enabling new methods for treating neurological disorders and physical impairments that were previously considered untreatable. 16. Cathrine Ro Heuch and Nordic Brain Tech: Digital Biofeedback for Neurological Care Cathrine Ro Heuch, CEO and co-founder of Nordic Brain Tech, leads a spin-off from NTNU and St. Olav's Hospital that aims to transform migraine care globally. The company’s flagship product, Cenli, is a digital biofeedback solution for home use that helps patients predict and prevent migraine attacks without the side effects of medication. Heuch’s leadership is notable for its personal motivation, she has lived with migraines since her youth and her strategic utilisation of the Norwegian ecosystem. She has been named a "Rising Star" and appeared on the "40 under 40" list for leadership talent. Under her direction, Nordic Brain Tech successfully completed the NOME program and expanded its reach into the U.S. market through collaborations with the Mayo Clinic. 17. Saeid Hosseini and Vilje Bionics: Empowering Patients with Arm Exoskeletons Saeid Hosseini, CEO and co-founder of Vilje Bionics, is overseeing the development of VilPower, a full-arm exoskeleton designed to restore movement for people with arm and hand paralysis. The system combines shoulder, elbow, wrist, and hand support in an innovative AI-driven device. Hosseini, who moved to Norway in 2011 and co-founded the company at the age of 24, is motivated by the desire to use technology to bridge physical limitations. The company has raised $4 Million in funding and partnered with leading European medical institutions to validate the device's ability to mimic natural motion. Hosseini’s leadership represents the potential of impact-driven entrepreneurship to solve massive global health challenges affecting over 60 Million people. Strategic Leadership in Biotech and Diagnostic Infrastructure 18. Jonas Hallén and Calluna Pharma: Tackling Fibrotic and Inflammatory Disease Calluna Pharma, founded in 2024 through the merger of Oxitope and Arxx Therapeutics, is directed by Co-founder and Chief Medical Officer Jonas Hallén. The company focuses on developing therapeutics for inflammatory and fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF), where there is a significant unmet need for better-tolerated treatments. Hallén, who brings drug development experience from Boehringer Ingelheim and Novartis, has overseen the advancement of CAL101, an S100A4 targeting monoclonal antibody currently in Phase II clinical trials. Calluna successfully raised €75 Million (approximately $81.7 Million) in a Series A round, one of the largest such rounds in the Norwegian biotech sector, to advance its pipeline. Hallén’s leadership emphasises the need for Norwegian startups to build international networks to access specialised manufacturing and clinical expertise. 19. Morten Isaksen and Bio-Me: Scaling Microbiome Diagnostics Dr. Morten Isaksen, founder and CEO of Bio-Me, is developing a Precision Microbiome Profiling platform. This technology allows for the rapid, high-throughput analysis of the human gut microbiome, which is increasingly linked to diseases ranging from obesity to autoimmune disorders. Isaksen has successfully utilised the Aleap Pre-Seed Fund to accelerate Bio-Me’s development program and market introduction. His leadership is central to Norway's efforts to become a hub for personalised nutrition and microbiome-based diagnostics, bridging the gap between molecular biology and clinical application. 20. Stig Morten Borch and SpinChip Diagnostics: Rapid Point-of-Care Testing Stig Morten Borch, founder of SpinChip Diagnostics, is leading the development of a cutting-edge diagnostic platform designed for rapid and accurate point-of-care testing. SpinChip’s technology aims to provide lab-quality results within minutes, which is critical in emergency settings such as suspected cardiac events. Borch’s leadership has focused on the engineering challenges of miniaturizing complex diagnostic procedures into a centrifugal microfluidic chip. The company represents the high-tech manufacturing capability that exists within the Norwegian MedTech cluster, where precision engineering meets clinical diagnostics. Analysis of the Supporting Ecosystem: Clusters and Tech Transfer The success of these twenty leaders is predicated on a highly coordinated support system that mitigates the risks associated with early-stage life science ventures. The Role of Technology Transfer Offices (TTOs) Inven2, the TTO for the University of Oslo and Oslo University Hospital, is a pivotal player in this ecosystem, managing a portfolio of approximately 50 companies with a combined value of around NOK 5 Billion. In 2024 alone, Inven2-backed startups raised NOK 670 Million in private capital. Similarly, NTNU Technology Transfer AS has established 73 spin-off companies, many of which are focused on HealthTech and MedTech. These organisations provide the legal, commercial and financial expertise required to move research from the laboratory to the market. TTO / Incubator Core Metric (2024-2025) Key Outcome Source Inven2 116 New Inventions; NOK 670M raised Transition of researchers to entrepreneurs Various NTNU TTO 73 Spin-off companies to date Scaling academic IP into MedTech firms Various Aleap >18 Alumni; $19M Capital raised Norway's largest health startup incubator Various Norway Health Tech 308 Members; 38 International activities National driver of public-private collaboration Various Collaborative Test Environments: The Smart Care Lab The "Smart Care Lab," a service provided by Norway Health Tech, allows companies like DNV Imatis and Dignio to document the clinical and operational benefits of their solutions in real-world municipal settings. This independent validation is crucial for overcoming the "challenges of the Norwegian market," where high-quality standards can sometimes slow down the adoption of new technologies. For example, DNV Imatis demonstrated time savings of 390 hours annually in a single municipality, providing the "hard data" required for larger-scale implementation. Market Trends and the Future of Norwegian Health Innovation The Norwegian HealthTech and MedTech sectors are characterised by several emerging trends that will define the next decade of growth. 1. Capital Concentration and Global Integration Global venture capital data from 2024-2025 indicates a shift toward fewer but larger funding rounds. While overall deal counts are lower than historical averages, the average financing round in the MedTech sector reached $36 Million in the first half of 2025. This "capital concentration" favors mature startups and AI-native firms that can demonstrate clear clinical value and a path to international scaling. 2. The Rise of "HealthFjords" as a Regional Brand Western Norway, centered around Bergen, has launched the "HealthFjords" identity to position the region as an international powerhouse for health technology. This initiative, supported by the Eitri Innovation Centre and major grants from Agenda Vestlandet, emphasises "human scale" innovation—small enough to be agile, but large enough to lead in diagnostics and digital patient pathways. 3. Sustainability and Social Impact There is an increasing focus on the "sustainability" of healthcare systems. Leaders like Hege Hansen (Induvita) and Saeid Hosseini (Vilje Bionics) are not just focused on profitability but on creating a more "dignified" and "accessible" healthcare experience. This alignment with Nordic values, trust, equality and sustainability, is viewed as a competitive advantage in international markets where health equity is becoming a priority. Conclusion The future leaders of Norwegian HealthTech and MedTech are distinguished by their ability to combine deep clinical research with sophisticated engineering and AI integration. From Jasper Kurth’s industrialisation of medical isotopes at Thor Medical to Cathrine Ro Heuch’s decentralised migraine care at Nordic Brain Tech, these innovators are solving some of the most complex problems in modern medicine. The success of these individuals is supported by a robust national strategy that prioritises public-private collaboration, internationalisation, and the documentation of real-world clinical benefits. As Norway continues to transition its economy, the HealthTech and MedTech sectors represent a significant pillar of future growth, capable of delivering both economic value and profound improvements in patient lives worldwide. The transition from "garage startups" to "global leaders" is well underway, secured by a unique ecosystem that balances Nordic values with international commercial ambition. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Romanian HealthTech and MedTech Leaders The technological landscape of Romania has experienced a seismic shift between the fiscal years of 2024 and 2026, transitioning from a secondary outsourcing destination into a primary forge for high-valuation HealthTech and MedTech intellectual property. This metamorphosis is not merely anecdotal; it is substantiated by a radical escalation in capital inflow and a strategic pivot toward "Born Global" enterprises that prioritise international scalability from their inception. The year 2025 stands as a historical inflection point for the region, where a single landmark financing event, the $165 Million Series C round for the robotics firm Dexory, nearly equaled the entire venture capital output of the Romanian ecosystem in 2024. This surge in liquidity, backed by global institutional heavyweights such as Atomico, Eurazeo and Lakestar, signals that the operational ceiling for Romanian-founded companies has been permanently elevated, transitioning the narrative from a regional hub to a consistent producer of global category leaders in medical and assistive technologies. The maturation of the sector is further evidenced by the increasing density of DeepTech and AI-native startups. By early 2026, the Romania Tech Startup Association (ROTSA) and accelerators like Techcelerator had mapped over 100 artificial intelligence startups with Romanian roots, many of which are dedicated to solving high-complexity problems in oncology, radiotherapy, microbiome analysis and feline longevity. This report analyses 20 such leaders, representing a mix of high-growth scale-ups, innovative pre-seed ventures and visionary individuals who are redefining the intersection of healthcare and technology. The Vanguard of Robotics and Assistive Technology The intersection of hardware, sensor fusion, and healthcare has emerged as a dominant vertical within the Romanian innovation space. These companies leverage advanced engineering backgrounds, often rooted in automotive and aerospace sectors, to address fundamental human mobility and supply chain challenges. 1. Dexory: Autonomous Systems in the Healthcare Supply Chain While Dexory is often categorized within the logistics and robotics sector, its implications for MedTech are profound. Founded by Andrei Danescu (CEO), Oana Andreea Jing, and Adrian Negoita, the company develops autonomous platforms that provide real-time digital twin technology for warehouse operations. The $165 Million Series C round in October 2025 provided the capital necessary to deploy these systems at a global scale. In the context of healthcare, Dexory’s technology addresses the critical requirement for high-precision logistics in the pharmaceutical and medical device industries. The digital twin capabilities allow for the granular monitoring of sensitive medical inventories, ensuring that temperature-controlled environments are maintained and that the traceability of life-saving equipment meets stringent regulatory standards. By automating data collection, Dexory eliminates the human error inherent in medical supply chains, a second-order effect that significantly enhances patient safety by ensuring that the right medical assets are available exactly when needed. 2. dotLumen: Advanced Mobility for the Visually Impaired Founded by Cornel Amariei, dotLumen represents the pinnacle of Romanian assistive technology. Amariei, an inventor and researcher who previously led sensor innovation at Continental Automotive, has applied automotive-grade autonomous driving principles to human mobility. dotLumen produces smart glasses that utilize 3D scanners and vibrating sensors to assist the blind in navigating complex environments. By 2025, dotLumen had secured approximately $30 Million in total funding, including an €11 Million grant from the European Innovation Council (EIC) Fund. The technological mechanism involves real-time spatial mapping, where the device "sees" the environment and provides haptic feedback to the user, effectively acting as a high-tech alternative to traditional guide dogs or walking canes. This innovation is a testament to the Romanian ecosystem’s ability to repurpose industrial engineering expertise for direct clinical and social impact. AI-Driven Diagnostics and Radiography Leaders Radiology and medical imaging have become the primary battlegrounds for AI adoption in Romania, driven by a deep talent pool in computer vision and machine learning. 3. Rayscape: The Maturation of Computer Vision in Radiology Formerly operating as XVision, Rayscape has evolved into a comprehensive digital assistant for radiologists. Co-founded by Stefan Iarca, Cristian Avramescu, Bogdan Bercean, and Andrei Tenescu, the platform utilises deep learning to analyse chest X-rays and lung CT scans. The company’s trajectory from its 2018 founding in Timisoara to its 2024-2026 expansion exemplifies the successful scaling of a Romanian MedTech startup. Rayscape’s impact is measured by clinical efficiency; in pilot projects at the County Emergency Clinical Hospital in Timisoara, the platform allowed radiologists to interpret 20% more images per day by prioritizing pathological cases. As of 2024, the company secured additional seed funding of €460,000, bringing its total financing to nearly €2 Million as it targets Western European and North American markets. The success of Rayscape is foundational to the Romanian MedTech narrative, proving that local algorithms can meet international clinical standards. 4. Synaptiq Technologies: Precision in Oncological Planning Synaptiq Technologies addresses the "contouring" bottleneck in radiotherapy, where doctors must manually delineate tumors and organs at risk before treatment can begin. The team, led by Dragoș Dușe, Dragoș Grama and Marius Stănescu, brings together academic excellence from Heidelberg, Amsterdam and Bucharest. Dragoș Dușe, a physicist and machine learning researcher, previously designed algorithms at the German Cancer Research Institute. Synaptiq’s AI reduces the time required for treatment planning from several hours to a matter of minutes, directly increasing the throughput of oncology departments. Nominated for "Best DeepTech Startup" and "Healtech & Longevity Innovator" at the 2026 Romania Startup Awards, the company represents a shift toward specialised AI that integrates deeply into the clinical workflow. Leading HealthTech Entities Primary Vertical Key Founders / Leaders Funding / Status (2025/26) Dexory Robotics / Supply Chain Andrei Danescu, Oana Jinga $165M Series C dotLumen Assistive Tech Cornel Amariei $30M Total Rayscape Radiology AI Stefan Iarca, Cristian Avramescu €1.93M Total Synaptiq Technologies Oncology AI Dragoș Dușe, Marius Stănescu Best DeepTech Nominee NostraBiome Microbiome / Biotech Calin Popescu, Valerio Lo Giudice Best Fundraising Performer The Cat Health Company Longevity Biotech Alex Voda, Alex Bacita €1.8M Total Digitail Veterinary SaaS Sebastian Gabor, Ruxandra Puiu $37M Total Apollo AI Technologies Pharma / NLP Mihaela Onofrei, Vlad Trandafir Female-Led Startup 2026 Hilio (Atlas) Mental Health Mihai Bran, Mihnea Bran Telemedicine Leader Orbotix MedTech / Robotics Bogdan Ochiana, Gregory Letare €7M Seed Microbiome, Longevity and Precision Medicine The Romanian sector is increasingly exploring the frontiers of longevity and microbiome analysis, moving from reactive medicine to proactive, personalised health interventions. 5. NostraBiome: The Personalisation of Immune Response NostraBiome is a DeepTech health company that utilises AI simulations to analyse the human microbiome, specifically targeting Inflammatory Bowel Disease (IBD) and oncology-related digestive issues. Founded by Calin Popescu, a serial entrepreneur with over 100 patents, the company was born from Popescu’s own decade-long struggle with IBD. By identifying unique microbial signatures, NostraBiome provides chronological recommendations to "hack" the inflammatory code of the individual patient. The company’s leadership team includes CTO Valerio Lo Giudice and CMO Dr. Dragomir Radu Dumitru, a specialist at OncoHelp, the largest oncology center in Western Romania. NostraBiome has achieved remarkable results, with 90% of IBD patients in their studies reaching sustained remission. The startup’s success at the 2026 Romania Startup Awards, winning for revenue growth and fundraising, underlines the market’s appetite for precision medicine solutions that bridge the gap between AI and biological data. 6. The Cat Health Company (TCHC): Feline Longevity as a Human Proxy Founded in 2024 by Oxford-trained scientist Alex Voda and former Charles River Labs senior scientist Alex Bacita, The Cat Health Company focuses on feline longevity. While the immediate product is longevity medicine for companion cats, the underlying mission is to accelerate human therapy discovery by using cats as a biological model for aging research. TCHC secured €1.8 Million in seed funding, with participants including Early Game Ventures and Alex Zhavoronkov, the founder of the AI-driven pharma unicorn Insilico Medicine. The company’s approach involves in silico research to explore drug candidate libraries faster and more cost-effectively than traditional methods. By targeting the root causes of aging rather than just symptoms, TCHC is positioning Romania as a key node in the global longevity biotech network. Veterinary and Pharmaceutical Innovations The automation of clinical workflows and the democratisation of pharmaceutical data have emerged as critical sub-sectors, significantly reducing the administrative and cognitive load on healthcare providers. 7. Digitail: Revolutionising Veterinary Practice Management Digitail, co-founded by Sebastian Gabor, Ruxandra Puiu, and Alexandru Tabolcea, is an all-in-one veterinary practice management platform (PIMS) that utilises AI to automate clinic workflows and pet owner communication. In November 2025, the company raised a $23 Million Series B round, bringing its total funding to $37 Million. The platform’s global reach is extensive, supporting 10,000 veterinarians across 40 countries. Digitail’s success is a prime example of the "Born Global" Romanian strategy, where the founders moved rapidly to capture international market share, backed by elite investors like Google’s Gradient Ventures and Atomico. The second order insight here is the role of VetTech as a precursor to human HealthTech trends, particularly in remote monitoring and automated patient engagement. 8. Apollo AI Technologies: AI-Native Pharma Solutions Founded in Iaşi in 2022, Apollo AI Technologies specializes in NLP and data mining for the healthcare sector. Led by Mihaela Onofrei and Vlad Trandafir, the company developed "Diabeta," a medical chatbot for diabetologists and "Pharmachat," which processes the specifications of all medicines approved in Romania. Apollo’s most significant contribution is the creation of a map encompassing 1.7 Million drug-to-drug interactions, a tool that has been deployed in pharmacy chains to prevent adverse reactions. As the winner of the "Female-Led Startup of the Year" award in 2026, Apollo AI exemplifies the integration of computational linguistics into the pharmaceutical safety chain. Mental Health and Telemedicine Pioneers Mental health, once a neglected area in Eastern European healthcare, has seen a surge in digital innovation driven by the normalisation of remote care. 9. Hilio (formerly Atlas): The Maturation of Tele-Mental Health Hilio, founded by psychiatrist Mihai Bran and Mihnea Bran, represents the evolution of the Romanian telemedicine market. Originally known as Atlas, the platform has transitioned into a comprehensive mental wellness ecosystem, providing access to therapy, coaching and corporate wellness programs. Dr. Mihai Bran’s work highlights the critical intersection of clinical expertise and entrepreneurial spirit, using the platform to improve the quality of life and accessibility of mental health services in Romania. 10. Medicai and Mircea Popa: Collaborative Medical Data Mircea Popa, through his involvement with Medicai, has been a key figure in the digitization of medical records and image sharing in Romania. Medicai provides a platform that allows patients and doctors to securely share and collaborate on medical images, reducing the reliance on physical media like CDs. Popa’s academic and professional activity through 2024 and 2025, including co-organising major IEEE conferences in intelligent engineering and medical cybernetics, demonstrates the deep scholarly roots of Romanian MedTech. 20 Future Romanian HealthTech and MedTech Leaders The "Innovator" Cohort: Emerging Leaders of 2026 The 2026 Romania Startup Awards nominated several early-stage companies that represent the next wave of HealthTech leadership. These entities focus on niche applications of DeepTech and specialised clinical needs. 11. Revelio Medical: Industrial MedTech Innovation Nominated as a "Healtech & Longevity Innovator," Revelio Medical is part of a new class of startups focusing on the industrial application of medical technology. While specific technical details are often proprietary at this stage, their nomination alongside giants like Synaptiq indicates a high degree of market validation and investor interest. 12. Medical Pilot: Clinical Workflow Optimisation Another ROTSA nominee, Medical Pilot, focuses on the "pilot" phase of healthcare delivery, optimising the initial interaction between patient data and clinical assessment. This startup addresses the critical need for more efficient triage and data-driven navigation within the Romanian healthcare system. 13. Nutribalance HealthTech: Personalising Nutritional Science Nutribalance HealthTech represents the convergence of nutrition and digital health. By using data-driven insights to manage metabolic health and longevity, the company aligns with the broader global trend toward preventative healthcare and "nutrition as medicine." 14. Brain Symphony: Neuro-Focused Therapeutics Nominated in the 2026 "Healtech & Longevity" category, Brain Symphony focuses on the complex field of neuroscience.Their work likely involves digital therapeutics or diagnostic tools designed to address cognitive decline and neurological performance, a sector of increasing importance as the European population ages. 15. Origin BCI: The DeepTech Frontier of Brain-Computer Interfaces Origin BCI is perhaps the most ambitious of the 2026 nominees, categorised under "Best DeepTech Startup". By developing brain-computer interfaces, the company is pushing the boundaries of how humans interact with medical hardware, potentially offering new solutions for patients with severe motor or neurological impairments. Financial Milestone Startup Amount / Stage Date Key Investors Largest Series C Dexory $165M Oct 2025 Atomico, Eurazeo, Lakestar Largest Debt Raise Databricks (Zaharia) $5B Jan 2025 Institutional Debt Top Series B Digitail $23M Nov 2025 Gradient Ventures, Partech EIC Grant dotLumen €11M 2025 EIC Fund Top Seed Round Orbotix €7M 2025 Bravo Victor VC Pre-Seed Biotech TCHC €500k 2024 Early Game Ventures Diaspora Leaders and Global Category Shapers The influence of Romanian talent extends far beyond the nation’s borders, with founders in the United States and Western Europe leading some of the most innovative HealthTech companies in the world. 16. Emi Gal and Ezra: Early Cancer Detection Emanuel "Emi" Gal, a serial entrepreneur from Bucharest, founded Ezra in 2018 with the mission of making full-body MRI cancer screening accessible. In May 2025, healthcare technology giants Function Health and Ezra announced their merger, with Function Health acquiring Ezra to integrate its MRI capabilities with lab-based health assessments. Gal’s trajectory, from his education in Applied Mathematics at Spiru Haret University to leading a global AI healthcare merger, serves as an inspiration for the entire Romanian tech community. 17. Valar Labs and the 30 Under 30 Influence The team at Valar Labs, including Romanian-linked founders featured in the Forbes 30 Under 30 Class of 2025 and 2026, represents the cutting edge of AI in oncology. Valar Labs uses AI to analyze tumor images to predict treatment response, helping patients find the most effective therapies. Their presence on international stages validates the high level of Romanian machine learning expertise on a global scale. 18. Etiq AI: Ensuring Ethical Algorithms in Healthcare While often categorized under General AI, Etiq AI’s focus on ethical machine learning has significant implications for HealthTech, where algorithmic bias can have life-or-death consequences. Nominated for "Excellence in Artificial Intelligence" at the 2026 Romania Startup Awards, the company provides the oversight necessary for medical AI companies like Synaptiq or Rayscape to deploy their technologies safely and fairly. 19. Kinderpedia: Paediatric Health and Communication Co-founded by Evelina Necula, Kinderpedia is an education and health management platform for children. While its primary market is EdTech, its role in pediatric health, tracking medical records, vaccinations and child development, makes it a critical leader in the "Healtech & Longevity" space. Their 2026 nomination for "Female-Led Startup of the Year" highlights the importance of integrated child-health management. 20. Parol: Automating the Clinical Record Parol is an emerging leader focused on automating medical documentation. By using AI to capture and structure patient-doctor interactions, Parol reduces the administrative burden on Romanian healthcare providers, allowing for more patient-centric care. The company was recognised as a "Best Fundraising Performer" in 2026, signalling strong investor confidence in its ability to solve a universal pain point in healthcare systems. Synthesis of Trends and Strategic Implications The collective data from these 20 leaders suggests several critical trends shaping the Romanian HealthTech and MedTech landscape through 2026. First, there is a definitive shift from "SaaS-only" solutions to "DeepTech and Hardware-Enabled AI". Startups like dotLumen and Dexory prove that Romania can compete in capital-intensive hardware manufacturing when it is paired with proprietary AI software. Second, the "Born Global" ethos has become the standard for Romanian founders. Companies like Digitail and The Cat Health Company target US and UK markets immediately, utilising Romania as a high-efficiency R&D hub while capturing higher-margin markets abroad. This strategy is supported by local venture capital firms like GapMinder, which manages a €45 Million fund, and Early Game Ventures, which recently launched a €60 Million Fund II specifically to back early-stage CEE innovators. Third, the emergence of longevity as a central theme, from feline studies (TCHC) to microbiome hacking (NostraBiome) and metabolic health (Nutribalance), indicates that Romania is moving beyond the management of acute illness toward the science of human healthspan extension. Conclusion: The Path Toward the Next Unicorn The Romanian HealthTech and MedTech sectors have moved beyond the experimental phase and are now in a period of aggressive scaling. The success of the 20 leaders profiled in this report, anchored by the record-breaking capital raises of 2025, suggests that the country’s first "HealthTech Unicorn" is imminent. The convergence of academic excellence, a high-performing engineering workforce, and a maturing investor ecosystem has created a resilient infrastructure for innovation. As these companies navigate regulatory submissions in 2026 and expand their clinical trials globally, they will not only bring prestige to the Romanian startup ecosystem but, more importantly, deliver transformative technologies to the global healthcare market. The transition from "Hackerville" to a "Global HealthTech Hub" is well underway, fuelled by a generation of founders who are as scientifically rigorous as they are entrepreneurially ambitious. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Irish HealthTech and MedTech Leaders The Republic of Ireland has established a formidable global position within the medical technology and digital health sectors, characterised by a unique synthesis of indigenous entrepreneurial agility and high-density multinational presence. As of 2025, the sector generates approximately €16 Billion in annual exports, representing 14% of the nation’s total export economy. With over 700 life sciences and health technology firms, more than 400 of which are homegrown, Ireland has successfully leveraged its academic research infrastructure and favourable venture capital environment to become the largest employer of MedTech professionals per capita in Europe. In 2024, the ecosystem reached a decade-high record in venture capital investment, securing €491.3 million across 89 deals, even as global life sciences funding experienced a dramatic contraction. This resilience is largely attributed to the maturing profile of the cluster, where late-stage and venture-growth deals now constitute 46% of total volume, reflecting a shift from speculative early-stage ventures to clinically validated, scalable platforms. This report analyses the twenty leaders and organisations at the vanguard of this evolution, examining the technological mechanisms, leadership backgrounds and market dynamics that define the next wave of Irish healthcare innovation. The Macro-Economic Foundations and Institutional Catalysts The trajectory of Irish MedTech leadership is inextricably linked to the state-supported infrastructure that de-risks innovation. The Disruptive Technologies Innovation Fund (DTIF), a €500 million vehicle administered by Enterprise Ireland, has been a critical engine for collaborative research, having awarded €298 million to 68 projects in the health and wellbeing sector to date. Investment and Deal Flow Maturity (2014-2025) The maturation of the Irish MedTech ecosystem is evidenced by the surging deal values and the increasing involvement of international Tier-1 investors. The following table delineates the capital flow and the pivot toward growth-stage financing. Metric 2014 Baseline 2024 Peak Performance 2025 Projected Outlook Total VC Investment €117.9 Million €491.3 Million Record Late-Stage Megadeals Total Deal Count 47 Deals 89 Deals Sustained High Activity Late-Stage Volume % 23% 46% Increasing Institutional Focus Key Sector Driver Early MedTech Prototypes AI & Interventional Platforms Integrated Home-Based Care This structural shift indicates that Ireland has moved beyond being a manufacturing hub for multinationals to becoming a primary source of intellectual property and clinical breakthroughs. The density of expertise in Galway, Dublin, and Cork has created a self-sustaining cycle where successful founders (e.g., those from Crospon or BiancaMed) reinvest their social and financial capital into the next generation of "spin-outs". 1. Conor Hanley (CEO, FIRE1): Redefining Chronic Disease Management Conor Hanley represents the archetype of the sophisticated Irish MedTech executive, combining deep technical training with international commercial experience. Hanley holds a PhD in Chemical Engineering and an MBA from INSEAD, having previously led BiancaMed through its acquisition by ResMed in 2011. As the CEO of FIRE1 (Foundry Innovation and Research 1), he oversees a Dublin-headquartered company that has secured one of the largest health tech rounds in Europe, a $120 Million late-stage financing in early 2025. The mechanism of FIRE1’s Norm™ system addresses the "proxy problem" in heart failure. Most current monitoring solutions rely on pressure proxies or indirect symptoms. In contrast, the Norm™ system utilises a sensor implanted in the inferior vena cava (IVC) to monitor fluid volume directly. The IVC is a highly compliant vessel and its diameter changes sensitively in response to small volume shifts that precede acute heart failure events. By measuring these dynamics, the system enables physician-directed self-management, allowing patients to adjust their own treatment at home and avoid hospitalisations that can cost the healthcare system upwards of $30,000 per visit. Under Hanley’s leadership, FIRE1 has received FDA Breakthrough Device Designation and is progressing toward a 2029 FDA approval target, a timeline supported by robust data from pivotal clinical trials. 2. Wayne Allen (CEO, Perfuze): Advancing the "First Pass" Gold Standard in Stroke Wayne Allen, CEO and co-founder of Galway-based Perfuze, leads a team that addresses the time-critical nature of ischemic stroke. Allen and co-founder Liam Mullins brought over 35 years of combined experience to the venture, identifying that less than 50% of current stroke patients achieve positive clinical outcomes due to the complexity of clot removal. Perfuze’s innovation lies in its Millipede88 Aspiration Catheter, which features a patented corrugated design. This engineering allows the "superbore" catheter to navigate the tortuous neurovascular anatomy without collapsing or losing its aspiration force at the clot face. In the MARRS (Millipede Aspiration for Revascularization in Stroke Study) pivotal trial, the device achieved a remarkable 77% First Pass Effect (FPE) for M1 occlusions. This is scientifically significant because the "first pass" is the primary predictor of positive patient recovery; every additional pass increases the risk of vessel damage and distal embolisation. With €22 million in Series A funding and recent FDA 510(k) clearance, Allen has positioned Perfuze for a limited market release in the US, supported by high-profile investors like EQT Life Sciences and Seroba. 3. Dr. Lucy O'Keeffe (CEO, CroíValve): Targeting the "Forgotten" Tricuspid Valve Dr. Lucy O’Keeffe is at the forefront of the structural heart revolution. As CEO of CroíValve, she leads a firm dedicated to treating tricuspid regurgitation, a condition where the heart's tricuspid valve fails to close properly, leading to backward blood flow and progressive heart failure. O’Keeffe, who holds a PhD in Biomedical Engineering and previously led R&D programs at Medtronic, has navigated CroíValve through the complex transition from concept to clinical stage. The DUO System developed by CroíValve is a minimally invasive coaptation heart valve device that repairs the tricuspid valve without surgery. This is critical for the vast majority of tricuspid patients who are currently considered too high-risk for open-heart procedures. The company is currently spearheading a €5.9 Million DTIF project to develop a solution suitable for over 90% of patients with this condition. O’Keeffe has strategically maintained a dual presence, with R&D and operations in Ireland and clinical/regulatory functions in the US, targeting a market opportunity estimated at over €3 Billion. 4. Jason Mowles (CEO, CergenX): The Convergence of AI and Neonatal Neurotechnology Jason Mowles transitioned from a senior career in banking and digital transformation to lead CergenX, a University College Cork (UCC) spin-out. Founded in 2021, CergenX leverages AI to solve a profound problem in neonatal care: the early detection of brain injury in newborns. Approximately five in every 1,000 babies suffer from some form of brain abnormality at birth, yet these injuries often remain undetected until developmental delays manifest years later. CergenX’s Wave device utilizes a vast databank of neonatal EEG signals, significantly different from adult brainwaves, to train algorithms that can perform a non-invasive screening in under 15 minutes. This technology democratizes neonatal neuro-assessment, as it does not require a resident neurologist to interpret the data. In 2025, Mowles oversaw the company’s receipt of FDA Breakthrough Device Designation and its acceptance into the TAP program, significant milestones for the company’s entry into the US and European markets. Under his leadership, the firm secured €6.7 Million from the DTIF, highlighting the strategic value of AI-driven diagnostics in the paediatric space. 5 & 6. John and Caroline O'Dea (Leaders, Palliare): Safety in the Modern Operating Room The husband and wife team of John and Caroline O’Dea are seasoned leaders within the Galway cluster. Having previously founded Crospon and sold it to Medtronic for $45 Million in 2017, they launched Palliare in 2018 as a spin-out focused on surgical safety. John O’Dea, a PhD in Electronics Engineering and past President of Engineers Ireland, serves as Group CEO, while Caroline O’Dea manages the Irish operations. Palliare’s flagship innovation, the EVA15 insufflator, addresses the hazardous buildup of surgical smoke during laparoscopic and robotic procedures. Surgical smoke contains aerosolized biological matter and chemical byproducts that pose long-term health risks to medical staff. The EVA15 system combines continuous pressure insufflation with integrated smoke evacuation, ensuring a clear visual field for surgeons and a safer environment for the team. Palliare was crowned Emerging Medtech Company of the Year at the 2025 Irish Medtech Awards, a recognition of its turnover doubling annually since 2022 and its successful US market launch. 7. Dr. Elizabeth McGloughlin (Co-Founder, Tympany Medical): Revolutionizing ENT Imaging Dr. Elizabeth (Liz) McGloughlin embodies the transition from clinical practice to high-tech entrepreneurship. A former doctor in anaesthesia and critical care, she identified a workflow bottleneck during her BioInnovate fellowship: surgeons must frequently remove and clean endoscopes during procedures, disrupting their focus and extending surgery times. Tympany Medical, based in Galway, developed the Solascope, a variable-angle, self-cleaning endoscope specifically designed for ENT (ear, nose, and throat) procedures. By utilising "chip-on-tip" CMOS sensors, the Solascope allows for high-resolution imaging and real-time angle adjustment without withdrawing the device. McGloughlin, recognised as a finalist for the 2025 European Prize for Women Innovators, has expanded the team to include experts in optical physics and miniaturised electronics, securing over €3.5 Million in seed funding to advance toward FDA certification. 8. Donal O'Shea (CEO, Deciphex): Scaling Digital Pathology Globally Donal O’Shea, the CEO and founder of Deciphex, is transforming the traditionally analog field of histopathology. Based in Dublin, Deciphex addresses the global shortage of pathologists by offering the Diagnexia platform, which connects hospitals to a network of over 250 subspecialty pathologists. This allows for rapid diagnostics and the reduction of surgical backlogs that have plagued healthcare systems post-pandemic. Under O’Shea’s guidance, Deciphex has grown to over 220 employees and raised €15 million in venture debt in late 2025 to accelerate its US expansion. The company’s secondary focus involves AI-driven clinical medication safety systems, which use diagnostic decision-support tools to identify risks in colorectal screening. Deciphex won the Collaboration in Medtech Award at the 2025 Irish Medtech Awards, underscoring its success in integrating AI into the clinical workflow across multiple international markets. 9. Dr. Alison Liddy (CEO, Relevium Medical): Disrupting the Osteoarthritis Market Dr. Alison Liddy leads Relevium Medical, a University of Galway spin-out that targets the "hidden disability" of knee osteoarthritis (OA). Liddy, who holds a PhD in Biochemical Engineering and previously worked at Boston Scientific and Roche, developed RM-010, an injectable gel-based therapeutic. The technological insight behind RM-010 is the controlled release of capsaicin. While capsaicin is a powerful pain blocker, its raw application causes intense burning. Relevium’s delivery system gradually releases the compound into the knee joint at concentrations below the threshold for burning pain but high enough to achieve nerve ablation for up to six months. This offers a superior alternative to steroids, which can advance joint disease, and hyaluronic acid, which often lacks efficacy. Liddy secured €4.6 Million in DTIF funding in 2024 and is currently raising a €10 Million Series A to fund clinical trials, positioning the company to capture a share of a market opportunity estimated at $7.7 Billion. 10. Tom Fitzmaurice (CEO, LaNua Medical): Modernizing Embolization Procedures Tom Fitzmaurice, a former Vice President at Medtronic, is the CEO of LaNua Medical, a NovaUCD spin-out founded in 2024. LaNua addresses the risks associated with embolisation, a procedure where blood flow is intentionally blocked to treat tumours or bleeding. Traditional embolisation can carry risks of reflux, where the blocking agent travels to non-target areas. LaNua’s flagship device, ECORE™, is an umbrella-shaped occlusive barrier that is deployed deep within blood vessels to form a precise barrier. Fitzmaurice led the company to win the 2024 Enterprise Ireland Big Ideas competition and secured a €6 million seed round. The company is currently collaborating with Integer Holdings to clinically validate ECORE™ across a wide range of vessel sizes, aiming to reduce hospital costs and procedure times for interventional radiologists. 11. Judi O'Malley (CEO, Spiorad Medical): Closing the Gap in Cardiovascular Access Judi O’Malley, CEO and co-founder of Spiorad Medical, brings extensive clinical and commercial expertise to the cardiovascular field. A former vascular physiologist with the HSE and a sales manager for multinationals like Medtronic and Abbott, she identified a critical unmet need for efficient large-bore vascular closure devices. Spiorad’s focus is on the safety of procedures such as TAVI (Transcatheter Aortic Valve Implantation), which require large incisions in the femoral artery. O’Malley founded Spiorad alongside interventional cardiologist Dr. Samer Arnous to create devices that make closure easier for physicians and safer for patients. In 2025, the company secured a €1.7 million DTIF award, allowing it to accelerate the development of advanced cardiovascular support solutions. Spiorad’s presence in the University of Galway’s Business Innovation Centre highlights the strong regional support for female-led MedTech ventures. 12. Brian Shields (CEO, Neurent Medical): Neurostimulation for Chronic Rhinitis Brian Shields is the CEO and founder of Neurent Medical, a Galway-based company that has developed a breakthrough treatment for chronic rhinitis. Shields, a former management consultant and BioInnovate fellow, led the company through several financing rounds to bring its Neuromark™ product to the US market. Chronic rhinitis is characterised by an overactive autonomic nervous system in the nasal cavity. Neurent’s technology uses a handheld probe to apply targeted neurostimulation, disrupting the nerves that cause persistent nasal discharge and congestion. In early 2026, Neurent closed an oversubscribed €62.5 Million Series C round led by MVM Partners. Shields has been instrumental in building an international team and establishing a strategic partnership with Northwell Health, ensuring that Irish-developed neuro-clinical solutions have a clear commercialisation pathway in the US. 13. Aaron Hannon (CEO, Luminate Medical): Enabling In-Home Cancer Care Aaron Hannon, co-founder and CEO of Luminate Medical, represents the new generation of Irish leaders focused on patient-centered "at-home" care. Co-founding the company at 19 with Dr. Barbara Oliveira and Professor Martin O’Halloran, Hannon has developed a mission to deliver every cancer treatment in the patient’s home. Luminate’s wearable medical devices mitigate the side effects of chemotherapy, such as hair loss and peripheral neuropathy. The company raised $15 Million in a Series A round in late 2024 to advance its first-in-patient clinical trials. Hannon’s leadership has been recognised by several awards, including the 2022 EIT Health Catapult Audience Choice Award, and the company has expanded from its initial trio of founders to a team of 14 as it prepares for large-scale US trials. 14. Aidan Crawley (CEO, Amber Therapeutics): Precision Neuromodulation for Bladder Control Aidan Crawley is the CEO and co-founder of Amber Therapeutics, a company developing bioelectrical therapies for peripheral nervous system disorders. Crawley founded the company while serving as an Entrepreneur-in-Residence at Oxford Science Enterprises, partnering with world-class scientists to address the problem of urinary incontinence. Amber’s Picostim™ system is the first fully implantable, closed-loop neuromodulation therapy for mixed urinary incontinence. By targeting the pudendal nerve, the system can both sense physiological responses and provide dynamic stimulation to restore natural bladder function. Crawley, whose background includes a career at Goldman Sachs and the growth-stage US firm Addepar, has led the company through successful AURA-2 and AURA-3 studies. In 2025, Amber established a headquarters within a validated manufacturing facility to execute its US-European pivotal trial at scale. 15. Grace O'Donnell (CEO, Phyxiom): Digital Transformation of Respiratory Care Grace O’Donnell, CEO and co-founder of Phyxiom, leads a digital health spin-out from RCSI that targets the mismanagement of asthma and COPD. Co-founded with Professor Richard Costello, Phyxiom leverages a decade of clinical research and patented algorithms to provide a device-independent analytics platform. The Phyxiom platform integrates data from smart inhalers and spirometry devices, providing physicians with an intelligent decision-support system. This supports more accurate diagnoses and ensures that patients adhere to medication protocols, potentially saving payers up to $13.5 Billion annually in the US alone. O’Donnell and her team completed a seed funding round in mid-2025 and are currently live across 13 HSE asthma clinics, with expansion plans for the UK in 2026 and the US in 2027. 16. Seamus Fahey (CEO, ICS Medical Devices): Leading the Irish CDMO Surge Seamus Fahey is the CEO and founder of ICS Medical Devices, a contract design and manufacturing organization (CDMO) that has become a vital partner for global start-ups. Fahey, with 27 years of experience including a senior role at Creganna Medical, established ICS in 2019 to provide world-class catheter solutions. ICS Medical Devices has grown rapidly, opening a new facility in Galway and announcing the creation of 72 new jobs in 2025 to support its international expansion into Asia and the Middle East. The company’s success reflects the broader trend in Ireland where technical expertise in catheter manufacturing is being commercialized as a high-value service. ICS was a finalist for Emerging Medtech Company of the Year and Medtech Partner/Supplier of the Year at the 2025 Irish Medtech Awards. 17. Martina Skelly (CEO, Yellow Schedule): AI for Patient Flow Efficiency Martina Skelly is the co-founder and CEO of Yellow Schedule, one of the primary winners of the HIHI.AI 2025 call. Her company’s Triage Link system uses AI to automate the clinical triage process, improving patient flow and reducing bottlenecks in hospital outpatient departments. Skelly’s leadership represents the application of AI to operational healthcare challenges. By ensuring solutions are "trustworthy and human-centered," Yellow Schedule aligns with the Irish national AI strategy. The pilot programs facilitated by Health Innovation Hub Ireland will allow Skelly to clinically validate the efficiency gains and patient experience improvements generated by her AI-powered triage platform. 18. Andrew Glass (CEO, Vivasure Medical): Pioneering Large-Bore Vascular Closure Andrew Glass has led Vivasure Medical through one of the most successful exits in recent Irish MedTech history. As CEO, he oversaw the development of PerQseal Elite, a fully absorbable, suture-less vascular closure device. In January 2026, Vivasure was acquired by Haemonetics for €185 million, a testament to the company’s progress in advancing large-hole closure technology. The technology behind Vivasure uses a synthetic polymer implant to provide high-integrity closure for the large-bore arterial incisions required in structural heart and endovascular procedures. Glass, who brought a background in international MedTech leadership to the firm, has noted that joining Haemonetics provides the global scale necessary to make PerQseal Elite available to physicians and patients worldwide. 19. Brian Thornes (CEO, X-Bolt Orthopedics): Surgical Innovation in Fragile Bone Dr. Brian Thornes, an orthopedic surgeon and founder of X-Bolt Orthopedics, has developed a revolutionary solution for hip fracture fixation in elderly patients. Thornes, also the inventor of the TightRope® treatment for ankles, founded X-Bolt to address the clinical failure of traditional lag screws in osteoporotic (fragile) bone. X-Bolt’s expanding technology provides a stronger anchor in the femoral head than traditional screws, significantly reducing reoperation rates. The Pro-X1 trochanteric nailing system received FDA clearance in 2023 and launched commercially in the US in 2024. Thornes’ ability to translate a "lightbulb moment" (observing domestic wall anchors in his apartment) into a patented medical device highlights the role of clinical observation in driving MedTech innovation. 20. Susan Treacy (CEO, HealthTech Ireland): Strategic Leadership and Policy Advocacy Susan Treacy, while not a startup founder, is arguably the most influential leader shaping the future of Irish HealthTech.Since becoming CEO of HealthTech Ireland in 2021, she has led the organization through a period of strategic transformation, including the delivery of a Memorandum of Understanding with the HSE. Treacy serves as the only industry representative on the HSE AI Implementation Group and participates in HIQA working groups on AI and Health Technology Assessment (HTA). She was named Winner of the Women in STEM Award in the Health Technology category at the 2025 Business Post Awards. Her role is vital in ensuring that industry perspectives are embedded in national health strategy, providing the policy framework that allows innovators like Mowles and O’Donnell to scale their technologies within the Irish and international markets. Structural Analysis of Leadership Origins The twenty leaders analyzed in this report do not exist in isolation; their success is a product of the "Innovation with Impact" strategic pillar of the Irish government. The following table summarises the origins and developmental support for these leaders. Origins of the Future Leaders Leader Organization Origin/Incubator Key Funding/Support Conor Hanley FIRE1 The Foundry (Silicon Valley) $120M Megadeal Lucy O'Keeffe CroíValve Medtronic Alumna €5.9M DTIF Award Jason Mowles CergenX UCC / INFANT Centre €6.7M DTIF Award Liz McGloughlin Tympany Medical BioInnovate Ireland €3.5M Seed Round Alison Liddy Relevium Medical University of Galway €4.6M DTIF Award Brian Shields Neurent Medical BioInnovate Ireland €62.5M Series C Aidan Crawley Amber Therapeutics Oxford Science Enterprises US Pivotal Trial Support Tom Fitzmaurice LaNua Medical NovaUCD €6M Seed Funding The Role of BioInnovate Ireland BioInnovate Ireland, founded by the late Ian Quinn and currently led by Professor Martin O’Halloran, is the single most influential program for training this new cohort of leaders. Affiliated with Stanford Biodesign, the program has trained 159 fellows to date, with approximately half progressing to lead their own startups. As of 2025, BioInnovate startups have generated €84 Million in wages and supported 1,460 jobs in Ireland, creating a Gross Value Added (GVA) of €277 Million. The program focuses on solving real-world clinical challenges through a 10-month intensive bootcamp and hospital immersion process. Technological Trajectories and Second-Order Insights A second-order analysis of the Irish MedTech landscape reveals a significant shift away from hardware-only devices toward integrated platforms that combine mechanics, optics, and AI. The Shift Toward Software-as-a-Medical-Device (SaMD) Firms like CergenX and Phyxiom are leading a transition where the primary value resides in the algorithm rather than the sensor. This requires a fundamental shift in regulatory strategy, moving away from 510(k) clearances for physical devices toward "Breakthrough Designations" for AI software. The implication for future leaders is a need for dual expertise in both clinical medicine and data science, a combination exemplified by Jason Mowles’ transition from banking to neonatal neurotechnology. The Proximity of Multinationals and Spin-Outs The presence of nine of the world's top ten MedTech multinationals in Ireland (e.g., Medtronic, Boston Scientific, Stryker) provides a "training ground" for future entrepreneurs. Leaders like Lucy O’Keeffe (Medtronic), Tom Fitzmaurice (Medtronic), and Seamus Fahey (Creganna) utilize their "MNC pedigree" to build startups that are designed for acquisition from day one. This created a "ripple effect" where the exit of one company (Crospon, Vivasure) immediately fuels the creation of several more through the recycling of leadership talent. The Democratisation of Complex Diagnostics AI is being used to move complex assessments from the specialist clinic to the bedside or home. CergenX’s ability to screen for brain injury without a neurologist and Phyxiom’s remote asthma monitoring represent a broader trend of "de-skilling" diagnostic interpretation, thereby increasing access and lowering costs. This is particularly relevant in the US market, where hospital-based care is increasingly being replaced by home-based management models. Conclusions and Future Outlook The Irish MedTech and HealthTech landscape from 2024 to 2026 is defined by a level of maturity that allows for sustained global impact. The combination of seasoned serial entrepreneurs (The O'Deas, Thornes, Hanley) and a structured innovation pipeline (BioInnovate, CÚRAM, NovaUCD) ensures that Irish firms are no longer merely manufacturing components but are defining global clinical standards. The strategic focus on AI-driven diagnostics, minimally invasive structural heart repairs, and bioelectrical therapeutics aligns perfectly with global healthcare trends toward efficiency, safety, and personalized care. Furthermore, the massive influx of late-stage capital and the formalization of US clinical pathways through partnerships with health systems like Northwell Health provide the necessary "runway" for these firms to reach commercial maturity. As Ireland continues to punch above its weight in the global sector, these twenty leaders will likely remain at the center of the most significant healthcare acquisitions and clinical breakthroughs for the remainder of the decade. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Polish HealthTech and MedTech Leaders The Polish healthcare technology ecosystem has transitioned from a localised secondary market into a primary driver of European deep-tech innovation as of the first quarter of 2026. This transformation is underpinned by a structural shift from traditional software development to the application of advanced artificial intelligence, multimodal biological simulations, and high-precision medical hardware. Currently, Poland hosts over 3,300 active startups, with the Warsaw and Kraków hubs serving as the principal gravity centers for venture activity and technical talent. The sector's expansion is validated by significant capital inflows; in 2025, venture capital investment reached approximately PLN 3.4 Billion (~EUR 800 Million) across 180 distinct transactions, a momentum that has rallied into the current fiscal year. The institutional backbone of this growth is reinforced by the launch of "Future Tech Poland," a €350 Million fund-of-funds initiative spearheaded by the European Investment Fund (EIF) and Bank Gospodarstwa Krajowego (BGK). This program provides critical liquidity for high-tech ventures at various stages of growth, emphasizing the Polish government’s commitment to establishing the nation as a global tech hub and enhancing the competitiveness of the European Union’s fifth-largest economy. Within this fertile landscape, a cadre of twenty leaders and their respective organizations have emerged as the vanguard of the Polish HealthTech and MedTech renaissance. The Pillars of Digital Health Infrastructure The first category of leadership focuses on the foundational layers of the medical experience, scheduling, triage, and data interoperability. These figures have successfully navigated the transition from initial digital adoption to building core infrastructure that integrates directly into the global healthcare stack. 1. Mariusz Gralewski and the DocPlanner Global Network Mariusz Gralewski, the founder and CEO of DocPlanner, remains the preeminent figure in the Polish digital health landscape. Since its inception in 2012, DocPlanner has evolved from a simple doctor-review platform (ZnanyLekarz) into a global digital health network that links millions of patients with medical professionals across multiple continents. Gralewski’s strategic vision focused on international market expansion, leading to the acquisition of platforms such as Doctoralia, MioDottore and ClinicCloud, thereby creating a unified ecosystem for patient management. As of late 2024, the DocPlanner group reported over 30 million monthly unique visitors and nearly 5 million monthly appointments managed through its various interfaces. The company’s financial trajectory, characterised by a total raise exceeding $240 million and a recent Series E valuation, positions it as a veteran leader in the Polish unicorn landscape. Gralewski's impact extends beyond mere scheduling; by centralising patient data and doctor-patient interactions, he has established a standardised digital layer that reduces administrative friction for over 1,300 employees and thousands of clinical partners worldwide. 2. Piotr Orzechowski and the AI Triage Standard at Infermedica Piotr Orzechowski, through Infermedica, has pioneered the use of artificial intelligence in medical triage and clinical decision support. The "computer brain" developed under his leadership serves as a diagnostic engine that guides patients and clinicians through the complexities of health symptomatic analysis. Infermedica’s B2B SaaS model has gained international traction, notably through a strategic partnership with Microsoft and successful expansion into the German and U.S. markets. In 2022, the company secured $30 million in Series B funding led by investors such as Karma Ventures and Inovo Venture Partners, reflecting a deep industry confidence in its AI-native architecture. Orzechowski’s focus on integrating smart programs into the quiet "background" of hospital routines allows clinics to improve patient visit quality without disrupting existing workflows. This focus on non-intrusive integration is a key characteristic of the second-order evolution in Polish HealthTech, where technology is seen as a supportive partner rather than a disruptive burden to the clinician. 3. Robert Lugowski and the Real-Time Data Revolution of CliniNote Robert Lugowski, as CEO of CliniNote, addresses one of the most persistent bottlenecks in modern healthcare: the structuring and utilization of clinical data. Founded in 2020, CliniNote utilizes Natural Language Processing (NLP) to "unlock" the power of clinical data by structuring it in real-time as medical professionals enter notes into existing Hospital Information Systems (HIS) and Electronic Health Records (EHR). This innovation addresses the massive inefficiencies in clinical data management, which traditionally require manual processing and significant administrative time. The CliniNote platform, developed in collaboration with clinicians from the National Institute of Oncology in Warsaw, includes modules like the CliniNote Assistant and DataCollector, which are designed to support pharmaceutical companies and Contract Research Organizations (CROs). The company’s strategic growth was accelerated by its 2023 funding round led by Sunfish Partners, enabling its solutions to be implemented in major European projects such as Idea4RC and DigiOne. Lugowski’s leadership represents a critical shift toward data-driven decision-making, where the "exhaust" of clinical encounters is converted into high-quality, interoperable data for research and drug development. 4. Marta Lacka and the Strategic Data Insights of Quantia While many HealthTech founders focus on the patient-provider interaction, Marta Lacka, CEO and founder of Quantia, addresses the data visibility gap for consumer healthcare brands. Quantia is an AI-driven e-commerce data platform that provides real-time insights into market dynamics, including product availability, pricing, and sales performance for enterprise-level retail and health brands such as Nespresso and Procter & Gamble. In May 2024, Quantia secured $1.2 Million in pre-seed funding led by Inovo.vc and Team X. Lacka’s leadership is defined by her "enterprise-first" background, allowing Quantia to compress strategic planning cycles that typically take ten working days into just 3-5 minutes. By ensuring that both brands and retailers have equal access to performance data, Quantia drives category growth and ensures the right medical and wellness products are available to consumers when needed. DeepTech and the Future of Pharmaceutical Simulation The second tier of Polish leadership operates at the intersection of biology and computation, aiming to resolve the high failure rates and astronomical costs associated with traditional drug development and synthesis. 5. Piotr Surma and the Generative Simulation of Ingenix.ai Piotr Surma, co-founder and CEO of Ingenix.ai , is perhaps the most prominent representative of the "AI-native" wave in Polish MedTech. Surma, who previously co-founded Applica (an AI firm acquired by Snowflake), launched Ingenix in 2023 alongside Adam Dancewicz to address the 90% failure rate of pilot drugs. The startup recently secured €9 Million in seed funding, led by Inovo.vc with participation from OTB Ventures and the IFC—to develop a multimodal generative AI co-pilot that simulates clinical trials with unprecedented granularity. The Ingenix platform utilizes "digital twins" and is trained on diverse multimodal datasets, including genomic, transcriptomic, and imaging inputs. By simulating biological processes from the molecular level through cellular, tissue, and population-level analysis, the system predicts clinical endpoints and potential adverse events before a physical trial begins. Surma’s vision is to make the drug development process predictable, potentially delivering the "GPT moment" for the pharmaceutical sector and significantly reducing the $50 billion annual global investment in clinical trials. 6. Piotr Byrski and the Retrosynthesis AI of Molecule.one Piotr Byrski and Paweł Włodarczyk-Pruszyński, founders of Molecule.one , identified a fundamental bottleneck in drug discovery: the manufacturing feasibility of hypothetical compounds. Molecule.one ’s proprietary AI uses retrosynthesis to identify cost-efficient and chemically sound pathways for synthesising new compounds, effectively working backward from a desired molecule to available elements. Founded in 2016 during the founders' medical studies in Warsaw, Molecule.one closed a $4.6 million seed round in 2021.The company’s SaaS model provides pharmaceutical companies with predictive informatics that suggest optimal reaction conditions and score hypothetical synthesis pathways. By unlocking "digital chemistry," Byrski’s team allows for the exploration of previously inaccessible structures, accelerating the development of innovative drugs to meet emerging health challenges. Startup Leader Core Innovation Key Funding / Investors Ingenix.ai Piotr Surma Multimodal AI simulations for clinical trials €9M Seed / Inovo.vc , OTB, IFC Molecule.one Piotr Byrski AI-driven retrosynthesis and drug discovery $4.6M Seed / Atmos Ventures, Sunfish Partners CliniNote Robert Lugowski Real-time NLP for medical data structuring Seed / Sunfish Partners Quantia Marta Lacka AI e-commerce analytics for health brands $1.2M Pre-Seed / Inovo.vc , Team X Cardiovascular Innovation and High-Precision Hardware Hardware-enabled medical technology in Poland is witnessing a resurgence, led by founders who combine surgical experience with advanced materials science. 7. Professor Paweł Buszman and the i4hv Longevity Initiative The startup i4hv, led by interventional cardiologists including Professor Paweł Buszman (Medical Director) and Dr. Piotr Hirnle, is developing a biological heart valve with a significantly extended lifespan. Standard biological valves typically last 10–15 years, necessitating repeat high-risk surgeries for patients over their lifetime. i4hv’s innovation uses polymer or transgenic biological materials to extend this lifespan to 20–30 years. The project, which received over PLN 30 Million in funding from the European Funds for a Modern Economy (FENG), focuses on Transcatheter Aortic Valve Implementation (TAVI). This minimally invasive, percutaneous therapy is traditionally reserved for older patients; however, i4hv’s long-lasting valves aim to make the procedure accessible to younger patients in their 40s and 50s, allowing them to maintain active lives without the threat of frequent repeat surgeries. 8. Dr. Honorata Hafke and the Remote Diagnostics of StethoMe Dr. Honorata Hafke founded StethoMe to bridge the gap between home-based monitoring and professional diagnostic accuracy. StethoMe has developed a wireless, AI-powered stethoscope that enables parents and patients to conduct lung and heart examinations from home. The device identifies abnormalities in breath sounds and provides immediate feedback through a consumer-friendly interface, while also sharing high-quality audio data with medical professionals for remote triage. StethoMe’s trajectory is defined by its partnerships with tech giants like Amazon Web Services and Nvidia, which support its AI development. Having secured $2.5 million in Series A funding from investors like TDJ Pitango Ventures and Movens VC, StethoMe represents a shift toward "decentralised diagnostic hubs" that alleviate the burden on paediatric and primary care clinics. The Rise of the Polish Femtech Sector Femtech has emerged as a particularly high-growth vertical in Poland, with fifteen innovative startups identified as changing the landscape of women's health through AI, specialised hardware, and community-driven care. 9. Michał Matuszewski and the AILIS Breast Health System Michał Matuszewski is the originator and CEO of AILIS, which has developed the world's first AI-powered breast health monitoring capsule. The system uses Parametric Dynamic Imaging (PDI) to distinguish areas of increased activity from normal tissue, identifying cancerous lesions at a very early stage where the recovery rate is up to 99%. Matuszewski’s vision centers on a "fee-for-health" model, transitioning breast screening from hospitals to accessible locations like shopping malls and offices. AILIS's methodology is non-invasive, radiation-free, and painless, allowing for frequent examinations without the health risks associated with traditional mammography. The company has collaborated with more than 100 experts over seven years and is currently conducting clinical trials with the National Oncology Institute in Kraków. The design of the AILIS capsule, which won the Red Dot Award, emphasizes a "woman-centric" sensory experience to reduce the psychological stress associated with medical screenings. 10. Ula Sankowska and the IVF Optimization at MIM Fertility Ula Sankowska and PhD Piotr Wygocki founded MIM Fertility to revolutionize the reproductive medicine sector using artificial intelligence. The startup’s software platforms, EMBRYOAID and FOLLISCAN, assist IVF doctors and embryologists by automating the grading of embryos and the measurement of ovarian follicles. These tools significantly increase success rates while reducing the time and costs associated with fertility procedures. MIM Fertility originated from the Faculty of Mathematics, Informatics, and Mechanics at the University of Warsaw, highlighting the critical link between academic research and commercial MedTech in Poland. In December 2023, the startup raised $2 million in seed funding from Tangent Line and Peleton to expand its global presence. Their recent research presented at ASRM 2025 demonstrates that their AI models match the accuracy of expert sonographers in follicle measurement, validating the clinical utility of their algorithms. 11. Kaja Rybicka-Gut and the Transparency of Your KAYA Kaja Rybicka-Gut, co-founder of Your KAYA, has led the charge in the organic intimate health and care sector. Your KAYA operates on a subscription model, offering organic cotton menstrual products that emphasize health safety and environmental sustainability. While categorised as an e-commerce brand, Rybicka-Gut has used the platform to build a comprehensive wellness ecosystem that provides education on women's health, representing the intersection of HealthTech and consumer empowerment. 12. Aleksandra Staniszewska and the Precision of My OVU Aleksandra Staniszewska is the creator of My OVU, an innovative ovulation thermometer that utilizes a vaginal silicone disc for precise cycle monitoring. By combining specialized hardware with an AI-integrated app, My OVU provides women with accurate data on fertile days and overall hormonal health. This approach reflects the broader trend of "miniaturized medical labs" where hardware-software integration allows for diagnostic-level monitoring outside of clinical settings. 13. Karolina Szymczak-Adamczyk and the EndoMe Community Karolina Szymczak-Adamczyk founded EndoMe to support women struggling with endometriosis, drawing from her decade-long struggle with the disease. EndoMe combines a supplement brand with a supportive community, addressing the holistic needs of patients who often face long diagnostic delays and inadequate support in traditional health systems. Szymczak-Adamczyk’s leadership highlights the importance of "patient-led innovation," where lived experience dictates the design of health solutions. Femtech Startup Leader Focus Area Technology / Approach AILIS Michał Matuszewski Breast Cancer Detection Parametric Dynamic Imaging (PDI) + AI MIM Fertility Ula Sankowska Infertility Treatment EMBRYOAID (Embryo grading) + FOLLISCAN My OVU Aleksandra Staniszewska Fertility Monitoring Vaginal silicone disc + AI app EndoMe Karolina Szymczak-Adamczyk Endometriosis Support Specialized supplements + Community Your KAYA Kaja Rybicka-Gut Intimate Care Subscription-based organic products Primary Care, Wellness and Mental Health A new generation of Polish HealthTech leaders is redefining the "front door" of healthcare, moving beyond episodic treatment to continuous wellness management and integrated primary care. 14. Adam Janczewski and the Hybrid Model of Jutro Medical Adam Janczewski, founder of Jutro Medical, has pioneered a hybrid model that combines advanced digital triage with a network of modern physical clinics. Founded in 2020, Jutro Medical aims to revolutionise primary healthcare (POZ) accessibility in Poland by automating administrative tasks and offering seamless telemedicine integrations. In 2024, the startup secured debt financing from mBank to fuel its physical expansion. Janczewski’s model addresses the chronic underfunding and administrative bloat of traditional primary care, offering a blueprint for a more efficient, patient-centred public-private health integration. 15. Dominik Swadzba and the Diagnostic Access of uPacjenta Dominik Swadzba founded uPacjenta in 2021 to promote preventive laboratory testing among Poles. The company utilizes a B2B, B2C, and marketplace business model to offer at-home blood collection services, making diagnostic testing more accessible and less time-consuming. By lowering the barriers to regular health monitoring, uPacjenta facilitates early intervention and supports the broader shift toward proactive health management. The startup secured nearly €4.7 million in seed funding, underscoring the market's demand for decentralised diagnostic services. 16. Jakub Zielinski and the Mental Wellness Platform Mindgram Jakub Zielinski founded Mindgram in 2021 as a comprehensive science-based platform for mental wellness in the workplace. Mindgram provides employees with access to psychologists, psychotherapists, and mental health resources through a mobile app. The company secured $7.7 million in seed funding led by Market One Capital, reflecting the rapid prioritisation of mental health as a core component of corporate wellness and HealthTech infrastructure. 17. Piotr Sosnowski and the Metabolic Focus of Holi Piotr Sosnowski and Kuba Koziej are the leaders behind Holi, a HealthTech startup dedicated to metabolic health management. Holi provides a structured treatment process that integrates medical monitoring, e-prescriptions, and educational resources, particularly focusing on the rising demand for obesity management and metabolic optimisation. With over 2,500 patients served and €3.5 Million in funding, Holi represents the "TechBio" approach to chronic disease management, where software serves as the delivery mechanism for complex medical protocols. 18. Patrycja Brzozowska and the Personalized Protocols of Mos Health Patrycja Brzozowska, alongside co-founders Paweł Chrzan and Paweł Sobkowiak, launched Mos Health to deliver personalised health protocols through an AI-driven platform. Mos Health analyzes user-provided data, lab results, and wearable device data to generate interventions focused on energy, sleep, and nutrition. In early 2026, the Polish-American company raised $1.1 million in a pre-seed round led by SMOK Ventures and Movens Capital. Brzozowska’s goal is to build a "digital partner" that guides users step-by-step through health optimizations, initially targeting the U.S. and Polish employer benefit markets. 19. Michał Kaczor and the Software Benchmarking of Gralio.ai Michał Kaczor, CEO and co-founder of Gralio.ai , is building a critical infrastructure tool that assists medical and business professionals in navigating the increasingly complex HealthTech software market. Gralio.ai uses AI models and web bots to analyze thousands of product reviews and user experiences, creating impartial, "apples-to-apples" comparisons of software tools. As HealthTech becomes "bedrock infrastructure," Kaczor’s platform ensures that healthcare providers can find, compare, and choose the right AI-driven tools for their unique needs, bringing order to a chaotic marketplace. 20. Michal Czyz and the Respiratory Management of FindAir Michal Czyz founded FindAir in 2016 to digitize the management of asthma and COPD. FindAir’s smart inhaler devices and mobile app provide patients and doctors with real-time data on medication usage and environmental triggers. By combining IoT hardware with sophisticated data analytics, Czyz has created a system that improves patient compliance and allows for more precise adjustments to treatment plans, representing the future of "connected respiratory care". Market Context and Structural Dynamics The individual successes of these 20 leaders are part of a broader "tale of two markets" occurring within the Polish and European digital health space. On one hand, AI-native upstarts like Ingenix and AILIS are attracting substantial rounds at unprecedented speeds; on the other, established players are becoming the "core infrastructure" that incumbents rely on to navigate digital transformation. Venture Capital and Institutional Support The funding landscape for Polish HealthTech is increasingly characterized by "mega-deals" and the entry of global "Goliath" investors such as Andreessen Horowitz and General Catalyst into the broader European market. Locally, funds like Inovo.vc , OTB Ventures, and Market One Capital have been instrumental in backing the current generation of leaders. Entity Role Impact on HealthTech Future Tech Poland €350M Fund-of-Funds Provides liquidity for early and growth-stage tech startups. Inovo.vc Early-stage VC Lead investor in Ingenix, Jutro Medical, and Quantia. BGK / EIF Institutional LPs Creating the national "Innovate Poland" program to boost CEE competitiveness. PARP (FENG) Grant Provider Funding deep-tech breakthroughs like i4hv's heart valves. Second-Order Implications of AI Dominance The massive integration of AI into Polish startups is no longer just a vertical focus but an infrastructure layer. This transition has several profound effects: Commoditisation of Software Creation: As AI drives the marginal cost of coding toward zero, the "defensible moat" for HealthTech leaders shifts from proprietary software to network effects and unique, high-quality datasets. Agentic AI in Healthcare: We are entering an era of "Agentic AI," where autonomous agents handle supply-side tasks like vetting medical records, scheduling, and brokering, thereby improving platform liquidity and efficiency. The Clinical "GPT Moment": The pharmaceutical industry’s traditional R&D model is being challenged by foundational models that can reason across multiple biological scales, potentially making drug development a predictable engineering task rather than a game of chance. Future Outlook: The Path Toward 2030 The Polish MedTech sector is entering a phase of decentralised growth, with Kraków emerging as a global leader in DeepTech and life sciences while Warsaw remains the financial and software hub. The success of current leaders depends on their ability to navigate the increasingly demanding regulatory environment, particularly CE certification for medical AI and the evolving ISO 13485 standards. Strategic partnerships between startups and traditional IT giants like Asseco Poland, Comarch and Netguru, who remain the top IT partners for the Polish health sector, will be crucial for scaling these innovations into the broader public health system. As these 20 leaders continue to validate their models clinically and commercially, the Polish HealthTech renaissance is poised to redefine not only the domestic medical landscape but also the standards of care across the European and global markets. The transition from "fee-for-service" to "fee-for-health," driven by early detection, personalised simulation, and remote monitoring, represents the ultimate strategic objective for the Polish innovators of 2026 and beyond. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Icelandic HealthTech and MedTech Leaders The Icelandic healthcare technology (HealthTech) and medical device (MedTech) sectors have entered a period of unprecedented expansion, transitioning from a localised research infrastructure into a globally competitive innovation hub. This evolution is fundamentally rooted in the unique intersection of Iceland’s high-fidelity genomic data, a single-payer nationalised healthcare system, and a robust academic-clinical nexus centered at the University of Iceland and Landspítali University Hospital. Historically known for pioneering work in population genetics through deCODE genetics, the contemporary Icelandic ecosystem has matured, giving rise to a new generation of leaders who are leveraging artificial intelligence (AI), advanced biotechnology and digital health platforms to address global medical challenges. The emergence of Kerecis as the nation’s first "unicorn", achieving a $1.3 Billion valuation upon its acquisition by Coloplast, serves as a definitive proof-of-concept for the Icelandic model of innovation, catalyzing increased venture capital interest and proving that a small-market environment can produce world-leading medical solutions. The Ecosystem Architecture: Institutional Drivers and Funding Landscapes The trajectory of Icelandic HealthTech is inextricably linked to the institutional support provided by the University of Iceland (UI) and the strategic oversight of Landspítali University Hospital. The rate of innovation has accelerated significantly in recent years, with patent applications from the research community increasing from one per year to nearly one per month by 2024. This productivity is fostered through formalised recognition programs such as the UI Science and Innovation Awards, which provide critical seed funding and institutional validation for projects in health and wellbeing. Strategic Funding and Governance Entity Primary Function in HealthTech Development Key Initiatives and Recent Actions Technology Development Fund (Rannís) National grant provider for early-stage R&D. Awarded ISK 15 million to Kaldur Therapeutics for brain injury research. Frumtak Ventures Leading domestic venture capital firm for HealthTech. Led seed rounds for PLAIO ($4.7M) and Optise ($2.2M). Brunnur Ventures Venture capital firm focusing on global scalability. Early investor in Oculis and contributor to its Nasdaq NY listing. Klak Icelandic Startups Primary business accelerator and mentorship hub. Manages Startup Supernova and facilitates TINC accelerator in Silicon Valley. Kría - New Business Venture Fund Government-backed investment fund. Provided matching fund offers to 11 startups including Kaldur Therapeutics in 2025. The connectivity within the Icelandic startup community, characterised by a "small world" effect where the degree of separation between clinical experts, engineers and investors is minimal, serves as a primary success factor for domestic firms. This proximity allows for rapid prototyping and clinical validation, making Iceland an ideal "test market" for HealthTech products before they scale into the European and United States markets. 1: Guðmundur Fertram Sigurjónsson (Kerecis) - The Regenerative Benchmark Guðmundur Fertram Sigurjónsson, the Founder and CEO of Kerecis, is widely credited with establishing the blueprint for modern Icelandic MedTech success. His innovation, using intact fish skin for tissue regeneration and wound repair, initially faced the challenge of converting a natural byproduct into a high-technology medical product. The Kerecis technology utilizes the biological similarities between fish skin and human skin, providing a scaffold for cell ingrowth that is naturally rich in Omega-3 fatty acids, which reduce inflammation and accelerate healing. Sigurjónsson’s leadership was characterized by an early focus on the United States market, recognizing that the scale required for a MedTech exit could not be achieved domestically. His tenure saw Kerecis grow into a global leader in the wound-care space, culminating in its $1.3 Billion sale to Danish medical giant Coloplast in 2023. Sigurjónsson’s contributions have been recognised with the Asa Gudmundsdottir Wright Award, and he remains a central figure in the newly established Icelandic Academy of Science and Innovation, where he serves as a mentor for the next generation of life science entrepreneurs. 2: Dr. Tryggvi Þorgeirsson (Sidekick Health) - Scaling Digital Therapeutics Sidekick Health, led by CEO and co-founder Dr. Tryggvi Þorgeirsson, represents the pinnacle of the Icelandic digital health sector. The company has developed a patient-centric digital care platform designed to empower individuals with chronic illnesses through behavioural modification and clinical monitoring. Dr. Þorgeirsson, a physician by training, founded the company on the premise that healthcare must move beyond the clinic to manage the daily habits that drive chronic disease outcomes. Sidekick Health has raised over $210 Million to date, positioning it as one of the most well-funded HealthTech companies in the Nordic region. The company’s strategic growth has been marked by high-profile partnerships with five of the world’s twenty largest pharmaceutical companies, integrating digital therapeutics with traditional drug regimens to improve patient adherence and quality of life. Despite maintaining a global presence with offices in Europe and the US, Dr. Þorgeirsson emphasizes that the Icelandic market remains a critical research and development hub due to the country’s high-quality health metrics and collaborative clinical environment. 3: Dr. Hákon Hákonarson (Arctic Therapeutics) - The Genomic Strategist Dr. Hákon Hákonarson is a preeminent figure in the transition of genomic research into clinical applications. As the founder of Arctic Therapeutics (ATx), Hákonarson leverages a career that includes serving as the Chief Scientific Officer of deCODE genetics and founding the Center for Applied Genomics (CAG) at the Children’s Hospital of Philadelphia, the world’s largest pediatric biobank. His expertise is reflected in a scientific output exceeding 1,000 publications, ranking him among the world’s most influential scientific minds. Arctic Therapeutics, established in 2015, uses bioinformatic approaches and AI to repurpose existing drugs and develop new therapies for millions of patients. The company operates a clinical laboratory in Akureyri and maintains commercial operations in Reykjavik and Philadelphia. Hákonarson’s approach minimises the traditional risks of drug development by using genetic data to identify targets with a high probability of clinical success, particularly in the field of rare and hereditary diseases. Leader Key Background and Expertise Primary Organization Leadership Focus Dr. Hákon Hákonarson Former CSO of deCODE; Founder of CAG (CHOP). Arctic Therapeutics Genomic-driven drug repurposing and AI bioinformatics. Ivar Hakonarson Experience in IT startups (Basis, Sensa). Arctic Therapeutics Clinical laboratory operations and commercial growth. Lisa DeMarco 25+ years in pharma (GSK); M&A specialist. Arctic Therapeutics Business development and IP strategy. Dr. Charlly Kao Immunologist; Operational leader at CAG. Arctic Therapeutics Scientific advisement and proof-of-concept design. 4: Dr. Örn Almarsson (Axelyf) - RNA Therapeutics and LNP Platforms In the rapidly evolving field of nucleic acid medicine, Dr. Örn Almarsson, CEO and Co-founder of Axelyf, is positioning Iceland as a center for next-generation drug delivery. Axelyf, founded in 2022, focuses on the development of RNA therapeutics for oncology and autoimmune diseases. The company’s core innovation is its AXL lipid nanoparticle ($LNP$) platform, which was bolstered by the acquisition of assets from 76Bio, Inc., including a library developed by former Moderna mRNA-LNP experts. Dr. Almarsson’s leadership integrates deep expertise in lipid chemistry and delivery biology with AI-driven design to solve the "delivery problem" that has historically limited the efficacy of RNA-based medicines. Axelyf operates as both a platform-enabling collaborator and an internal drug discovery house, with operations spanning Massachusetts and Iceland. The company is supported by a board of directors that includes Árni Blöndal of Brunnur Ventures, reflecting a strong connection to the Icelandic venture ecosystem. 5: Jóhann Guðbjargarson (PLAIO) - Disrupting Pharma Operations with AI Jóhann Guðbjargarson, CEO and Founder of PLAIO, is addressing one of the most persistent inefficiencies in the global pharmaceutical industry: production planning. Despite the high-tech nature of drug manufacturing, many companies still rely on manual spreadsheets for demand and supply planning. PLAIO’s AI-powered software platform, which raised $4.7 Million in seed funding in 2024, digitises these processes to ensure that medicines are delivered to patients on time and with minimal waste. Guðbjargarson’s 25-year career in the software industry, including roles at AGR and Rhino-Aviation, informed his vision for a "Coplanner" AI tool that supports production planners with optimisation suggestions. PLAIO’s platform is currently utilized by prominent European clients such as Coripharma, Camurus, and MS Pharma. Guðbjargarson emphasises that his mission is to "shake up the pharma world" by replacing human-error-prone manual work with precise, predictive technology. 6: Maria Bech (EpiEndo Pharmaceuticals) - Advancing Barrier Science Maria Bech, CEO of EpiEndo Pharmaceuticals, leads a clinical-stage company with a unique focus on the impairment of epithelial barriers as a driver of inflammatory conditions. Bech joined the company in 2021 to guide its transition into clinical development. Under her leadership, EpiEndo has developed "Barriolides," a new class of orally available macrolides that have negligible antimicrobial activity but possess potent anti-inflammatory and immuno-modulatory properties. The company’s lead asset, glasmacinal ($EP395$), is being developed primarily for Chronic Obstructive Pulmonary Disease ($COPD$), which the WHO projects will cost the global economy $4.8$ Trillion by 2030. In early 2026, EpiEndo completed a €9 Million convertible bond issue to fund a larger Phase 2b exacerbation reduction trial, demonstrating consistent investor confidence in Bech’s strategic direction and the potential of barrier-promoting therapies. 7: Dr. Martin Ingi Sigurðsson (Kaldur Therapeutics) - Mitigating Neurological Traumas Kaldur Therapeutics, co-founded in 2024 by Dr. Martin Ingi Sigurðsson, represents a specialised frontier in MedTech: the mitigation of neurological damage caused by cerebral oxygen deprivation. This condition, which occurs during cardiac arrest or oxygen deprivation at birth, currently has limited therapeutic options. Dr. Sigurðsson, who serves as a primary contact for the firm, has overseen its rapid maturation, including the launch of its website in March 2025 and securing significant funding offers from the Icelandic Technology Development Fund and Kría. The startup’s research is based on understanding the molecular mechanisms of hypothermia, a natural protective state against brain injury, to develop new drug derivatives and biomarkers. Kaldur Therapeutics’ potential to significantly reduce the long-term costs and human suffering associated with hypoxic brain injury makes it one of the most high-impact emerging companies in the Icelandic life science landscape. 8: Orri Guðmundsson (NeckCare) - Precision Wearable Diagnostics Orri Guðmundsson, CEO of NeckCare, is leading the commercialisation of sensor technology for cervical spine assessment. NeckCare’s innovation centres on wearable sensors that provide objective analysis of neck mobility and motor control, addressing a significant gap in the diagnosis and treatment of head and neck injuries, including concussions. Under Guðmundsson’s leadership, NeckCare has established the first Cervical Center of Excellence in Iceland and has recently expanded its operations into the United States. The "NeckSmart" technology is used by interdisciplinary teams of healthcare professionals to provide objective data for clinical decision-making, moving beyond the subjective assessments that have traditionally dominated physical therapy and rehabilitation. Guðmundsson’s background in sales and commercial leadership at Airtame and Siteimprove has been instrumental in positioning NeckCare for global market penetration. Leader Core Background Focus Area Technology Application Orri Guðmundsson Financial Economics ($MSc$); Commercial leadership. Cervical Diagnostics Wearable sensors for objective mobility analysis. Adeline Tracz Innovation leader at Landspítali. AI Medical Coding Clinical $NLP$ for multilingual record documentation. Finnur Magnússon Product management (Nox Health, Meniga). Connected Home Care Care coordination platform for aging-in-place. Ólafur Þór Guðbjörnsson Physiotherapist and CEO. Digital Rehabilitation Adaptive home-exercise programs with data-tracking. 9: Adeline Tracz (KatlaCode) - AI-Driven Administrative Efficiency The administrative burden of medical coding is a major source of operational friction in modern hospitals. Adeline Tracz, CEO and Innovation Leader at KatlaCode, is solving this through an AI-powered system specifically designed for Icelandic and Nordic clinical records. KatlaCode, which won the UI Science and Innovation Award in 2024, uses advanced Icelandic language models to assist healthcare professionals in accurate and efficient documentation. The founding team of KatlaCode includes Dr. Arnar Þór Guðjónsson, Head of ENT Surgery, and Dr. Hafsteinn Einarsson, an Associate Professor of Computer Science at the University of Iceland. This multidisciplinary team has already launched a live deployment at Landspítali University Hospital. Tracz’s vision extends beyond Iceland, with a roadmap that includes scaling to other Nordic hospitals and eventually launching multilingual clinical $NLP$ tools for international markets. 10: Dr. Einar Stefánsson (Oculis and Retina Risk) - The Veteran Innovator Dr. Einar Stefánsson is perhaps the most prolific individual innovator in the Icelandic MedTech history, having co-founded at least four biotechnology firms including Oculis, Retina Risk, and Oxymap. Stefánsson, a leading ophthalmologist and professor at the UI Faculty of Medicine, has successfully transitioned from bench research to commercial exits, such as the acquisition of Cyclops ehf. by deCODE genetics in 2000. Oculis, his most prominent venture, has raised over $192 million and is dual-listed on Nasdaq New York and Nasdaq Iceland. The company’s nanoparticle eye drops represent a paradigm shift in ophthalmology, potentially eliminating the need for intravitreal injections to treat retinal diseases. Simultaneously, Stefánsson’s work with Retina Risk provides a digital solution for diabetic patients, using risk calculators to prevent vision loss. His career exemplifies the "physician-entrepreneur" model that is central to the Icelandic innovation ecosystem. 11: Finnur Magnússon ( dala.care ) - Revolutionizing Home Based Care Finnur Magnússon, CEO and Co-founder of dala.care , is addressing the global challenge of aging-in-place through technology-enabled coordination. Founded in early 2023, dala.care is a custom-designed app and platform that connects care recipients, families, and professional caregivers to ensure seamless communication and management of home-based support. Magnússon’s background in product management, including leadership roles at Nox Health and Meniga—informed the intuitive design of the dala.care platform. The project has a deeply personal origin, as Magnússon developed the foundation of the platform while managing care for his father, who lived with Parkinson’s for 13 years. In 2025, dala.care was selected to participate in the TINC business accelerator in Silicon Valley, reflecting its potential for international expansion and its role as a leader in the "connected home care" movement. 12: Brynja Ingadóttir (NúnaTrix) - Gamifying Pediatric Surgery Prep Pediatric surgery is a significant source of trauma for both children and their parents. Brynja Ingadóttir, a co-founder of NúnaTrix, has developed a solution that uses gamification to mitigate this anxiety. Founded in 2019, NúnaTrix creates computer games that prepare children for the surgical experience, helping them understand the process and reducing the fear associated with the clinical environment. The company is part of a broader trend in Iceland of utilizing software to improve patient outcomes through behavioral and psychological interventions. Ingadóttir’s work at NúnaTrix is supported by research conducted at the University of Iceland, highlighting the continued importance of academic spin-offs in the HealthTech sector. 13: Dr. Björn Lárus Örvar (ORF Genetics) - Plant-Based Protein Innovation Dr. Björn Lárus Örvar is a pioneer in "molecular farming," a field that uses plants to produce high-value recombinant proteins. As a co-founder and Chief Scientific Officer of ORF Genetics, Örvar developed a method for growing these proteins inside bioengineered barley plants. This plant-based system is exceptionally pure and safe, making it ideal for use in scientific research and high-end skincare through their BIOEFFECT brand. Founded in 2001, ORF Genetics has raised over $8.2 Million and serves as a model for how Icelandic biotechnology can combine traditional agricultural practices with cutting-edge genetic science. Örvar’s leadership has kept the company at the forefront of the growth factor market, with applications expanding into cellular agriculture and cultured meat production. 14: Kjartan Thorsson (Prescriby) - Data-Driven Opioid Risk Management Kjartan Thorsson, CEO and Co-founder of Prescriby, is a doctor-turned-entrepreneur focusing on the root causes of the opioid crisis. Prescriby is a data-driven platform that helps clinicians manage the tapering of high-risk medications, such as opioids and benzodiazepines, to prevent addiction and ensure safe recovery. Thorsson’s firm secured €2 Million in funding in 2024 to innovate its software, which provides structured recovery plans and objective monitoring for patients. Thorsson advocates for Iceland’s status as a "fantastic test market" for research and development, particularly for public health initiatives that require close collaboration between healthcare providers and technology developers. 15: Dr. Eyþór Rúnar Eiríksson (Euler) - High-Precision MedTech Manufacturing Dr. Eyþór Rúnar Eiríksson, CEO and Co-founder of Euler, is bridging the gap between deep-tech AI and industrial MedTech manufacturing. Euler is a spin-out from the Technical University of Denmark (DTU) but is based in Iceland, and it provides real-time monitoring and fault detection for industrial 3D printing ($LPBF$ and $SLS$ processes). Eiríksson’s leadership has led to a €2 Million seed round in late 2025, co-led by Frumtak Ventures and Kvanted. Euler’s software uses existing printer cameras and AI to identify potential defects during the build process, which is critical for the production of high-stakes medical implants and tools. Eiríksson notes that Euler’s platform can reduce failed builds by 77%, potentially saving $115,000 per printer annually, a crucial advancement for making large-scale 3D printing viable for medical applications. 16: Dr. Jón Jóhannes Jónsson (Lífeind and Parkinson's Test) Dr. Jón Jóhannes Jónsson is a central figure in Icelandic clinical biochemistry and the founder of Lífeind, which specializes in nucleic acid analysis for DNA damage. His leadership in the academic sphere recently culminated in a significant breakthrough: the development of a blood test to diagnose Parkinson’s disease. The project, which won the Health category at the 2025 UI Science and Innovation Awards, uses "Northern Lights analysis" to detect structural defects in mitochondrial genetic material isolated from blood platelets. This innovation offers the potential for early, non-invasive diagnosis of Parkinson’s, which could fundamentally transform how the disease is managed and treated globally. Dr. Jónsson’s ability to bridge university research with clinical practice continues to drive significant advancements in the MedTech space. 17: Guðjón Ólafsson (ProDiGY and Molecular Glues) Guðjón Ólafsson, an Assistant Professor at the UI School of Health Sciences, was the overall winner of the 2025 UI Science and Innovation Prize for the ProDiGY project. ProDiGY (Proximity-driven Discovery of Molecular Glue Targets) uses synthetic human-yeast protein interactions to identify targets for "molecular glues"—a revolutionary class of drugs that help cells eliminate disease-causing proteins . This technology offers a rapid and cost-effective method for cancer drug development, representing the next wave of Icelandic biotech leadership. Ólafsson’s work exemplifies the transition from observational genomics toward functional synthetic biology, providing a new set of tools for the global pharmaceutical industry to address "undruggable" targets. 18: Ólafur Þór Guðbjörnsson (Euneo Health) - Digital Physical Therapy Ólafur Þór Guðbjörnsson is the CEO and a co-founder of Euneo Health, a startup dedicated to making physical therapy more effective through digital tools. Founded in 2021 by a team of physiotherapists, Euneo addresses the problem of low patient adherence to home-exercise programs. The Euneo platform allows clinicians to personalize evidence-based rehabilitation programs and provides real-time data on patient progress. Guðbjörnsson’s leadership has focused on clinical groundedness, ensuring the software meets the actual needs of both therapists and patients. With reports of 73% higher exercise adherence and 93% improved therapy experience from early users, Euneo is a leader in the digital physical therapy space. 19: Sigurður Thorarinsson (Landspítali Innovation) While often working within the institutional framework, Sigurður Thorarinsson, the CTO and Head of Innovation at Landspítali University Hospital, is a pivotal leader in the Icelandic HealthTech ecosystem. Thorarinsson acts as a gatekeeper and facilitator, ensuring that startups have the necessary access to clinical environments for testing and validation. Thorarinsson emphasizes that the small degree of separation between people in Iceland is a key success factor, allowing for agile collaboration between hospital staff and private innovators. His leadership in establishing an innovation path within the hospital has been instrumental in the success of projects like KatlaCode and the specialized one-year program for healthcare professionals focusing on digital technology. 20: Arna Harðardóttir (Helix) - Infrastructure Evolution Arna Harðardóttir, CEO of Helix, manages the digital infrastructure that supports the entire Icelandic healthcare system.Helix originated from a 1993 entrepreneur-led mission to digitise the Icelandic health system and currently services the national Electronic Health Record (EHR) system. Harðardóttir’s leadership is focused on the next evolution of EHRs—moving beyond simple records toward intelligent systems that support the patient journey and provide real-time clinical insights. As a central player in the ecosystem, Harðardóttir ensures that Iceland’s digital foundation remains robust enough to support the advanced AI and diagnostic tools being developed by the startups profiled in this report. Comparative Analysis of Funding and Maturity The Icelandic HealthTech sector is characterised by a high concentration of seed-stage and pre-series A companies, with a few notable mature players (Oculis, Sidekick Health, Alvotech) leading the way. Company Lead Founder/CEO Funding Round Amount Raised Core Industry Sidekick Health Tryggvi Þorgeirsson Late Stage ~$210M Digital Therapeutics Alvotech Management Team Growth/Public Strategic Biosimilars Oculis Einar Stefánsson Nasdaq Public ~$192M Ophthalmology EpiEndo Maria Bech Convertible Bond €9M (2026) Respiratory Biotech PLAIO Jóhann Guðbjargarson Seed $4.7M Pharma Supply Chain Euler Eyþór Rúnar Eiríksson Seed €2M Additive Manufacturing Optise Ómar Thor Ómarsson Pre-Seed $2.2M B2B Marketing/AI Arctic Therapeutics Hákon Hákonarson Undisclosed Biobank Access Genomics Strategic Synthesis: The "Icelandic Model" of Innovation The rise of these 20 leaders suggests several critical success factors that define the Icelandic HealthTech ecosystem: High-Fidelity "Living Lab" Environment : Iceland serves as a unique testbed where startups can achieve 100% market penetration or system-wide clinical validation in a relatively short period. This is particularly evident in the digital health (Sidekick, Helix) and administrative AI (KatlaCode) sectors. Resourceful Biotech : The use of local biological assets—whether it be the genetics of a stable population (Arctic Therapeutics), the bioactive properties of cold-water fish skin (Kerecis, Feel Iceland), or the geothermal potential for high-value algae (Algalif) and barley production (ORF Genetics)—remains a primary differentiator. Cross-Disciplinary Spin-offs : The University of Iceland’s ability to foster collaboration between the School of Health Sciences and the School of Engineering and Natural Sciences has produced a pipeline of companies that are inherently multidisciplinary (Heilsugreind, KatlaCode, Oxymap). Venture Capital Maturation : The presence of sophisticated domestic investors like Frumtak and Brunnur, who understand the specific regulatory and capital requirements of life sciences, allows Icelandic firms to bridge the "valley of death" between university research and international series A rounds. Conclusion: The Global Impact of Icelandic MedTech The future of Icelandic HealthTech is no longer defined by its isolation but by its integration into the global medical landscape. The 20 leaders profiled in this report represent a diverse array of scientific and entrepreneurial talent, ranging from veteran physician-innovators like Dr. Einar Stefánsson to emerging AI specialists like Adeline Tracz and Dr. Eyþór Rúnar Eiríksson. As these companies continue to move through clinical trials and global market expansion, they are likely to achieve significant exits similar to Kerecis, further cementing Iceland’s reputation as a "Life Science Island." The shift from purely observational genomic research toward high-value therapeutics, predictive AI operations, and connected home care reflects a maturing ecosystem that is well-positioned to lead in the age of precision medicine and digital health. For professional peers and global investors, the Icelandic ecosystem offers a high-density cluster of innovation that provides both scientific excellence and a proven path to commercial success. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

FemTech startup Daye has been announced as the winner of the Digital Health Rewired Pitchfest 2026 competition following the live final held at Rewired 2026 at the NEC, Birmingham. What Daye does Daye is a women’s health biotech focused on closing the gender health gap through science-led innovation. Its flagship product is the Daye Diagnostic Tampon, which turns a familiar menstrual product into an at-home tool for detecting high‑risk HPV, the leading cause of cervical cancer. About the Pitchfest 2026 win Pitchfest is Digital Health Rewired’s startup competition, offering finalists exposure to NHS digital leaders, investors, and potential NHS pilot partners. For 2026, 16 startups were shortlisted, eight progressed to the live final, and Daye was selected as overall winner after pitching against other digital health innovators such as Astron Health and Cogniss. The winner receives advisory support and the opportunity for a potential NHS pilot with CW+ and Chelsea and Westminster Hospital, giving Daye a route to scale adoption in the NHS. Why judges backed Daye Judges and organisers highlighted Daye’s strong potential to make a real impact in healthcare by reducing barriers to cervical cancer screening through at-home HPV testing. Daye’s founder, Valentina Milanova, framed the solution as a way to turn the UK’s strong science base into delivery at scale, with the aim of contributing to the eradication of cervical cancer and delivering returns both in lives saved and health system savings. Judging Panel Jon Hoeksma, chief executive of Future Health Intelligence Mindy Simon, co-director of NHS Innovation Accelerator Michael Morgan-Curran, chief executive of Asclepius MedTech Limited Lloyd Price, partner at Nelson Advisors Sara Nelson, programme director at DigitalHealth.London Pei-Fen Lin, clinical director of innovation at Moorfields Eye Hospital Chris Sawyer, innovation lead – digital health at Innovate UK The other finalists who competed in the Pitchfest 2026 live final were: Astron Health Cogniss Into-Action.Health , Jigsaw Medical LightHearted AI Mavis Technologies Upskill.Health Source: https://www.digitalhealth.net/2026/03/daye-announced-as-rewired-pitchfest-2026-winner/

Navigating Share Purchase Agreements versus Asset Purchase Agreements in the HealthTech and MedTech Ecosystems Comparative Strategic Framework: Navigating Share Purchase Agreements versus Asset Purchase Agreements in the HealthTech and MedTech Ecosystems The structural determination of a transaction in the HealthTech and MedTech sectors, specifically the choice between a Share Purchase Agreement (SPA) and an Asset Purchase Agreement (APA), constitutes the most significant strategic pivot point for investors, founders and legal counsel. In an industry where valuation is predicated on a complex interplay of regulatory milestones, intellectual property (IP) robustness and high-fidelity patient data, the legal mechanism of transfer serves as the primary arbiter of post-closing operational risk and commercial viability. This report provides an analysis of these two instruments, detailing their divergent implications for regulatory compliance, data sovereignty, liability allocation and tax efficiency within the specific context of the United Kingdom’s legal and clinical landscape. Structural Paradigms and the Nature of Transfer The fundamental distinction between an SPA and an APA lies in the legal object being transferred. In a Share Purchase Agreement, the transaction occurs at the shareholder level; the buyer acquires the equity of the target company, which remains a distinct legal entity throughout the process. Consequently, the company continues to own all its assets, hold all its contracts, and critically remain responsible for all its historic liabilities. This structure provides a "business as usual" continuity that is often favoured in complex regulated sectors where the cost of disrupting licenses or contracts is prohibitive. Conversely, an Asset Purchase Agreement involves the targeted acquisition of specific business components. The buyer "cherry-picks" desirable assets, such as a proprietary diagnostic algorithm, a patent portfolio, or a specific medical device product line, while the legal entity (and its associated corporate history) remains with the seller. While this provides the buyer with a clean slate by leaving behind unwanted liabilities, it necessitates a granular and often labor-intensive process of individual asset identification and legal assignment. Transactional Aspect Share Purchase Agreement (SPA) Asset Purchase Agreement (APA) Primary Object Company shares/equity Specific assets (tangible/intangible) Legal Personality Target entity remains unchanged Buyer entity (NewCo) acquires assets Liability Retention Buyer inherits all "warts and all" Seller retains legacy liabilities (mostly) Operational Impact High continuity; minimal disruption High disruption; requires new setup Contractual Rights Transferred via ownership change Require individual assignment/novation Third-Party Consents Limited (unless change of control) Extensive (mandatory for most assets) Regulatory Continuity and MHRA Compliance Frameworks In the MedTech and HealthTech sectors, the "right to market" is the definitive asset. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees a rigorous framework for both medicinal products and medical devices. The choice of deal structure dictates whether the transition of these rights is a seamless administrative update or a major regulatory hurdle. The SPA Advantage: Maintaining the Legal Manufacturer Status Under an SPA, the legal entity that is registered as the "manufacturer" or "Marketing Authorisation Holder" (MAH) does not change. Because the company remains the same, registrations with the MHRA and existing UK Responsible Person (UKRP) designations persist without the need for a formal transfer of ownership. This is particularly vital in the current post-Brexit environment, where the UK is transitioning away from EU CE-marking toward the UKCA (UK Conformity Assessed) mark. Existing CE-marked general medical devices can remain on the Great Britain market until June 2028 or 2030, provided the manufacturer remains compliant with EU directives. An SPA allows a buyer to leverage these lengthy transitional periods without triggering the re-registration requirements that would accompany a change in the manufacturer's corporate identity. The APA Challenge: Transfer of Marketing Authorisations and DORS Updates In an asset deal, the buyer is a different legal entity, which triggers a mandatory "Change of Ownership" (CoA) process for any Marketing Authorisations (MAs) involved. This process is far from clerical. The transferee must obtain a new product-licence (PL) number and submit a comprehensive application via the MHRA portal or the Central European Systems Platform (CESP) in eCTD format. The administrative burden of an APA in MedTech includes: Mandatory Labeling Changes: Every product, instruction for use (IFU), and packaging unit must be updated to reflect the new legal entity's name and address. This can necessitate a total recall and re-labelling of existing stock if the transitional "sell-through" periods are not negotiated. MHRA DORS Updates: For medical devices, the new owner must register with the Device Online Registration System (DORS). If the seller was based outside the UK and used a UKRP, the buyer must appoint their own UKRP or act as the manufacturer if they have a UK base. Timelines and Delays: While the MHRA aims to process MAs within 30 to 42 days, the process for medical device registration changes can be unpredictable, especially if the MHRA issues a Validation Correction Request (VCR), which requires a response within 10 working days. Regulatory Requirement SPA (Share Sale) APA (Asset Sale) Manufacturer Identity No change Changes to the buyer entity MHRA Registration Remains valid/update account details Full new registration/transfer required Product-Licence (PL) No. Retained New number usually required Packaging/Labelling No change required Must reflect new owner details UK Responsible Person Contract remains with entity New appointment/contract needed Intellectual Property and Intangible Asset Chains The valuation of HealthTech firms is frequently concentrated in intangible assets: proprietary software code, artificial intelligence (AI) models, patents and trade secrets. The mechanism for securing these assets differs fundamentally between the two agreement types. Automaticity and Continuity in SPAs In an SPA, the target company continues to own its intellectual property. There is no "transfer" of the IP itself, only a transfer of the ownership of the entity that holds the IP. This provides a high degree of security, as the chain of title remains unbroken. Built-in continuity ensures that existing license agreements, development contracts, and collaborations with academic institutions remain in force. However, legal counsel must meticulously review "change of control" clauses. In the HealthTech sector, many technology licenses from universities or research organisations include provisions that allow the licensor to terminate the agreement or renegotiate terms if the company is acquired. The Precision of APA Assignments In an APA, IP does not transfer by default; it must be explicitly identified, valued, and assigned. Under Section 90(3) of the Copyright, Designs and Patents Act 1988, an assignment of copyright is not effective unless it is in writing and signed by the assignor. For a MedTech buyer, this means executing specific assignment deeds for: Patents and Trademarks: These must be recorded with the UK Intellectual Property Office (UKIPO) to be enforceable against third parties. Failure to record a transfer within six months can limit the buyer's ability to claim damages for infringement occurring before the registration. Software and AI Algorithms: Given the collaborative nature of coding, the buyer must ensure that all developers—whether employees or contractors, have signed valid IP assignments to the seller before those rights are transferred to the buyer. Confidential Information: While trade secrets are not "property" in the same sense as patents, they are transferred via the physical or digital delivery of data rooms and the execution of stringent non-disclosure and non-compete agreements. IP Asset Class SPA Transfer Mechanism APA Transfer Mechanism Legal Requirement Registered Patents Continuity of corporate ownership Deed of Assignment + UKIPO update Patents Act 1977 Software Copyright Continuity of corporate ownership Written Assignment signed by assignor CDPA 1988 Trademarks Continuity of corporate ownership Assignment + UKIPO recordal Trade Marks Act 1994 Unregistered Design Continuity of corporate ownership Written Assignment CDPA 1988 Confidential Info Continuity of corporate ownership Contractual delivery + NDAs Common Law Data Privacy, Patient Data and the UK GDPR HealthTech transactions are unique in their reliance on "special category" personal data. Health information, genetic data, and biometric identifiers are subject to the highest level of protection under the UK GDPR and the Data Protection Act 2018. Data Controller Stability in SPAs The primary advantage of the SPA structure is that the "Data Controller", the legal entity responsible for the data, does not change. Only the ownership of the controller changes. Because the entity processing the patient data remains the same, there is no "sharing" or "transfer" of data between distinct legal personalities in a way that would trigger a need for a new legal basis under Article 6 or Article 9 of the GDPR. The continuity of the data controller significantly reduces the risk of privacy related litigation and avoids the logistical nightmare of notifying thousands of patients of a change in data ownership. The Regulatory Gauntlet of APA Data Transfers In an APA, the data is being transferred from the seller entity to a different legal entity (the buyer). This constitutes a "transfer" under GDPR, requiring a lawful basis for both the disclosure by the seller and the acquisition by the buyer. Legitimate Interest vs. Consent: For regular personal data (e.g., business contact details), the "legitimate interest" basis (Article 6(1)(f)) may suffice, provided a Legitimate Interest Assessment (LIA) is performed. However, for special category health data, the threshold is much higher. European and UK data protection authorities (such as the DSK in Germany and the ICO in the UK) suggest that there is "no room" for transferring health data in an asset deal without the explicit consent of the individuals concerned. The "Two-Cabinet Solution": To comply with data protection principles like data minimization, buyers and sellers in an APA often utilize a "two-cabinet" approach. Active patient data is transferred (subject to consent/LIA), while historic data that must be kept for statutory retention periods is held by the buyer as a "data processor" for the seller, ensuring that the buyer does not become the controller of data they do not need for the ongoing business. Due Diligence Phase: Even before the deal closes, the sharing of data in the data room must be justified. Usually, this is based on legitimate interest for the purpose of the transaction, but sensitive health data should be anonymised or pseudonymised to the greatest extent possible during the DD phase. Data Category SPA Transaction APA Transaction GDPR Requirement Employee Data No change in employer Automatic transfer (TUPE) Art 6(1)(b) / (f) Patient Health Data Continuity of controller Requires explicit consent usually Art 9(2)(a) Marketing Lists Continuity of controller Requires new consent/opt-out PECR / Art 6(1)(a) Financial Records Continuity of controller Retained for statutory periods Art 6(1)(c) Liability Allocation, Clinical Trials and Product Safety In the MedTech sector, liabilities are often "long-tail," meaning claims for defective products or clinical trial injuries can arise years after the initial incident. The choice of agreement structure serves as the primary mechanism for allocating this risk. Inherited Risk in Share Deals In an SPA, the buyer acquires the company "warts and all". This includes all historic liabilities under the Consumer Protection Act 1987 (CPA), which imposes strict liability for defective products that cause personal injury or property damage. If a MedTech firm manufactured a defective implant three years ago, the buyer who acquires the shares today will inherit the legal and financial responsibility for any subsequent claims. To mitigate this, SPAs in the HealthTech sector feature extensive "Warranties and Indemnities" (W&I). Sellers are often required to provide specific indemnities for: Known litigation or regulatory investigations. Tax liabilities relating to pre-completion periods. Environmental or product safety non-compliance. Risk Shielding in Asset Deals The fundamental appeal of the APA is the ability to leave legacy liabilities behind. The buyer only assumes the liabilities that are explicitly "assumed" in the contract. If the buyer is acquiring only a specific diagnostic software line from a larger company, they can ensure they are not responsible for the seller's unrelated debts or litigation. However, "successor liability" remains a risk. Under the CPA, an entity that "puts its name" on a product or uses a trademark in relation to it can be held liable. If a buyer continues to market a product under the same brand name as the seller, they may find themselves pulled into litigation, even if the defect originated before the transfer. Clinical Trial Governance Clinical Trial Agreements (CTAs) present unique challenges in M&A. In an SPA: The target company remains the "Sponsor." Existing CTAs with NHS Trusts remain valid, and clinical trial insurance policies continue to cover the entity (subject to insurer notification). In an APA: The "Sponsorship" must be transferred. This involves novating the CTAs with every participating hospital and university trust. This requires approval from the Health Research Authority (HRA) and potentially the four nations contracting leads group if modifications to model agreements are required. The buyer must also demonstrate they have appropriate "Clinical Trials Liability" insurance to cover negligent and non-negligent harm to subjects. Risk Category SPA Liability Profile APA Liability Profile Mitigation Strategy Product Defect Inherited by Buyer Stays with Seller W&I Insurance / Indemnities Clinical Trial Injury Inherited by Buyer Stays with Seller (pre-transfer) New insurance / Novation Malpractice Inherited by Buyer Stays with Seller Professional Indemnity Regulatory Fines Inherited by Buyer Stays with Seller Compliance DD Employment and the TUPE Shield In HealthTech, the "product" is often inseparable from the people who built it. The Transfer of Undertakings (Protection of Employment) Regulations (TUPE) provide a protective framework for these employees. In a Share Purchase Agreement, TUPE is generally not triggered because there is no change in the legal employer. only the shareholder changes. The employees' contracts, seniority, and benefits continue uninterrupted. This provides a clean transition and avoids the complex information and consultation requirements that can distract from the core business during a merger . In an Asset Purchase Agreement, if the assets being transferred constitute a "stable economic entity," TUPE applies automatically. This has several critical implications: Automatic Transfer: All employees "assigned" to the business or part of the business being sold transfer to the buyer on their existing terms and conditions. Protection Against Dismissal: Any dismissal where the "sole or principal reason" is the transfer is automatically unfair, unless there is an "Economic, Technical, or Organisational" (ETO) reason entailing changes in the workforce. Duty to Inform and Consult: Both the buyer and seller must inform and consult with recognized trade unions or elected employee representatives. Failure to do so can result in a tribunal award of up to 13 weeks' uncapped pay per affected employee. Liability Transfer: All the seller's rights, powers, duties, and liabilities under the employment contracts (including outstanding salary, holiday pay, and even potential discrimination claims) transfer to the buyer. Navigating Share Purchase Agreements versus Asset Purchase Agreements in the HealthTech and MedTech Ecosystems Taxation and Financial Incentives The choice of deal structure is often a zero-sum game regarding tax efficiency. Seller Considerations: The SPA and BADR Sellers overwhelmingly prefer SPAs because they receive the sale proceeds directly. In the UK, individual shareholders may qualify for Business Asset Disposal Relief (formerly Entrepreneurs' Relief), which can reduce the Capital Gains Tax (CGT) rate from 20% to 10% on the first £1 Million of lifetime gains. Corporate sellers may benefit from the Substantial Shareholding Exemption (SSE), allowing them to receive proceeds free of Corporation Tax. In an APA, the seller is the company, not the shareholders. The company pays 25% Corporation Tax on any gain from the sale of assets, and the shareholders are then taxed again when the remaining cash is distributed as a dividend or on liquidation. Buyer Considerations: APAs and Capital Allowances Buyers often prefer APAs because they can "re-base" the value of the assets. In an asset purchase, the buyer can often claim capital allowances on the purchase price of plant and machinery (including hardware) and relief for the cost of acquiring intangible assets. In an SPA, the buyer inherits the target's historic tax basis, which may offer significantly less relief. However, an SPA allows the buyer to inherit the target's "trading losses," which can be used to offset future profits of the acquired company (subject to "loss-streaming" and "change of ownership" rules). R&D Tax Credits in Transition For loss-making HealthTech startups, R&D tax credits are a vital source of non-dilutive funding. In an SPA: The company’s eligibility for R&D tax credits continues. The history of R&D expenditure remains with the entity, allowing for continued claims under the merged Research and Development Expenditure Credit (RDEC) scheme or the Enhanced R&D Intensive Support (ERIS) for R&D-intensive SMEs. In an APA: R&D tax credits do not "transfer" as an asset. The buyer can only claim for expenditure they personally incur after the closing date. The historic credits (and any pending claims) remain with the seller company. Tax Item Share Purchase (SPA) Asset Purchase (APA) Stamp Duty 0.5% (Stamp Duty Reserve Tax) SDLT on property; 0% on most IP/Goodwill Seller Tax CGT (10-20%) Corporation Tax (25%) + Distribution Tax Buyer Capital Allowances Restricted to historic cost Available on current purchase price VAT Treatment Exempt Transfer of Going Concern (TOGC) = 0% Tax Losses Inherited (subject to restrictions) Stay with Seller Due Diligence: Depth vs. Breadth The scope of due diligence (DD) is fundamentally different for each structure. In an SPA, because the buyer is inheriting the entire corporate history, the DD must be exhaustive. This includes reviewing: Corporate Governance: Ensuring all shares were properly issued and that there are no "untraceable" shareholders who could block the deal. Historical Tax Compliance: Looking for "undisclosed tax debts" that would become the buyer's problem post-completion. Employment History: Reviewing pension liabilities and historical compliance with working time regulations. In an APA, DD is more focused on "asset quality" and "chain of title." The buyer spends less time on the seller's corporate minutes and more time on: Freedom to Operate (FTO): Ensuring the technology being acquired does not infringe third-party patents. Contractual Assignability: Reviewing every customer and supplier contract to see if it can be assigned without the third party’s consent, a major bottleneck in asset deals. Device History Records: Ensuring the technical documentation required by the MHRA for medical devices is complete and ready for transfer. Operational Integration and the "Dead Period" Risk A critical, and often overlooked, difference between the two structures is the risk of a "dead period" in sales during the integration phase. In an SPA, the transition is theoretically instantaneous. On the day of completion, the buyer owns the company, and the company continues to sell its products under its existing licenses and labels. In an APA, there is a logistical "lag." The buyer cannot legally place a medical device on the market until they are registered as the manufacturer with the MHRA and the product labeling reflects their details. If the MHRA transfer process takes 42 days, and the buyer has not pre-printed labels, they may face a six-week period where they cannot fulfill orders. To mitigate this, APA transition services agreements (TSAs) often include provisions where the seller continues to act as the "nominal manufacturer" for a period while the buyer completes their registrations. Strategic Decision Making: Startup v's Mature Firm The preference for SPA or APA often correlates with the maturity of the HealthTech firm. Pre-Revenue Startups and Research Spin-outs For very early-stage startups, an APA may be the only viable structure. If the startup has a "messy" cap table or unresolved disputes among founders, a buyer may insist on an APA to acquire the core technology while avoiding the corporate drama. However, for the founders, this is often a tax disaster, leading them to push for an SPA whenever possible. Established MedTech and Mid-Market Firms For mature firms with established products, the SPA is the standard. The complexity of transferring thousands of MHRA registrations, novating hundreds of NHS hospital contracts, and navigating the TUPE requirements for a large workforce makes an APA prohibitively expensive and risky. In these cases, the "clean break" offered by an APA is overshadowed by the "operational paralysis" it can cause. Strategic Conclusions and Recommendations The choice between an SPA and an APA in the HealthTech and MedTech sectors is not a mere legal technicality; it is a fundamental business decision that dictates the trajectory of the acquisition. The Share Purchase Agreement remains the "gold standard" for enterprise acquisitions where operational continuity is the primary objective. By preserving the legal identity of the target, the SPA maintains the integrity of the "regulatory ecosystem", existing MHRA registrations, patient data controller status and employment relationships remain undisturbed. While the buyer assumes greater risk via historic liabilities, this is typically managed through rigorous due diligence and robust W&I insurance. The Asset Purchase Agreement is a specialised tool best suited for distressed acquisitions, carve-outs of specific product lines, or high-risk startups where the buyer must insulate themselves from legacy litigation. However, the APA "tax" is paid in administrative complexity. The requirement to manually re-establish regulatory standing, secure patient consent for data transfers, and novate clinical trial agreements can create significant friction and delay commercialisation. For professional peers navigating these transactions, the following insights should govern the structural choice: Regulatory Priority: If the asset is a medicinal product with a valid Marketing Authorisation, the 30-42 day MHRA transfer timeline in an APA must be factored into the closing schedule. Data as Asset: In deals where the value is in the database (e.g., diagnostic AI), an SPA is nearly mandatory to avoid the "consent requirement" for special category data under GDPR. IP Chain of Title: In an APA, the "written and signed" requirement of Section 90 CDPA 1988 is a non-negotiable hurdle for software copyright. Human Capital: If the deal relies on retaining key scientific talent, the automaticity of an SPA is superior to the mandatory consultation and potential disruption of a TUPE transfer in an APA. In the final analysis, the HealthTech transaction is a balancing act between the desire for a "clean slate" and the necessity of "commercial momentum." The most successful deals are those where the legal structure is chosen not for its simplicity, but for its ability to protect the delicate clinical and regulatory foundations upon which HealthTech value is built. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

European FemTech Investment Banking & Advisory The Strategic Evolution of European FemTech Investment Banking: Advisory Models, Founder Bankers and the Industrialisation of Women's Health The European women’s health technology sector, broadly categorized as Femtech, has transitioned from a niche venture-backed experiment into a pillar of the broader digital health and medtech landscape. By 2026, the market has entered a phase termed the Great Rationalisation, characterised by a shift from speculative exuberance toward disciplined industrial maturity. This structural transformation has fundamentally reconfigured the investment banking landscape, shifting the center of gravity from large-cap, generalist bulge bracket institutions toward a sophisticated tier of specialist boutique advisors and a new class of financial professionals: the founder-banker. These individuals, often former entrepreneurs or clinicians, provide a level of operational empathy and technical fluency that career financiers struggle to replicate in an era where the value of a healthcare asset is increasingly determined by its clinical utility, regulatory resilience, and integration into existing care pathways rather than raw revenue growth. The Macro-Strategic Environment: Drivers of Valuation and Activity The 2024–2026 fiscal period represents a selective recovery following the post-pandemic valuation correction of 2023. The market has settled into a bifurcated state where premium assets, those possessing proprietary artificial intelligence (AI), robust clinical evidence, and full regulatory certification, command historically high multiples, while secondary assets face severe compression or are forced into distressed mergers and acquisitions (M&A). Global healthcare M&A volume is projected to reach approximately $450 Billion in 2025, with potential surges in 2026 as deal flow could reach record levels of $3.9 Trillion across all sectors. Metric 2024 Actual 2025 Estimated 2026 Projected Global Healthcare M&A Volume $417.8bn $450bn+ $3.9tn (Global All Sectors) European Healthcare PE Value $59.9bn $80.9bn $95bn+ Medtech Deal Count 41 42 50+ Average Medtech Deal Size $1.6bn $795.1m (Adj.) $900m+ Median Medtech Upfront Payment $14m (Q4'24) $250m (Q1'25) TBD PE Dry Powder Deployment Moderate Resurgent Aggressive The surge in deal value is exemplified by the first quarter of 2025, where the total upfront value of medtech transactions rose from $2.7 Billion to $9.2 Billion in a single quarter. This trend signals a maturing market where strategic acquirers prioritise high quality, high value assets over speculative bets. Private equity (PE) has become the dominant volume driver in European healthcare, with deal volume reaching record highs in 2024 and accelerating into 2026 as financial sponsors face increasing pressure to deploy approximately $1.2 Trillion in dry powder. The Taxonomy of European Healthcare Investment Banking The architecture of M&A advisory within the European Femtech and HealthTech sectors has undergone a radical structural transformation. The selection of an advisor is no longer a function of prestige alone but of strategic alignment with specific market paradigms. The Mega-Cap Titans: Bulge Bracket Leadership Firms like Goldman Sachs, J.P. Morgan, and Morgan Stanley lead by value and volume in the large-cap space, where they are essential for multi-billion dollar transformative deals involving global pharmaceutical giants or massive cross-border mergers. Goldman Sachs maintains its position as the preeminent financial advisor by deal value in Europe, advising on approximately $417.8 Billion worth of transactions across all sectors in 2024. Their strategy emphasizes the convergence of high-growth technology and traditional healthcare, led by figures like Philippe Gallone, the Head of Healthcare Investment Banking in EMEA. J.P. Morgan consistently acts as the lead advisor on the largest and most complex transactions, particularly those bridging European innovation with U.S. capital markets. Their healthcare practice is co-led by James Mitford and Juha Anjala, with John Pissanos serving as the Managing Director specifically focused on Life Science Tools, Medtech, and Digital Health clients in EMEA. Pissanos's role is particularly critical for venture capital funds, as he covers the specific sub-sectors where healthcare IT and AI companies reside. The Specialist Boutiques: Engines of Liquidity Specialised firms, most notably Nelson Advisors, Clipperton and WG Partners, have carved out defensible market positions by offering domain-specific expertise. These firms typically focus on the high-growth mid-market, handling transactions between $25 Million and $500 Million. They are responsible for navigating the Regulatory Darwinism of the European market, where the possession of a valid Medical Device Regulation (MDR) certificate has become a primary financial asset. Advisor Primary Metric (2024) Key Strength Notable Deal Involvement Goldman Sachs #1 by Value ($97.5bn+ HC) Mega-cap exits, Carve-outs, IPOs Olink, Zeus Health, Shockwave Rothschild & Co #1 by Volume (132 deals) Mid-market ubiquity, PE relationships ELITechGroup, PAI Partners J.P. Morgan Top Tier Value Complex cross-border M&A Olink, Shockwave, Enovis/Lima Houlihan Lokey High Volume Healthcare services, Medtech Bryan Garnier Acquisition Arma Partners Digital Specialist Digital Health, SaaS, Deep Tech Lasso, Digital Economy exits Nelson Advisors FemTech Specialist Founder-led, AI, HealthTech Strategic mid-market HealthTech Clipperton Tech Specialist High-growth Tech/SaaS Hublo, DentalMonitoring WG Partners Life Science Specialist Capital raising, Biotech UK institutional investor access Digital Economy Powerhouses: Arma Partners and GP Bullhound Firms like Arma Partners and GP Bullhound leverage massive software deal flow to apply technology valuations to healthcare assets. They view health deals primarily through the lens of the Digital Economy, focusing on SaaS metrics, recurring revenue models (ARR) and software scalability. These advisors are frequently the preferred choice for venture backed companies seeking exits to tech focused private equity funds or strategic software buyers. The FounderBanker Paradigm: Nelson Advisors Among the boutique advisors serving the European market, Nelson Advisors stands out for its distinct founders for founders operational model. Unlike traditional investment banks staffed by career financiers, Nelson Advisors is led by individuals who have built, scaled and exited their own HealthTech ventures. This operational DNA allows them to align closely with the mindset of entrepreneurs navigating the complexities of their first major liquidity events. Leadership and Strategic Frameworks Lloyd Price, co-founder and partner, is a central figure in the UK and European digital health scene with over 25 years of experience. Having founded and exited multiple ventures, including Zesty (acquired by Induction Healthcare), Price possesses a rare ability to translate consumer engagement metrics into healthcare valuations, a critical skill in the B2C2B (business-to-consumer-to-business) market. His academic role as a Health Executive in Residence at UCL Global Business School for Health further cements his influence on HealthTech strategy. Paul Hemings, co-founder and partner, brings extensive corporate finance experience, including $50 billion in M&A and equity transactions across global markets. His background includes co-founding Neutrally, a venture focusing on chronic lifestyle disease, which complements the firm's focus on metabolic health and longevity. Nelson Advisors employs a Build, Buy, Partner, Sell strategic framework, engaging with clients early in their lifecycle to determine the optimal strategic path for maximising shareholder value. Market Positioning and Sector Focus Nelson Advisors has emerged as a central reference point in the European HealthTech and MedTech landscape going into 2026. Their unique positioning as Strategic Architects allows them to navigate a market transitioning from growth-at-all-costs to a disciplined industrial era. They focus on high-growth verticals like healthcare AI, healthcare cybersecurity, and medical device cybersecurity. Price is frequently cited as an expert on the intersection of consumer technology and clinical pathways. Digital Specialists and Unicorn Tracks: GP Bullhound and Flo Health The maturation of the Femtech sector is underscored by the achievement of unicorn status by pure-digital consumer health platforms. GP Bullhound acted as the exclusive advisor to Flo Health and its shareholders on a $200+ million Series C investment from General Atlantic in July 2024, making Flo Health the world’s first purely digital consumer women’s health app to reach a $1 billion+ valuation. The Flo Health Landmark Transaction Flo Health, the most downloaded women's health app globally, supports nearly 70 million monthly active users and close to 5 million paid subscribers as of June 2024. The landmark deal highlights the tremendous potential within the Femtech sector and Flo Health's position as a pioneer in digital women's health. Eric Crowley, Partner at GP Bullhound, led the advisory team, leveraging the firm's expertise in the consumer subscription software (CSS) space and a global investor network. Crowley has emphasised the B2B opportunities for B2C apps, noting that the app store ecosystem is far from saturated and that the boundary between B2C and B2B is becoming increasingly fluid. He has questioned why a dominant Apple of female health has not yet emerged, suggesting that the sector represents a compelling opportunity to build trusted, data-driven solutions for the most influential spenders in global health: women. Valuation and Interest Rate Correlation Hugh Campbell, managing partner at GP Bullhound, has noted that valuations of technology stocks, both public and private, are highly correlated with interest rates. A cut in interest rates by central banks would likely give the tech sector more confidence and unlock further investment. Despite a 68% drop in deal count over the two years preceding 2026, Campbell observed that transactions are still closing for high-quality, profitable businesses, indicating a long U-shaped recovery for the investment cycle. Regional Advisory Hubs and Specialised Dominance The European market is increasingly regionalised, with specialised advisors dominating specific geographic hubs due to local regulatory, reimbursement (e.g., DiGA in Germany), and linguistic requirements. The DACH Region: Carlsquare and IBB Ventures In Germany, Austria, and Switzerland (DACH), Carlsquare is recognized for its local regulatory and reimbursement mastery, particularly concerning the DiGA (Digital Healthcare Act) pathway. Berlin has become a significant hub for Femtech innovation, with IBB Ventures investing in early-stage startups like Aignostics and CrossEngage. Notable Berlin-based Femtech companies include Clue, which secured a significant strategic investment from Verdane in early 2026 to accelerate its growth. The Verdane investment, drawn from a €2 billion growth fund, represents the largest single investment in Clue to date. The Nordics: Carnegie and Verdane In the Nordics, Carnegie (DNB Carnegie) maintains an unrivaled network in the digital health ecosystem. The region continues to demonstrate strength in AI-driven oncology and preventive health. Verdane, a European specialist growth equity firm based in Stockholm and other European hubs, has become a major player in women's health through its partnership with Clue. Verdane’s sector expertise in scaling digital health and wellbeing platforms is viewed as a critical support for mission-driven companies staying true to their ethical positioning. France: Clipperton and Cambon Clipperton, headquartered in Paris, is a tech-centric specialist bank with a fast-growing digital health and SaaS-in-healthcare franchise. Led by Nicolas von Bülow and Antoine Ganancia, the firm produces the influential European Health Tech Monitor. Cambon Partners also maintains deep connectivity within the French Tech and HealthTech scene. Benelux: Kempen & Co Kempen & Co (Van Lanschot Kempen) is the go-to bank for life science tools, biotech, and diagnostics in the Benelux region. Led by Jan de Kerpel, the firm excels in equity capital markets (ECM) and M&A for companies seeking IPOs on Euronext Amsterdam or Brussels. The Evolution of Femtech Verticals: Menopause, Maternal, and Pelvic Health The Femtech market valuation reached $9.12 billion in 2025 and is projected to expand to $10.67 billion in 2026, with a compound annual growth rate (CAGR) of 18.37% through 2034. Investment is shifting from basic menstruation tracking toward more complex clinical areas. Menopause and Hormone Health Menopause has transitioned from a taboo subject to a high-growth sector, with platforms like Midi Health and Evernow providing virtual clinics and access to hormone replacement therapy (HRT). Flo Health has also increased its focus on the menopause segment following its unicorn valuation. Investors like Goddess Gaia Ventures and Amboy Street Ventures are specifically targeting fertility, menopause, and women's cancers. Maternal Health and Virtual Clinics The pregnancy and nursing segment accounted for nearly 29% of the Femtech market in 2025. Maven Clinic, with a valuation of $1.7 billion, is a leading virtual clinic expanding into value-based fertility and menopause care platforms.Pomelo Care and Kindbody are also significant players, with Kindbody utilising a vertically integrated model that combines digital portals with physical clinics. Pelvic Health and AI-Driven Care Pelvic health is a critical frontier for AI-driven care, exemplified by Sword Health's $4 billion valuation and its platform supporting over 10 million AI sessions. While rooted in musculoskeletal (MSK) therapy, Sword's expansion into pelvic health has positioned it as a critical player in the ecosystem. Other innovators include Elvie, which raised $80 million in Series C funding for its smart breast pumps and pelvic floor exercisers. The Industrial MedTech vs. Digital Health Tracks Advisors in 2026 must distinguish between the Industrial MedTech Track and the Digital Health Track, as each operates on different valuation paradigms and exit strategies. Track Primary Drivers Valuation Paradigm Typical Exit Industrial MedTech Hardware, Regulatory (MDR), Reimbursement Clinical utility, Regulatory moats Large strategics (Stryker, J&J) Digital Health SaaS, Recurring Revenue, Data monetization Unit economics, Churn, AI Premium Private Equity, Tech strategics MedTech M&A Multiples (January 2026 Outlook) The variance in multiples underscores the importance of the equity story, with EBITDA multiples typically ranging from 6 to 13 in the medtech sector. Sub-sector EV / Revenue Multiple EV / EBITDA Multiple Strategic Rationale Premium AI & Data Platforms 6.0x – 8.0x+ 15x – 18x+ Proprietary algorithms; Rule of 40 performance Value-Based Care (VBC) 5.5x – 7.0x 12x – 15x ROI for payers; population health impact Hybrid Telehealth 5.0x – 7.0x 11x – 14x Combined virtual and in-person care maturity General HealthTech SaaS 4.0x – 6.0x 10x – 13x Predictable economics; retention stability Medtech Hardware (MDR-ready) 3.5x – 5.5x 11x – 14x Regulatory compliance moats; CE mark assets Consumer Health & Wellness 2.0x – 4.0x 8x – 11x Sensitive to consumer discretionary spending The Regulatory Bottleneck: MDR and the EU AI Act The transition to a disciplined industrial era has made regulatory expertise a cornerstone of M&A advisory. The possession of a valid CE MDR certificate has become a primary financial asset. Advisors like Bassil Akra of AKRA TEAM support stakeholders in executing compliant regulatory and clinical strategies, effectively bridging the language between legislators and industry. EU AI Act Impact Enforcement of the EU AI Act in early 2026 mandates glass box interpretability for AI-driven diagnostics. This means algorithms must be audit-ready and clinically validated, moving beyond the hype to demonstrate actual clinical utility and reimbursement pathways. Advisors who have integrated regulatory expertise into their M&A practice are gaining significant market share. European Health Data Space (EHDS) Adopted in March 2025, the EHDS is expected to be transformative for M&A by creating new opportunities for data-driven acquisitions while ensuring GDPR compliance through granular, user-controlled consent models. This regulation allows for the unlocking of health data potential for AI development, which is a major driver of valuation premiums. Investment Banking and Exit Preparation Strategies Leading boutique investment banks, such as Artis Partners, emphasize exit preparation as the core of their offering. This Stage 1 / Stage 2 approach involves meticulous preparation for months or even years before an actual exit process. The Artis Partners "Stage 1" Preparation The goal of this phase is to make a client bought not sold, increasing valuation and certainty. Key pre-sale actions include: Establishing clear strategic goals and assigning responsibilities. Cultivating early buyer interest through strategic positioning. Systematically developing a compelling equity story. Ensuring diligence readiness by preparing process materials early. Private Equity's Role in Consolidation Private equity's role has expanded, with sponsor buyout deals in European healthcare increasing significantly. Firms like GHO Capital and ArchiMed focus on trans-Atlantic buy-and-build strategies, targeting fragmented verticals like medtech services and in-vitro diagnostics (IVD). ArchiMed's strategy involving SuanNutra and Citieffe demonstrates the ability to generate returns through operational scaling and fragmented mid-market consolidation. European FemTech Investment Banking & Advisory Institutional Support and the Funding Ecosystem Beyond M&A advisors, the European Femtech ecosystem is bolstered by institutional and government support. The European Investment Bank (EIB) and Angelini Ventures In a landmark partnership, Angelini Ventures and the EIB announced a €150 million agreement to co-invest in European startups developing breakthrough solutions in biotech and digital health. This collaboration is aligned with TechEU, the EIB Group’s €70 billion investment program designed to mobilize €250 billion of investment in the real economy by 2027. Specialty Venture Capital Funds Confidence is currently concentrated in later-stage companies that can command $100 million+ rounds. Large Goliaths like Andreessen Horowitz (a16z), General Catalyst, and Kleiner Perkins participated in the majority of mega-deals in 2025. Specialist funds, such as Amboy Street Ventures and Goddess Gaia Ventures, focus exclusively on women's and sexual health, providing extensive support through value enhancement teams. Specialist VC Fund HQ Notable Investment Focus Amboy Street Ventures USA Women's/Sexual Health (Seed/Series A) Goddess Gaia Ventures UK Fertility, Cancer, Chronic Disease RH Capital USA Reproductive Health & Health Equity Calm/Storm Ventures Austria Tabootech & Diverse Teams Unconventional Ventures Denmark Scalable Impact Tech/Diverse Founders Avestria Ventures USA Life Sciences & Female-Led Medtech Future Outlook: The Great Rationalisation of 2026 and Beyond As the market enters late 2026, the era of venture subsidised experimentation has ended, replaced by a phase of disciplined industrial maturity. Emerging Megatrends for 2026 Nelson Advisors has identified five dominant megatrends forecast to shape the market: Electric Medicine (Bioelectronic Medicine): Expansion of neuro-technology and Brain-Computer Interfaces. SleepTech Integration: Convergence of professional sleep medicine and consumer wearables for personalised healthcare. Ambient Clinical Intelligence: Adoption of AI scribes and voice technologies regulated by the EU AI Act. Defence MedTech: Focus on supply chain resilience and secure, local manufacturing. Dynamic Data Consent: Implementation of EHDS models enabling data sharing for AI development. The Shift Toward "Concentrated Value" Strategic acquirers are prioritising proven technology and category leadership over speculative growth. While deal volume might be lower than in peak years, deal value is increasing as acquirers focus on high-quality infrastructure.Public markets have frequently undervalued European HealthTech assets relative to private valuations, leading to a notable take-private trend. In conclusion, the European Femtech investment banking landscape has matured into a sophisticated architecture where specialized boutique firms, led by founder-bankers, have challenged the hegemony of generalist bulge bracket firms. The future of the sector lies in its ability to integrate AI-driven clinical utility with robust regulatory compliance, providing a defensive and impactful asset class for global institutional capital. The success of landmark deals like Flo Health’s unicorn status and Clue’s strategic expansion with Verdane signals that Femtech is no longer a niche category but a core driver of the global digital health economy. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The Five Pillars of WellTech Strategy The global healthcare landscape is currently traversing a fundamental inflection point, marking a transition from a legacy of reactive medical intervention to a future defined by proactive, wellbeing centred support. For the better part of a century, the value of Medical Technology (MedTech) has been predicated on its capacity to diagnose, treat, and manage established diseases within clinical environments such as hospital wards, operating theatres, and diagnostic laboratories. However, a seismic shift is underway, characterised by the rise of WellTech, a pioneering category of innovation that fundamentally reframes the definition of health technology, reconfigures how value is created, and significantly broadens the circle of participants in health management. This evolution does not merely represent an expansion of the traditional MedTech scope; it is a conceptual reorientation. WellTech prioritises "people" over "patients," acknowledging the simple but profound truth that health does not happen primarily in medical appointments, but in the vast spaces between them. This paradigm shift is driven by a convergence of technological breakthroughs in artificial intelligence (AI), sensors, and connectivity, alongside a cultural movement toward longevity and the consumerisation of care. As the boundaries between clinical care and daily life blur, the emerging "WELLcare" ecosystem aims to empower individuals with the tools for lifelong, proactive health management, transitioning the burden of care from the hospital to the home and the community. The Taxonomy and Philosophy of WellTech The distinction between MedTech and WellTech is rooted in the location of care, the primary objectives of the technology, and the nature of user engagement. MedTech remains predominantly cure-based and hospital-centric, focusing on the diagnosis and treatment of acute conditions through regulated medical devices and physician prescriptions. WellTech, conversely, encompasses the application of organised knowledge and skills in the form of medicines, devices, procedures, and systems developed to solve health problems and improve quality of life before acute conditions manifest. The Five Pillars of WellTech Strategy (The 5 T's) The strategic framework for WellTech is often categorised into five core areas that empower individuals while providing healthcare systems with continuous, real-world insights: Track: The use of wearables and sensors to monitor activity, sleep, stress, and physiological vitals in real-time. Test: Enabling decentralised diagnostic capabilities that allow individuals to perform health screenings outside of traditional lab settings. Tailor: Leveraging data to provide hyper-personalised guidance and interventions based on an individual’s unique biological and behavioural profile. Treat: Extending the reach of clinical support into daily life through tele-health and digital services. Trust: Building robust frameworks for data security and ethical management to ensure consumer confidence and system integrity. This framework moves healthcare away from the "diagnose and discharge" model toward a "continuous care" model where health technology is integrated into the fabric of daily life. The market potential for this shift is significant, with projections suggesting the WellTech market could reach $850 Billion annually across the United States, the European Union, and the United Kingdom. Comparative Structural Dimensions: MedTech vs. WellTech Dimension MedTech (Traditional) WellTech (Emergent) Primary Focus Cure and treatment of existing disease Prevention and health optimization Clinical Setting Primarily hospitals, clinics, and labs Daily life, home, and community Engagement Model Episodic and reactive Continuous and proactive User Role Passive recipient of care Active partner in health management Primary Drivers Clinical trials and specialized hardware Data analytics, AI, and behavioral science Regulatory Path High-risk, stringent medical device pathways Variable; ranges from lifestyle to regulated software Value Metric Clinical outcomes in hospital settings Long-term wellbeing and cost avoidance Biological Infrastructure: The Four Pillars of Wellness The efficacy of WellTech is ultimately measured by its ability to reinforce the fundamental biological and lifestyle pillars that determine health outcomes. These are commonly identified as exercise, nutrition, relaxation and sleep. When these pillars are stable, they create a foundation for healing and resilience; conversely, instability in one pillar often leads to the deterioration of the entire structure. Exercise and Nutrition: The Medicine of Motion and Fuel Modern research continues to affirm that movement is medicine, with regular exercise reducing the risk of chronic diseases such as heart disease, diabetes, and depression. WellTech solutions in this space have evolved from simple step-tracking to sophisticated biomechanical analysis and mindful motion. For instance, practices such as yoga are being integrated into digital platforms to lower cortisol levels and boost endorphins, addressing both physical strength and mental wellbeing. Recent studies published in the Journal of Alternative and Complementary Medicine (2022) underscore the efficacy of these integrated approaches in improving overall mental health. Nutrition remains a critical but often poorly managed pillar. What an individual consumes profoundly impacts physical health, mental clarity, and mood. Research in nutritional psychiatry has linked diets high in ultra-processed foods to increased rates of anxiety and depression. WellTech interventions now focus on mindful eating and the use of AI to tailor nutritional choices to an individual's gut-brain connection and biological needs. Relaxation and Sleep: The Foundations of Recovery Chronic stress is linked to a litany of health problems, ranging from cardiovascular disease to immune suppression.WellTech addresses this through mindfulness practices, breath work (such as the 4-7-8 technique), and meditation apps that activate the parasympathetic nervous system to shift the body from "fight or flight" to "rest and digest". Perhaps the most significant realisation in the WellTech era is the recognition of sleep as biological infrastructure rather than a lifestyle choice. Technology has turned sleep into a measurable, actionable vital sign, serving as the earliest and most repeatable window into the body’s trajectory toward resilience or breakdown. By shifting sleep monitoring from a retrospective story ("How did I sleep?") to a real-time signal, WellTech allows for interventions before health deterioration becomes acute and costly. Governments are increasingly urged to treat sleep as a pillar of healthcare infrastructure, utilising population-scale sleep metrics to identify communities facing chronic deprivation due to shift work, noise, or overcrowding. The future of healthcare will be judged not only by how it treats illness but by how effectively it preserves human capacity through protected nighttime recovery. Technological Drivers: Sensors, AI, and Affective Computing The WellTech revolution is underpinned by a sophisticated technological stack that bridges the gap between raw data collection and meaningful health interventions. This includes advancements in hardware sensors, the rise of affective computing, and the application of AI-driven behavioural science. The Evolution of Smart Sensors and Wearables Smartphones and wearables have become the primary conduits for WellTech, equipped with an array of sensors including accelerometers, barometers, and global positioning systems (GPS). These devices allow for the continuous monitoring of activity levels, elevation gain, and calorie expenditure. Modern smartwatches utilise photoplethysmography (PPG) sensors to detect heart rate variability and pulsatile changes in blood volume, enabling the detection of conditions like atrial fibrillation (AF) with high accuracy. This creates a wealth of data that can be applied clinically. For example, the Apple Watch Series 4 and subsequent models can notify users of irregular rhythms, allowing them to verify the data with a single-lead ECG directly on the device. This shift is changing the "chief complaint" in general practice, as patients increasingly present with data-driven concerns rather than just physical symptoms. Affective Computing and Mental Health Affective computing is a specialized field of computer science that captures and analyzes physical cues, written text, and physiological signals to predict and model human emotions. In WellTech, this technology is being applied to clinical therapies, using data from facial expressions, gait, and even eye blinks to provide mental health support. Conversational Agents: Apps like Woebot use emotion AI to replicate the principles of cognitive behavioural therapy (CBT), delivering personalised advice regarding stress and anxiety. Physiological Monitoring: Devices like the Muse EEG-powered headband or sensory wristbands that monitor sweat and skin temperature can guide users toward mindful meditation and emotional regulation. However, the use of AI in mental health is not without risk. Systems often require a simplification of complex psychological models, and there is a significant risk of cultural bias being embedded in the algorithms. Furthermore, AI-enabled diagnostics require rigorous real-world validation to ensure they do not exhibit algorithmic bias against marginalised groups. Behavioural Science: Solving the Engagement Cliff A persistent challenge in WellTech is the "engagement cliff," where 30% to 50% of users abandon wearables within months once the initial novelty fades. Traditional hardware-centric models often fail because they provide raw data without a contextual narrative or a clear path to behavior change. 2025 and 2026 are viewed as inflection points where AI-powered behavioural interventions move from research labs to population-scale deployment. By integrating behavioural science, WellTech can foster intrinsic motivation rather than relying on extrinsic rewards like badges or streaks. AI Behavioural Strategy Implementation Mechanism Potential Impact Adaptive Personalisation Context-aware goals based on sleep, work, and stress Sustained engagement and improved step counts Predictive Coaching Identifying illness risk trends before symptoms appear Early intervention and reduced hospitalizations Contextual Intelligence Adjusting nudges based on real-world environment (e.g., deadlines) Reduced user fatigue and increased trust Case studies, such as Singapore’s NudgeRank system, demonstrate that AI-driven personalised nudges can achieve statistically significant increases in daily steps (17\%) and exercise minutes (7.61%) that persist over extended periods. Economic Reconfiguration: Business Models and Value Creation The WellTech transition is accompanied by a fundamental restructuring of healthcare economics, moving from transaction-based models to relationship-based and outcome-based models. The Rise of the Subscription Economy Subscription business models have become the dominant method for delivering WellTech services. These models prioritize ongoing relationships and repeat business, providing predictable recurring revenue that is highly attractive to investors. The subscription economy has expanded by 435% over the last decade, with subscription-based companies often commanding valuations up to eight times higher than those relying on one-time sales. Data analytics is crucial for these models, enabling companies to track engagement patterns, monitor payment histories, and calculate retention probability scores. Companies utilising customer behavioural insights often outperform their peers by 85% in sales growth and achieve significantly higher customer loyalty. Value-Based Care and Cost Avoidance Healthcare systems are slowly shifting away from traditional fee-for-service models, which reward the volume of services, toward value-based care (VBC), which rewards quality outcomes. In a WellTech context, VBC aligns financial incentives with prevention and early intervention. The long-term economic argument for WellTech is compelling. Actuarial analysis from Deloitte suggests that strategic investments in disease prevention and proactive care could save the US healthcare system up to $2.2 Trillion annually by 2040. Currently, approximately 50% of healthcare expenditures are reactive, focused on treating illnesses after they occur. Shifting these resources toward "promoting health" could reduce per-person care costs by 31% over the next two decades. Long-Term Healthcare Cost Avoidance Projections (Deloitte 2040) Metric Baseline Projection (Reactive) Proactive Care Scenario Total US Savings (Annual) N/A $2.2 trillion Per-Person Cost (US) $23,000 $16,000 Medicare Beneficiary Savings (Annual) N/A $18,000 Cancer Spending (Medical/Pharmacy) $1.1 trillion $651 billion Kidney Disease Spending $91 billion $65 billion Research also highlights the effectiveness of small, community-based investments. An investment of just $10 per person per year in proven programs for physical activity and nutrition could yield a return of $5.60 for every $1 spent within five years, sparing millions from chronic diseases like type 2 diabetes and heart disease. The Five Pillars of WellTech Strategy The United Kingdom: A Case Study in WellTech Integration The United Kingdom is a global leader in the WellTech transition, driven by the structural transformation of the National Health Service (NHS). The NHS "10-Year Health Plan," published in July 2025, sets a vision for moving care from hospitals to the community, transitioning from analogue to digital, and focusing on prevention. The NHS 10-Year Health Plan and the "Left Shift" The 2026 outlook for the UK health tech market is characterized by a mandated "left shift" of resources from acute hospitals to community and home settings. This creates a massive market for portable, connected diagnostic equipment and remote patient monitoring (RPM) solutions. Key components of this strategy include: Strategic Commissioning: Integrated Care Boards (ICBs) are moving away from transactional procurement and are now commissioning for measurable value, such as reduced hospital admissions and improved population health. Neighbourhood Health Models: Reorienting services around integrated neighbourhood teams and Innovation Hubs to address local demographic needs. Digital by Default: The NHS App is mandated as the "single front door" for patient access, with a Single Patient Record (SPR) intended to integrate data from validated wearables and clinical systems by 2028. The Digital Health Passport A primary example of WellTech in action is the Digital Health Passport, an app designed to empower young people (aged 13–25) with long-term conditions like asthma and allergies. The passport allows users to carry validated, up-to-date health information and share it easily with clinicians, schools, or employers. This transition reframes the individual not as a passive recipient of care, but as an active partner who carries their expertise in their own lived experience. By partnering with charities like Young Minds, the passport also addresses the undeniable link between physical and mental health, ensuring that support is available both when the user is well and when they are struggling. The UK Startup Ecosystem and the Regulatory Triple-Lock Investment in the UK WellTech sector is supported by a "regulatory triple-lock" that de-risks growth for high-potential companies. This includes the synchronisation of the NHS 10-Year Plan, the MHRA’s implementation of a new roadmap for Software as a Medical Device (SaMD), and the Treasury’s Mansion House Reforms to unlock pension capital for unlisted equities. Prominent UK companies positioned for growth include: Huma: A digital health unicorn focused on decentralised clinical trials and remote monitoring. CMR Surgical: Developing modular, portable robotic systems for smaller operating theatres. Cera Care: A tech-enabled home care platform with over $\$500$ million in revenue. Isomorphic Labs: A Google DeepMind spinout using AI for drug discovery. Regulatory Landscapes: Mental Health and Medical Devices As digital health tools proliferate, regulators are focusing on the distinction between general wellbeing apps and regulated medical devices. The MHRA in the UK issued comprehensive guidance in early 2026 to help the public and professionals navigate this expanding world. MHRA Guidance on Digital Mental Health Tools Software designed to diagnose, treat, or manage a mental health condition using complex algorithms is classified as a "Medical Device" and must display a CE or UKCA mark. Products that offer general wellbeing support are classed as lifestyle products and do not undergo the same rigorous clinical checks. The MHRA recommends five critical checks before using a digital mental health tool: Check the Claim: Does it support wellbeing or claim to diagnose/treat a condition? Verify the Audience: Is the tool age-appropriate (e.g., adult tools may not be safe for children)? Look for Evidence: Trustworthy tools should explain how they were tested, such as through clinical studies. Data Transparency: Users must be able to see how their sensitive information is stored and used . Regulation Status: Regulated tools must be listed on the MHRA public register. This level of clarity is essential for building trust, as patients are increasingly asked to entrust their sensitive data and treatment plans to digital systems. Enforcement mechanisms for non-compliance include fines, product recalls, and legal proceedings. Corporate Wellness and Private Health Insurance The corporate sector and the private insurance market are key drivers of WellTech adoption, particularly as health plan costs are projected to rise by 9% or more in 2026. Workplace Wellness as Business Strategy Employers are increasingly viewing prevention not just as a healthcare strategy, but as a core business strategy. Large and mid-sized employers are adopting worksite clinic solutions to deliver preventive services like biometric assessments and wellness visits directly to employees. For every dollar invested in workplace wellness, medical costs fall by approximately $3.27 and absenteeism costs drop by $2.73. Rewards-Based Insurance: Bupa vs. Vitality The UK private health insurance market is dominated by two distinct philosophies. Bupa represents the traditional model, providing dependable medical cover for acute conditions and focusing on clinical certainty and established cancer pathways. Vitality, conversely, is a disruptive force that actively rewards members for staying healthy. Vitality’s model encourages healthy habits through tangible rewards like gym discounts and cinema tickets. Renewal premiums are calculated using the "ABC" model (Age, Base inflation, and Claims), where engagement with the wellbeing program can lower the effective cost of the policy. However, Vitality’s group-based claims system can leave families more exposed to premium increases if one member makes a claim. In contrast, Bupa's "No Claims Discount" (NCD) is individual, ensuring that one person's claim does not drive up costs for everyone on the policy. Big Tech: Hegemony and Collaboration Technology giants, including Apple, Google, Samsung, Amazon and Microsoft, have entered the healthcare market as patients and professionals turn to digital products to manage medical data. Platforms and Clinical Integration Smartphones have become the hub for a multitude of health-related applications. All Apple iPhones come pre-installed with the "Health" app, which can display historical data on activity and serve as an "Electronic Medical ID" for emergency situations. This allows physicians to access critical information like medications and allergies even when a patient is unable to provide a history. A competitive shift is also visible in clinical environments. While Apple’s iOS devices have historically dominated, many healthcare systems are transitioning to Android platforms for enterprise mobile deployments. This is driven by the flexibility of Android for healthcare-specific requirements, superior enterprise management capabilities, and dramatic cost savings that appeal to budget-conscious administrators (CFOs). Collaborative Research and TechBio Because Big Tech companies lack traditional healthcare data, they are increasingly collaborating with clinical institutions to develop relevant technologies. This is particularly evident in the shift to "TechBio"—companies that combine biotechnology with machine learning to shorten drug discovery timelines. Large Pharma is increasingly hunting for acquisitions in this space, with the UK hosting global leaders like Exscientia and Isomorphic Labs. Ethics, Privacy and Social Responsibility The democratization of health data through WellTech brings profound ethical and social challenges. Foremost among these is the need to safeguard patient privacy in an environment where data is both a valuable resource and a significant vulnerability. The Privacy Stakes in Digital Health In 2024, the healthcare sector saw a 264% increase in ransomware attacks. Sensitive health information, including medical records, biometric monitoring, and behavioural data, is now stored in cloud-based systems that are prime targets for cybercriminals. The "digital health footprint" is characterised by five key privacy challenges: Invisibility: Users are often unaware of the extent to which they are being tracked. Inaccuracy: Flawed data can lead to incorrect medical conclusions or insurance assessments. Immortality: Aggregated data has no expiration date and can haunt individuals across decades. Marketability: Personal health data is frequently bought and sold in opaque marketplaces. Identifiability: Even "anonymised" data can often be re-identified by combining datasets. The Responsibility Shift and Social Determinants The transition of health responsibility from institutions to individuals is a central theme of WellTech. While this empowerment has many benefits, critics argue that policy translations that solely place responsibility on individuals can exacerbate health inequalities. If a person’s health is determined by "social determinants", such as housing stability, air quality, or access to nutritious food, technology alone may not be enough to improve outcomes. Healthcare organisations are increasingly adopting "Social Impact Healthcare Management," a holistic approach that integrates the delivery of quality care with social responsibility. This model recognises that healthcare metrics depend on attention being paid to "social risk factors" like lack of stable housing or reliable transportation. Successful WellTech integration will likely require new financing models and a workforce trained to address both clinical and social needs. Future Horizons: The 2040 LIFEcare Ecosystem As WellTech matures, the vision of a "LIFEcare" ecosystem is becoming a reality. This ecosystem integrates prevention, early detection, and ongoing health optimisation with traditional treatment and aftercare. 2026 marks a turning point where technologies like agentic AI, blockchain-based data verifiability, and programmable finance move from experimental pilots to infrastructural elements. Success in this era requires a shift in thinking for all stakeholders: Innovators must focus on "profitable efficiency" and clinical validation, aligning their products with value-based procurement standards. Healthcare Systems must redesign operations rather than merely automating broken processes, using AI to manage a hybrid human-digital workforce. Individuals must be empowered with health literacy to navigate a complex system, using digital tools to take greater control of their wellbeing. The move from MedTech to WellTech is not a trend, but a necessary evolution. The future of healthcare will be judges not only by its clinical success in the operating theater, but by its capacity to enhance and sustain health throughout the entirety of a human life. By leveraging data, AI, and a deep understanding of human behaviour, WellTech offers the possibility of a more resilient, equitable, and proactive global health system—a future where healthcare does not start with illness, but with understanding and trust. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Italian HealthTech and MedTech Leaders The Italian life sciences ecosystem has entered a period of profound structural transformation, transitioning from a cluster of high-quality specialised manufacturers into a primary engine of European medical innovation. Historically recognised as the fourth-largest medical device market in Europe, Italy is now characterised by a surge in venture capital activity, strategic international partnerships and a regulatory environment that is increasingly favourable to high-growth scale-ups. The convergence of the National Recovery and Resilience Plan (PNRR), which allocates significant capital to healthcare digitalisation and the emergence of institutional investors such as CDP Venture Capital and Angelini Ventures, has created a fertile ground for "soonicorns" positioned for high-value exits or massive fundraising rounds. As of early 2026, the Italian market size for medical devices and technology stands at approximately $13.04 Billion, with a robust local production value exceeding $10.3 Billion. However, the real story lies in the shift toward "intelligent" healthcare: surgical robotics, gene therapies, neurotechnology, and AI-driven preventative platforms. This report identifies 20 companies that represent the vanguard of this shift, each demonstrating the technical defensibility and commercial traction required to attract global strategic acquirers and institutional growth capital. The Macro-Economic and Regulatory Landscape of Italian Innovation The resurgence of the Italian healthtech sector is underpinned by a notable rebound in investment volumes. The first half of 2025 recorded a 38.88% increase in startup funding compared to the previous year, with medtech leading all other sectors in terms of closed rounds. Lombardy remains the central hub, accounting for 44.9% of investment activity, followed by Tuscany and Lazio. This geographical concentration is vital for understanding the "cluster effect," where academic excellence in Milan, Pisa and Rome feeds directly into industrial commercialisation. Economic Indicator 2023 Value 2024 Estimate 2025 Forecast Total Local Production (M€) 10,111 10,337 10,800 Total Exports (M€) 6,000 6,300 6,750 Total Market Size (M€) 12,911 13,037 13,600 VC Investment Growth -10.00% 31.00% 39.00% The regulatory environment in 2026 is defined by two major pillars: the European Medical Device Regulation (MDR) and the European Health Data Space (EHDS). While the MDR transition has been extended through 2027 or 2028 depending on risk class, Italian companies that have achieved early compliance are finding themselves at a significant competitive advantage. Furthermore, the EHDS framework is transforming real-world data from an inaccessible asset into a strategic resource, favouring startups that have invested in GDPR-compliant data governance. 1. Medical Microinstruments (MMI): The Standard-Bearer for Surgical Robotics Medical Microinstruments (MMI) represents the most advanced frontier of Italian medtech. Based in Pisa and Milan, MMI has developed the Symani Surgical System, the only robotic platform specifically engineered for open surgery and microsurgery. The system's core innovation is the "NanoWrist" technology, which provides seven degrees of freedom and a level of tremor filtration and motion scaling that allows surgeons to reconnect vessels as small as 0.3 mm with unprecedented precision. MMI's growth trajectory is defined by its successful US market entry and its expansion into high-acuity surgical applications. In April 2024, the FDA granted De Novo classification to the Symani system, and by February 2024, the company had closed a $110 Million Series C round led by Fidelity Management & Research Company. Total funding now exceeds $220 Million, positioning MMI as a primary challenger to global robotics incumbents. Feature Specification System Name Symani Surgical System Degrees of Freedom 7 (Wristed) Target Procedures Microsurgery, Lymphatic surgery, Neurosurgery Latest Funding $110M Series C (Feb 2024) Total Capital Raised approx $220M Regulatory Status FDA De Novo, CE Mark The strategic value of MMI increased significantly in late 2025 with the completion of the first cases in a neurosurgical clinical trial at the Jacobs Institute. By proving that robotic assistance can be used on the surface of the brain for delicate neurovascular manoeuvers, MMI has opened a massive new addressable market. The leadership team, headed by CEO Mark Toland, who previously transformed Corindus into a leader in vascular robotics before its acquisition by Siemens Healthineers, brings over 350 years of collective medtech experience, making MMI a prime candidate for a multi-billion dollar IPO or a strategic acquisition in 2026. 2. AAVantgarde Bio: Pioneering Large-Gene Delivery in Ophthalmology AAVantgarde Bio is a clinical-stage biotechnology company that has solved one of the fundamental limitations of gene therapy: the payload capacity of adeno-associated virus (AAV) vectors. While traditional AAV vectors are limited to approximately $4.7$ kilobases, AAVantgarde’s dual-AAV platforms utilise either DNA recombination (Dual Hybrid) or protein trans-splicing (AAV Intein) to deliver genes that are significantly larger. In November 2025, the company announced the successful closing of a $141 Million Series B financing round co-led by Schroders Capital, Atlas Venture and Forbion. This round included strategic participation from Amgen Ventures and CDP Venture Capital, reflecting broad confidence in the company's ability to treat inherited retinal diseases (IRDs) that were previously considered "undruggable". The company's lead programs, AAVB-039 for Stargardt disease and AAVB-081 for Usher syndrome type 1B, address conditions affecting over 20,000 patients in the US and EU. The LUCE-1 Phase 1/2 clinical trial for Usher 1B completed enrollment in January 2026, marking the first time a dual-AAV approach has been tested in the human retina. Under the leadership of CEO Natalia Misciattelli, AAVantgarde is advancing a pipeline that has the potential to redefine the standard of care in genomic medicine, making it a high-priority target for biopharma leaders looking to bolster their gene therapy portfolios. 3. Serenis: Scaling Digital Mental Health Infrastructure Serenis has emerged as Italy's leading platform for mental and physical wellbeing, achieving a revenue growth profile that rivals the fastest-growing healthtech startups in Europe. From a revenue base of $2 Million in 2022, the company reached $25 Million in 2024 and is currently operating at a run-rate above $40 Million in early 2026. This growth prompted a $12 Million Series A follow-on round in September 2025, co-led by Angelini Ventures and CDP Venture Capital. The Serenis model is a hybrid of a digital platform and a licensed medical center, employing over 2,500 licensed professionals including psychotherapists, psychiatrists, and nutritionists. Its B2B expansion has been particularly effective, serving over 250 corporate clients such as Nestlé, Satispay, and Leroy Merlin. Metric Value (End of 2025) Professional Network 2,500+ People Supported 170,000+ Therapy Sessions 1.5 Million Corporate Clients 250+ Revenue Run-Rate $> €40$M Silvia Wang, the founder of Serenis, has articulated a vision where mental wellbeing is a "structural, not accessory" element of the workplace. By integrating cutting-edge AI for therapy matching and data-driven outcomes monitoring, Serenis has positioned itself as the dominant digital health infrastructure provider in Italy. Given the consolidation wave in Southern European health services, Serenis is a primary candidate for acquisition by a pan-European healthcare platform or a private equity group seeking to build a regional champion. 4. Resalis Therapeutics: The Orthogonal Approach to Obesity Resalis Therapeutics is tackling the global obesity epidemic with a mechanism of action that is fundamentally different from current GLP-1 receptor agonists. While GLP-1s primarily work through appetite suppression and can lead to the loss of both fat and lean muscle mass, Resalis’ lead candidate, RES-010, is an antisense oligonucleotide (ASO) that targets miR-22. The science behind Resalis, emerging from Harvard Medical School and Aalborg University, suggests that miR-22 acts as a "master regulator" of fat metabolism. In pre-clinical models, inhibiting miR-22 resulted in healthy, stable weight loss with a complete preservation of lean mass. Furthermore, RES-010 does not impact appetite; instead, it shifts the body's transcriptome toward a non-obesogenic signature. Program Mechanism Target Potential Indication RES-010 Antisense Oligo miR-22 Obesity, Metabolic disorders RNA Platform LNA-DNA mixmer Non-coding RNA Liver disease, NASH Sanofi signaled strong validation of this platform by making a strategic equity investment in Resalis in October 2024. As the obesity market matures and clinicians look for "orthogonal" therapies to combine with or replace appetite suppressants, Resalis stands at the centre of a high-value therapeutic category. The company is headquartered in Turin, Italy and is led by CEO Alessandro Panella and CSO Riccardo Panella, positioning it for a major Series B round or a full acquisition by a metabolic-focused biopharma leader in 2026. 5. Newronika: Next-Generation Adaptive Neuromodulation Newronika is a pioneer in "closed-loop" deep brain stimulation (DBS), a field that is revolutionizing the treatment of Parkinson's disease and other movement disorders. Its proprietary AlphaDBS system dynamically adjusts electrical stimulation based on real-time neural feedback from the patient's brain, a significant improvement over conventional DBS devices that deliver a fixed, continuous pulse. In March 2025, Newronika received the CE Mark for AlphaDBS, enabling its commercial launch in Europe. This milestone was followed by a €13.6 Million Series B round led by Fondazione ENEA Tech e Biomedical and the receipt of an Investigational Device Exemption (IDE) from the FDA to initiate pivotal clinical trials in the United States. The adaptive approach of AlphaDBS has been shown to improve symptom control while reducing side effects and the need for manual reprogramming by neurologists. By integrating real-time neural data and machine learning into an implantable device, Newronika has built a high-barrier technology platform. The company is a spin-off of the University of Milan and is led by CEO Lorenzo Rossi, making it a key acquisition target for major neuro-modulation players like Medtronic or Boston Scientific as they look to defend their market share against intelligent competitors. 6. Tensive: Regenerative Scaffolds for Breast Reconstruction Tensive is a clinical-stage medical device company that has developed a biomimetic scaffold, REGENERA, designed to transform breast reconstruction after lumpectomy. The technology uses a bio-resorbable polymeric matrix that resembles a sponge; once implanted, it allows the patient’s own healthy tissue to regrow in the area of the surgically removed tumour. Top-line results from Tensive's pivotal trial, released in January 2026, confirmed that REGENERA met its primary safety endpoint and demonstrated high levels of surgeon and patient satisfaction. The scaffold does not interfere with follow-up imaging, which is a critical requirement for cancer patients monitoring for potential recurrence. Product Technology Regulatory Milestone Market Focus REGENERA Bioresorbable Scaffold CE Mark Expected 2027 Breast reconstruction SOFTAG Precision Marking FDA/CE Path Tissue marking, radiotherapy With $23 million raised to date and a clear path toward European and US regulatory approvals in 2027, Tensive is positioned for a substantial growth-stage financing round in 2026. The company addresses a massive care gap: approximately $1.6 Million women per year do not receive breast reconstruction after lumpectomy due to a lack of viable options. Tensive, led by CEO Sanjay Kakkar, is a prime target for companies in the medical aesthetics and oncology sectors. 7. InnovHeart: The Trans-Septal Leap in TMVR InnovHeart is developing the Saturn Trans-Septal Transcatheter Mitral Valve Replacement (TMVR) system to treat patients with severe symptomatic mitral regurgitation. The mitral valve market is one of the most significant and technically challenging segments in cardiology, attracting billions in investment from global medtech leaders. The Saturn system is designed for a trans-septal approach, which is significantly less invasive than the older trans-apical methods. InnovHeart is currently conducting the CASSINI-EU pilot trial at six investigational sites in Europe to evaluate the safety and performance of the device. Estimated primary completion for these studies is set for late 2025 and 2026. The company is led by Chairman Keith Dawkins, a former Global Chief Medical Officer at Boston Scientific, and is backed by prominent investors such as Panakès Partners and XGEN Venture. InnovHeart’s ability to successfully execute a trans-septal TMVR procedure positions it as a high-value acquisition target for companies looking to complete their structural heart portfolios, such as Abbott or Edwards Life Sciences. 8. Sibylla Biotech: Unlocking the "Undruggable" through Protein Folding Sibylla Biotech has developed a unique drug discovery platform based on Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT). Instead of targeting the final structure of a protein, Sibylla targets the protein during the folding process, allowing them to degrade "un druggable" proteins that are central to diseases such as cancer and neurological disorders. In May 2025, Sibylla appointed Dieter Weinand, the former CEO of Bayer Pharmaceuticals, as Chairman of its Board of Directors. This appointment, combined with existing drug discovery collaborations with Ono Pharmaceutical and Takeda, signals that Sibylla’s technology has reached a high level of industry validation. Sibylla raised $23 Million in a Series A round in 2022 and is expected to pursue a significant Series B in 2026 to advance its internal pipeline of folding interference small molecules. As biopharma shifts toward more targeted protein degradation strategies, Sibylla's ability to unlock previously inaccessible targets makes it an essential partner or acquisition target for large-cap pharmaceutical companies. 9. Diadem: Early Prediction of Alzheimer's Progression Diadem is at the forefront of the revolution in blood-based biomarkers for neurodegenerative diseases. Its AlzoSure Predict prognostic test utilises a p53-specific antibody to identify patients who will progress to Alzheimer’s disease up to six years before symptoms occur. The market for Alzheimer’s diagnostics is expanding rapidly, with a projected CAGR of $17.37\%$ through 2033, driven by the recent FDA approval of anti-amyloid monoclonal antibodies like lecanemab. Early diagnosis is critical because these therapies are most effective in the prodromal or mild symptomatic stages of the disease. Diadem has already received a Breakthrough Device Designation from the FDA and CE-IVD certification for AlzoSure Predict. Under the leadership of CEO Michael Rasche, Diadem is positioned to become a key triage tool in dementia care pathways, reducing the need for invasive lumbar punctures and expensive PET scans. The company is a prime candidate for a strategic partnership with global laboratory networks or diagnostic imaging leaders such as Roche or Siemens Healthineers. 10. BionIT Labs: The Bionic Revolution in Upper Limb Prosthetics BionIT Labs, based in Soleto, Italy, has disrupted the bionics market with Adam’s Hand, a multi-articulating prosthetic hand that uses a single motor to drive all five fingers. This "fully-adaptive grip" technology allows the hand to automatically adapt its shape to the object being grasped, providing the versatility of much more expensive multi-motor devices at a fraction of the weight and cost. In July 2024, BionIT Labs received PDAC approval under code L6880, making Adam’s Hand eligible for reimbursement through Medicare and Medicaid in the United States. This was followed by FDA registration for its Wave Electrodes in January 2025. Regulatory Body Status Date PDAC (Medicare) Code L6880 Assigned July 2024 FDA Wave Electrode Registration January 2025 ISO 13485 Quality System Certified Current The US is the largest market for prosthetics globally, and BionIT Labs has established a North American team with decades of experience to support its commercial rollout. As a high-growth company in the assistive technology space with a proven reimbursement pathway, BionIT Labs is positioned for a significant fundraising round or acquisition by an orthotics and prosthetics (O&P) industry leader in 2026. 20 Future Italian HealthTech and MedTech Leaders 11. Echolight: Radiation-Free Bone Densitometry Echolight is transforming the diagnosis of osteoporosis with its Radiofrequency Echographic Multi Spectrometry (REMS) technology. Unlike the standard Dual-energy X-ray absorptiometry (DXA), which uses ionising radiation and is often limited to specialised hospital settings, REMS is a non-ionising, ultrasound-based approach that can be used at the point of care. REMS provides accurate bone mineral density (BMD) values and a "Fragility Score" that estimates fracture risk independently of BMD. A 2025 study in the US confirmed that widespread REMS implementation could save 30,000 life-years and prevent 100,000 fractures over a lifetime. The bone densitometry market is shifting toward portable, AI-ready devices, and Echolight is well-positioned with a sales network of over 40 distributors and hundreds of clinical customers worldwide. Echolight, a spin-off of the Italian National Research Council, has already secured FDA clearance and the CE mark, making it a highly attractive target for diagnostic equipment manufacturers looking to expand their osteoporosis screening capabilities. 12. Altheia Science: Curative Gene Therapy for Autoimmune Diseases Altheia Science is a gene therapy company targeting the root causes of autoimmune diseases, with its most advanced program, IMMUNOSTEM, focused on Type 1 Diabetes (T1D). The therapy involves collecting a patient’s own hematopoietic stem and progenitor cells (HSPCs), modifying them ex vivo with a lentiviral vector to express PD-L1, and re-injecting them into the patient. The goal of IMMUNOSTEM is to restore immune tolerance and protect the remaining pancreatic $\beta$-cells from autoimmune destruction. In August 2025, Altheia initiated a Phase I/II clinical trial (IMMUNOSTEM) to evaluate the safety and efficacy of the treatment in newly diagnosed T1D patients. Clinical Trial NCT06938334 (IMMUNOSTEM) Target Population Adults 18-40, Recently diagnosed T1D Primary Endpoint Safety, $\beta$-cell function (C-peptide) Estimated Completion August 2029 Mechanism PD-L1 overexpression in HSPCs The company's research has also demonstrated clinical benefits in pre-clinical models of multiple sclerosis, suggesting that its "immune-regulatory" platform has broad applicability in the autoimmune space. Given the significant unmet need for curative T1D treatments, Altheia Science is a high-conviction candidate for a large Series B funding round or a strategic partnership with a global cell and gene therapy leader. 13. Wise Srl: Flexible Electrodes for Minimally Invasive Neurostimulation Wise Srl, based in Milan and Berlin, is developing a new class of flexible and stretchable electrodes for neuro-stimulation. Its first product aimed at the spinal cord stimulation (SCS) market is the "Heron" lead, a multicolumn lead that can be implanted percutaneously. Traditional SCS paddle leads require a laminectomy, a major surgical procedure that involves removing part of a vertebra.The Heron lead aims to provide the performance of a paddle lead with the ease of a percutaneous lead, conforming to the dura mater within the epidural space. The company's core technology, Supersonic Cluster Beam Implantation (SCBI), allows for the fabrication of complex microelectronic circuits on stretchable elastomers. This ensures that the electrodes can maintain their electrical performance even after extensive cycles of bending and stretching. Wise Srl raised a seed round in 2013 and has since been developing its clinical evidence base. As the SCS market moves toward more durable and less invasive systems to reduce re-operation rates, Wise Srl is a key technology provider to watch. 14. Qura: AI-Powered Preventative Health Intelligence Qura is an Italian-founded AI preventative health platform that raised a €1.5 Million pre-seed round led by United Ventures in 2025. The platform targets patients with "persistent subclinical symptoms", conditions that fall below the threshold of acute illness but significantly impact quality of life. Qura's strategy is to build an "EU-native" platform that is fully GDPR-compliant and medically validated. The funding is being used to expand the medical and engineering teams and to integrate the platform with local laboratory networks. Strategic Priority Action Product Development AI health intelligence for subclinical symptoms Infrastructure Integration with local laboratory networks Compliance GDPR-compliant and medically validated Expansion Preparation for European market entry In an era where healthcare systems are shifting from reactive to proactive care models, Qura’s ability to leverage AI for preventative health screening makes it a highly relevant player for insurers and large-scale healthcare providers. 15. Corticale: The Next Frontier in Brain-Computer Interfaces (BCI) Corticale is an Italian neurotechnology company specialising in the development of ultra-high-density, implantable neuroelectronic devices. Its BCIs are designed for both research and medical applications, including restoring communication for paralysed patients and assisting with prosthetic control. The BCI market is entering a period of rapid acceleration, with the global market size projected to surpass $6 Billion by 2030. Major accelerators include improved neural decoding through AI and increased public funding through initiatives like the PNRR. Corticale stands alongside international leaders like Neuralink and Synchron as a pioneer in minimally invasive implanted BCIs. The company represents Italy's most serious entry into the "brain-spine interface" sector, making it a critical watch for deep-tech venture capital and large-scale neurotech incumbents. 16. Angiodroid: Innovative CO2 Injectors and Heart Pumps Angiodroid is a Bologna-based medtech company that has developed a proprietary CO2 injector device for peripheral angiography. This technology is a safer alternative to iodine-based contrast agents, which can cause complications in patients with kidney disease. The company has raised approximately $10.2 Million in funding, including a Series B round in 2023 that saw participation from CDP Venture Capital and ALIAD (the venture capital arm of Air Liquide). Angiodroid’s presence in the heart pump device market, a sector estimated to be worth $10.84 Billion by 2034, adds another layer of strategic importance. Angiodroid is a prime example of a specialised Italian manufacturer that has successfully attracted corporate venture capital to fund its global expansion. . 17. GreenBone Ortho: Biomimetic Bone Regeneration from Wood GreenBone Ortho has developed a highly innovative bone regeneration therapy using biomimetic scaffolds derived from bamboo. The technology mimics the porous structure and chemical composition of human bone, facilitating the regeneration of tissue in large defects. The bone graft substitutes market was valued at $4.29 Billion in 2025 and is projected to reach $7.64 Billion by 2034. GreenBone Ortho raised $8 Million in its Series B round and has reported excellent initial clinical results in patients. Market Driver Benefit of GreenBone Technology Rising Orthopedic Surgeries High-performance synthetic alternative Biocompatibility Needs Wood-derived scaffold mimics bone mineral phase Risk of Donor Site Injury Eliminates the need for autograft bone harvesting The company is based in Faenza, Italy and is positioned as a high-growth player in the ortho-biologics sector.GreenBone's unique technology makes it an attractive acquisition candidate for a large orthopaedic company like Orthofix or Smith+Nephew looking to add "second-generation" synthetic substitutes to their portfolio. 18. Paginemediche: The Backbone of Italian Telemedicine Infrastructure Paginemediche is a dominant force in Italy's digital healthcare landscape, serving as a primary provider of telemedicine and remote patient monitoring services. During the COVID-19 pandemic, the platform powered the national pre-triage and tele-monitoring services for infected patients, demonstrating its scalability and reliability. The company operates within the framework of the National Recovery and Resilience Plan (PNRR), which allocates $1 Billion to telemedicine infrastructure through 2025. Paginemediche’s ability to integrate with various medical devices for chronic disease management, including cardiac and respiratory monitoring, positions it as the "digital front door" to community-based care in Italy. As the Italian healthcare system undergoes a structural transition toward outpatient and home-based care, Paginemediche is a key infrastructure provider poised for further consolidation or large-scale strategic investment. 19. Patchai: Patient-Centric AI for Clinical Trials Patchai, now an Alira Health company, developed an AI-powered virtual assistant specifically for patients in clinical trials. The platform is designed to improve patient adherence, engagement, and data quality by providing a more conversational and personalised experience for trial participants. Founded in 2019 in Padua, Patchai represents the shift toward decentralized clinical trials (DCTs), a trend that has accelerated since the pandemic. By focusing on real-world evidence (RWE) generation and patient-reported outcomes (PROs), Patchai has built a platform that is essential for modern pharmaceutical R&D. Within the Alira Health ecosystem, Patchai continues to be a leader in the Italian digital health space, serving as a benchmark for how local AI startups can achieve high-value strategic exits. 20. KaiMed: Simplifying Surgical and Medical Treatments KaiMed is a healthcare company dedicated to making medical treatments simpler, safer, and more accessible through innovative surgical solutions. Based in Italy, the company focuses on developing tools that help patients heal faster and streamline surgical workflows for clinicians. While many companies in the Italian medtech space focus on high-complexity robotics, KaiMed addresses the "efficiency gap" in traditional surgery. Its focus on novel, easy-to-adopt solutions makes it a standard-bearer for the type of innovation that public health systems, strained by rising costs and aging populations, are increasingly prioritising. Strategic M&A and Funding Outlook for 2026 The Italian healthtech and medtech market in 2026 is at an inflection point. The "analog" healthcare service sectors, such as dental and specialty clinics, are seeing intense "buy-and-build" activity from private equity firms looking for geographic arbitrage and operational efficiency. Simultaneously, "high-tech" sectors like surgical robotics and gene therapy are entering a consolidation phase where large strategics are acquiring innovation hubs to fill pipeline gaps. The first half of 2025 saw a substantial spike in European healthcare M&A deal value, even as deal counts slightly decreased—a sign that investors are focusing on high-quality, proven assets. Italy, along with Spain, is viewed as the "Growth Frontier" of Southern Europe, offering the best opportunities for consolidation due to lower maturity in market concentration. Key Investment Drivers for 2026: Surgical Robotics Expansion: With the shift of surgery to ambulatory surgery centres (ASCs) to contain costs, modular and portable systems like those from MMI and CMR Surgical will be prioritised over the massive tele-operated systems of the past. The Weight-Loss Tailwind: The obesity market, currently a $100+ Billion opportunity, will drive investment into "orthogonal" mechanisms like the miR-22 inhibition from Resalis Therapeutics. Mental Health Consolidation: Regional leaders like Serenis will be targets for pan-European expansion as corporate wellness becomes a structural requirement for the modern workforce. Infrastructure Interoperability: Startups that serve as the "translation layer" between legacy hospital systems and modern apps, the so-called "App Store for Hospitals", will be viewed as critical infrastructure. The 20 companies identified in this report are not merely surviving; they are setting the pace for the digital transformation of European healthcare. Their success in 2026 will be defined by their ability to navigate the complex regulatory moats of the EU and US while delivering clear, system-level value in a resource-constrained environment. For strategic peers and professional investors, Italy represents one of the most compelling risk-adjusted entry points in the global healthtech and medtech landscape. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Spanish HealthTech and MedTech Leaders The Spanish healthcare technology landscape entering 2026 is defined by a transition from a nascent, fragmented ecosystem into a phase of "industrial maturity". This evolution is characterised by a disciplined approach to capital allocation, a focus on measurable clinical outcomes and the emergence of regional hubs that are increasingly competitive on a global scale. While historically overshadowed by the larger hubs of London, Paris and Berlin, the Spanish market, led by Catalonia, Madrid, and Valencia, has demonstrated a unique resilience and a high capacity for scientific production, particularly in biotechnology and advanced therapies. In 2025, the sector reached a milestone with €517 Million invested in health startups and scale-ups in Catalonia alone, reflecting a 43% year-on-year increase and signalling a robust resurgence in investor confidence following the post-pandemic correction. This maturity is further underscored by the shifting patterns of funding. While the absolute number of deals may have stabilised or slightly declined in certain subsectors, the average ticket size has increased dramatically. In 2025, venture capital remained the primary engine of growth, yet the market saw the return of "mega-deals" and concentrated late-stage rounds, where nearly 47% of total capital was raised by just three standout operations. This concentration suggests that investors are no longer making speculative bets across a wide range of early-stage ventures but are instead doubling down on "soonicorns" that have successfully built "compliance moats" around their core technologies, particularly in response to the full enforcement of the EU AI Act in March 2026. The strategic importance of the Spanish ecosystem is also tied to the broader European goal of "strategic autonomy" in health and life sciences. With the pharmaceutical industry committing to €9 Billion in investments in Spain between 2023 and 2025, the synergy between established multinational corporations and agile technology startups has become a critical driver for clinical research and production leadership. Spain now ranks first in Europe in the percentage of high-impact scientific articles and fourth in Europe for the number of active clinical trials, providing a fertile ground for companies focused on clinical trial optimisation and data-driven drug discovery. Macroeconomic Indicators of the Spanish Healthcare Innovation Hubs (2025-2026) The following data summarises the structural importance of the healthcare sector in Spain's leading innovation hubs, illustrating the depth of the talent pool and the volume of economic activity that supports high-growth startups. Metric Catalonia (BioRegion) Community of Madrid Community of Valencia Number of Companies 1,650 406 1,200+ (Total Startups) Sector Turnover €48.691 Billion €2 Billion (Valuation) €200M+ (Investment 2025) Employment 306,000+ Jobs 6,900+ Jobs High growth in Life Sciences GDP Contribution 7.6% Leading Digital Health hub 3rd Largest Spanish Hub Export Value €9.165 Billion High concentration of MNCs Growing International interest Clinical Trials (Active) 5,768 (92% of National) Strong Oncology focus 3rd in National Rankings Strategic Thematic Clusters and Market Drivers The analysis of the Spanish HealthTech and MedTech landscape reveals three primary thematic clusters that are attracting the majority of strategic M&A interest and large-scale fundraising: Advanced Biopharmaceutical Platforms, AI-Native Clinical Trial Infrastructure, and Surgical Robotics/Medical Devices. Each cluster is influenced by specific regulatory and economic drivers, such as the implementation of the European Health Data Space (EHDS) and the looming "patent cliff" for major pharmaceutical manufacturers. Advanced Biopharmaceutical Platforms and RNA Therapies The biotechnology subsector regained its leadership in investment attraction in 2025, accounting for 68% of the annual total in the BioRegion of Catalonia. This resurgence is driven by the maturation of gene therapy and RNA-based platforms that address rare genetic disorders with high unmet medical needs. The strategic rationale for large-scale investment in this area is the ability of these platforms to be "therapy-agnostic," meaning the underlying technology can be applied to a wide range of indications beyond the initial target. The "Strategic Compass" and the "Building the future with nature" communication from the European Commission have established a new institutional framework that prioritises biotechnology as a structural contribution to the continent's modernisation. In Spain, this has translated into increased R&D investment, reaching €865 Million in 2023, a 15% increase over the previous year. The creation of 66 new biotech companies in 2024 further highlights the vibrancy of the startup fabric, supported by a benchmark research community that ranks ninth in the world for scientific production. AI-Native Clinical Trial Infrastructure and Data Activation A persistent bottleneck in the global healthcare industry is the inefficiency and cost of clinical trials. The traditional model is plagued by protocol amendments that can pause recruitment for weeks and add up to €1 Million in costs per amendment. Spanish startups are increasingly leveraging artificial intelligence to modernise this process, utilising datasets of millions of clinical trials to anticipate risks and optimise trial design. The implementation of the EHDS, adopted in March 2025, is a transformative catalyst for this cluster. By enabling the secondary use of health data for research and AI training, the EHDS creates a secure and compliant framework for multi-site health data collaboration. Spanish companies that have successfully integrated into hospital workflows to extract and structure "Real-World Data" (RWD) from unstructured clinical notes are becoming essential partners for pharmaceutical companies facing revenue gaps as patents expire. Next-Generation Surgical Robotics and Specialised MedTech The MedTech industry recorded its seventh successive year of top-line growth in 2025, reaching a global market size of US$584 Billion. While overall M&A spending remained below historical averages, the average deal size increased significantly, reflecting a shift toward "fewer but bigger deals". Buyers are targeting high-growth areas such as pulse field ablation, robotics, and cardiovascular monitoring. In Spain, the MedTech sector is characterized by a mix of established diagnostic leaders and innovative startups developing modular and cost-effective surgical systems. The rise of "boutique" surgical centres and the decentralisation of care have created a demand for technologies that can fit into smaller outpatient settings. Spanish firms addressing these "niche" but high-growth specialties are prime targets for strategic acquisitions by multinational strategics like Boston Scientific, which has been the busiest acquirer in the space throughout 2025. Comparative Analysis of High-Growth Targets in the Spanish Ecosystem The following table provides a concise comparison of twenty key companies positioned for growth and strategic interest, categorised by their primary sector and recent funding milestones. Company Hub Core Technology / Application Latest Funding / Status Strategic Positioning Biorce Barcelona AI Clinical Trial Platform (Aika) $52.5M Series A Disrupting CRO and Pharma R&D SpliceBio Barcelona Protein Splicing for Gene Therapy $135M Series B Addressing large-gene delivery Arthex Biotech Valencia RNA-targeted therapies (DM1) $87M Series B Lead candidate in clinical stage Quibim Valencia AI Medical Imaging (Digital Twins) $50M Series A Precision medicine for Oncology Overture Life Madrid IVF Automation (Embryology Lab) €20M EIB Loan Scalable fertility infrastructure Integra Tx Barcelona FiCAT Gene Writing Platform €10.7M Round Advanced CAR-T and Liver therapy Savana Madrid NLP for Clinical Data Activation $44.4M Total Raised Real-world data for biopharma DeepUll Barcelona Sepsis Diagnostic System €50M Round Rapid infectious disease detection Inbrain Neuro Barcelona Graphene Neural Interfaces $89.6M Raised Neuroelectronic therapeutics Minoryx Tx Barcelona Small Molecules for Rare CNS $147.7M Total Raised Late-stage clinical CNS assets Oryzon Genomics Barcelona Epigenetic Therapy (Public) €40.7M Raised Clinical stage CNS and Oncology Atrys Health Madrid Precision Oncology/Diagnostics €145M Divestment Buy-and-build consolidation platform Osigu Madrid* Revenue Cycle Management (AI) $10M Series B Ext. Healthcare payments infrastructure Trak Valencia Digital Physiotherapy (AI Vision) $2.34M Raised Scalable MSK rehabilitation Prometheus AI Madrid Fetal Heart Defect AI Diagnosis Top 10 South Summit High-risk AI diagnostic accuracy Evolving Tx Valencia Phage Therapy (Phage Platform) €100k Seed/Angels Antimicrobial resistance solutions Oxolife Barcelona Female Fertility Drug (Endometrium) Top 10 South Summit Enhancing IVF success rates IOMED Barcelona AI for Health Data Extraction €10M Series A Enabling health data for research Medlumics Madrid Cardiovascular Imaging (OCT) $62.8M Total Raised A-Fib treatment visualization Trialing Health Madrid Oncology Trial Referral Platform Top 10 South Summit Modernizing clinical trial access * Osigu has a major focus on Latin America but maintains strong Spanish strategic and investment ties. Detailed Analysis of High-Growth Entities The selection of these twenty companies is based on their ability to demonstrate a clear path to market, technical defensibility, and alignment with global healthcare trends such as precision medicine and cost-containment. 1. Biorce: Accelerating Clinical Trial Lifecycles through AI-Native Infrastructure The founding of Biorce in Barcelona in 2024 marked a pivotal moment for the Spanish HealthTech sector, as the company quickly emerged as a leading player in clinical trial optimization. Its flagship platform, Aika, is an AI-native system designed to reduce clinical trial preparation timelines and limit protocol amendments. By leveraging a dataset of approximately one million clinical trials, Aika allows pharmaceutical companies, biotech firms, and contract research organisations (CROs) to anticipate regulatory risks and substantiate trial design decisions to authorities like the FDA and EMA. In February 2026, Biorce closed a $52 Million Series A round led by DST Global Partners, with participation from Norrsken VC, YZR Capital, and high-profile angel investors including Nik Storonsky. This funding, described as the largest Series A in the Iberian healthtech ecosystem to date, is intended to support a global rollout, including the opening of a development and R&D hub in Austin, Texas. The strategic value of Biorce lies in its potential to save time, money, and lives by bringing new treatments to patients faster through a more reliable and accessible trial process. Future developments for 2026 include modules for contract management, budget planning, and operational execution, aiming to create a comprehensive digital ecosystem for clinical studies. 2. SpliceBio: Overcoming Vector Constraints in Gene Therapy Based in Barcelona, SpliceBio is a clinical-stage biotechnology company that addresses a fundamental limitation in gene therapy: the payload capacity of standard viral vectors. Utilising a proprietary protein splicing platform, SpliceBio is able to deliver large genes that exceed the capacity of standard Adeno-Associated Virus (AAV) vectors. This technology is particularly critical for treating genetic diseases where the target gene is too large to fit into a single AAV. The company’s $135 Million Series B round, which was a significant contributor to the record-breaking investment in Catalonia in 2025, reflects the high strategic importance of its work in ophthalmology and other rare genetic disorders.SpliceBio’s approach allows for the reconstitution of full-length functional proteins from two separate AAVs using protein splicing. As global biopharma companies aggressively search for high-growth small/mid-cap companies to bolster their advanced therapy pipelines, SpliceBio represents a highly attractive target for strategic M&A or transformative late-stage fundraising. 3. Arthex Biotech: Precision RNA Modulation for Rare Genetic Disorders Arthex Biotech, headquartered in Valencia, is a clinical-stage biotechnology firm developing targeted RNA medicines.The company’s lead program, ATX-01, is a unique therapy currently in Phase I-IIa trials for Myotonic Dystrophy Type 1 (DM1), a debilitating neuromuscular disease for which no cure currently exists. ATX-01 targets miR-23b through a dual mechanism of action that has demonstrated the potential to become the standard of care by addressing the disease as a whole, rather than focusing solely on muscle symptoms. In September 2025, Arthex upsized its Series B financing round to $87 Million, led by the French public investment bank Bpifrance. This international backing underscores the global competitiveness of Valencia’s life sciences sector. The company's ArthemiR™ delivery platform has shown the ability to reach multiple affected tissues, including muscle, cardiac, and neurological tissues. With first clinical data expected in 2026, Arthex is positioned as a leader in the next generation of precision RNA medicines, making it a prime candidate for acquisition by large pharmaceutical companies seeking to diversify their neuromuscular portfolios. 4. Quibim: Transforming Radiology through Human Digital Twins Quibim is a medical imaging diagnostics pioneer that utilizes artificial intelligence to transform imaging data into actionable predictions. Founded in Valencia, the company has developed a cloud-based, tissue-agnostic platform called QP-Insights®, which extracts key radiomics drivers from large imaging data registries. Quibim's vision is to create "human digital twins" that allow for more precise disease monitoring and personalised treatment plans. The company closed a $50 Million Series A round in January 2025, led by Asabys and Buenavista Equity Partners, to strengthen its expansion in the United States. Quibim's platform is currently used at 221 sites worldwide and manages over 10 million de-identified research imaging data files. Its product ecosystem includes specialised software for prostate (QP-Prostate®), brain (QP-Brain®), and liver (QP-Liver®) analysis. The strategic value of Quibim lies in its ability to harmonise imaging data across different manufacturers and link it with Electronic Health Records and multi-omics, providing a one-stop-shop for biopharma companies to accelerate drug development. 5. Overture Life: The Industrialization of Reproductive Freedom Madrid-based Overture Life is disrupting the fertility market by automating assisted reproductive processes. Historically, IVF has been an expensive and throughput-constrained procedure that relies heavily on manual precision in the embryology lab. Overture's "embryology lab in a box" platform, including the DaVitri™ vitrification platform, aims to standardise procedural timing and cryoprotectant exposure, potentially improving oocyte survival rates and reducing the need for repeated cycles. In 2025, the company secured a €20 million loan from the European Investment Bank to support R&D, manufacturing scale-up, and clinical trials. This financing is part of the EIB’s commitment to support technological innovation and the use of AI to develop breakthrough medical solutions. Overture has raised approximately $70 Million in total funding from leading investors such as Khosla Ventures and GV. By making egg freezing and IVF cheaper and more clinically reproducible, Overture is reinventing the patient experience and regaining choice for families facing irreversible biological timelines. The company's global expansion, recently entering Brazil and pursuing clinical testing in the U.S., makes it a high-potential candidate for a major exit through either an IPO or a strategic acquisition by a global healthcare provider. 6. Integra Therapeutics: Pioneering High-Precision Gene Writing Integra Therapeutics is a biotechnology spin-off from Universitat Pompeu Fabra (UPF) that is developing an innovative next-generation gene editing platform. Its FiCAT gene writing technology is designed to increase the safety and efficiency of correcting genetic diseases by allowing for precise and efficient integration of large DNA segments into the genome.This technology has significant implications for advanced therapies, including the validation of new CAR-T therapies and therapeutic programs for rare paediatric diseases. In September 2025, the company closed a new €10.7 million funding round, supported by Columbus Venture Partners, the European Innovation Council (EIC), and CDTI. Headquartered at the Advanced Therapies Platform of Sant Joan de Déu Hospital in Barcelona, Integra is part of a leading environment for translational research. The strategic importance of Integra lies in its ability to address unmet medical needs through disruptive science, strengthening the biotech ecosystem in Spain and Europe. As large biopharma companies face "patent cliffs" and revenue gaps, Integra's gene writing capabilities represent a high-value pipeline asset. 7. Savana: Unlocking Precision Medicine via NLP Data Activation Savana is a Madrid-based health AI company that utilizes deep learning techniques to analyze the unstructured free text information written in electronic health records (EHR). Its platform, the Savana Manager Suite, integrates and structures clinical data to automatically extract valuable medical information, enabling medical professionals to improve clinical research and precision medicine. Savana's "living registries" are used for long-term clinical research and outcome monitoring, capturing longitudinal patient data across multiple sites. The company has raised a total of $44.4 Million in funding, including a Series C round in April 2022. Savana's top competitors include global players like Flatiron Health and Epic Systems. Its strategic value is underscored by its global network of hospitals, the Smart Health Alliance, which accelerates research and innovation through data collaboration. By helping healthcare providers structure and analyse their data native to the hospital environment, Savana provides the evidence necessary for value-based care and outcomes-focused therapeutic development. 8. DeepUll: Rapid Diagnostics for Acute Infectious Disease DeepUll is a medical diagnostics company focused on the early detection of sepsis and other acute infections. Sepsis is a life-threatening condition where rapid diagnosis is critical to patient survival. DeepUll's automated diagnostic system aims to identify pathogens and antibiotic resistance markers directly from whole blood samples in just a few hours, a significant improvement over traditional culture-based methods that take several days. The company's €50 Million funding round in 2025 was one of the three largest rounds in Catalonia, contributing to the region's historic record of investment in health startups. DeepUll's technology is highly relevant in an era where antimicrobial resistance (AMR) and rapid diagnostic accuracy are top priorities for global healthcare systems. For a strategic buyer in the diagnostics space, such as Abbott or Roche, DeepUll offers a "commercial-ready" target with clear expansion potential into high-growth outpatient and hospital settings. 9. Inbrain Neuroelectronics: Graphene-Based Intelligent Neural Systems Inbrain Neuroelectronics is a Barcelona-based provider of high-density and high-resolution graphene intelligent neural systems. These systems are designed for central and peripheral neuroelectronic applications to treat neurological disorders such as Parkinson's and epilepsy. Graphene’s unique properties, including high conductivity and biocompatibility, allow Inbrain to develop brain-computer interfaces that are significantly more sensitive and precise than traditional metal-based electrodes. Inbrain has raised nearly $90 Million to date and is considered a "soonicorn" in the European HealthTech landscape. The company's leadership in neuro-technology positions it at the intersection of medical devices and high-resolution data analytics. As MedTech companies aggressively leverage M&A to acquire innovative tech that enhances their pipelines, Inbrain's graphene interfaces represent a potential paradigm shift in the future of neuro-stimulation and neuro-electronic treatments. 10. Minoryx Therapeutics: Addressing Orphan Diseases of the CNS Minoryx Therapeutics is a Barcelona-based clinical-stage biopharmaceutical company focused on orphan diseases of the central nervous system (CNS). The company's lead candidate, leriglitazone, is being developed for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare and devastating genetic disorder. Minoryx has raised over $147 Million in funding, establishing itself as a key player in the rare disease space. The strategic value of Minoryx lies in its focus on small molecules for rare diseases, a sector that often benefits from orphan drug designations and accelerated regulatory pathways. As large pharmaceutical companies look to "GLP-1 proof" their portfolios and expand into niche, high-growth therapeutic areas, Minoryx's late-stage clinical assets are prime candidates for acquisition or major licensing deals. The company's successful rounds in 2025 further confirm the maturity of the Catalan biotech ecosystem and its ability to attract large-scale international venture capital. 20 Future Spanish HealthTech and MedTech Leaders 11. Oryzon Genomics: Leading the Epigenetics Revolution in Europe Oryzon Genomics is a clinical-stage biopharmaceutical company and the European leader in the development of epigenetics-based personalized medicines. The company focuses on the development of epigenetic inhibitors for the treatment of oncology and CNS disorders. Oryzon's pipeline includes several assets in Phase II clinical trials, making it one of the most advanced biotechnology entities in the Spanish market. As a publicly traded company on the Spanish main market, Oryzon has demonstrated a resilient ability to attract investment, including a €40.7 Million raise to support its clinical development. Its strategic positioning is centered on the intersection of genetics and therapeutics, addressing unmet medical needs in major disease areas. Oryzon's participation in major investment rounds in 2025 underscores its role as a key driver of innovation in the Catalan health hub. 12. Atrys Health: A Strategic Hub for Diagnostics and Oncology Consolidation Atrys Health is a global provider of precision diagnostics, telemedicine, and oncology treatments that has rapidly expanded through an aggressive buy-and-build strategy. Founded in Madrid, the group combines pathology, genomics, imaging, and radiotherapy across Europe and Latin America. In 2025, the company underwent a strategic shift to strengthen its balance sheet and focus on higher-growth segments. On January 15, 2026, Atrys completed the €145 Million sale of its prevention division, Aspy Global Services, to Grupo Echevarne. This transaction allowed Atrys to reduce its net financial debt/EBITDA ratio from 3.8x to approximately 1.1x, significantly lowering annual financial costs. The divestment signals a sharpening of focus on high-margin oncology and diagnostics services. With a market cap of approximately US$247 Million and trailing 12-month revenue of US$240 Million as of mid-2025, Atrys is a mature entity with the potential for further consolidation or to be a major target for private equity firms looking for a pan-European healthcare platform. 13. Osigu: The Operating System for Latin American Healthcare Payments Osigu is an AI-driven platform for health revenue cycle and claims management that acts as the operating system for transactions between insurers, healthcare providers, and patients. While headquartered in Miami and having a major impact on the Latin American market, Osigu maintains significant strategic and investment links to the Spanish tech ecosystem. The company addresses the fragmented and inefficient healthcare payment processes that plague Latin American systems, where patients often wait weeks for reimbursements and providers spend hours on manual paperwork. In August 2025, Osigu secured a $10 Million strategic investment from Eos Ventures, marking the firm's first foray into Latin America. This round was oversubscribed and included participation from Visa and IDC Ventures. Osigu already processes 1.5 Million transactions annually and generates an estimated annual revenue of $3.5 Million. Its platform manage everything from claims processing to embedded finance solutions, bringing transparency and transparency to a system that has long lacked it. Its partnership with Visa and its expansion into major markets like Mexico and Brazil position Osigu as a leading candidate for a high-value exit in the healthcare-fintech space. 14. Trak: Redefining Rehabilitation through AI Computer Vision Trak is a digital physiotherapy startup based in Valencia that offers an AI-powered platform for remote rehabilitation. The platform uses the camera of a patient's mobile device or laptop to read their movements in real-time, providing instant text and voice commands to correct their form during therapeutic exercise routines. This solution addresses the high rates of patient non-adherence to home-based treatments and allows physiotherapists to monitor progress remotely. Trak has raised US$2.34 Million from investors including Santalucía IMPULSA and Biozell Ventures. Its technology is presented as a form of business diversification for rehabilitation professionals, enabling them to create a digital helpline that makes physiotherapy more universal. Trak's inclusion in the Top 10 health startups at South Summit Madrid 2025 highlights its role in the growing digital MSK (musculoskeletal) care market. As virtual agents and chatbots become more integrated into clinical care, Trak's data-driven tracking and AI corrections offer a scalable model for modernising physical therapy. 15. Prometheus MedTech.AI: Enhancing Prenatal Diagnostic Accuracy Prometheus MedTech.AI is a medical technology company focused on the early and accurate detection of congenital heart defects in fetuses and newborns. Based in Madrid, the company develops AI-based medical software that supports clinicians in identifying heart defects during prenatal scans, a task that currently has a narrow margin for error and can often be missed in traditional practice. The company was selected as one of the Top 10 health startups at South Summit Madrid 2025 and has also gained international recognition in Korea's K-Startup Grand Challenge. Prometheus is actively pursuing U.S. market entry and has confirmed its regulatory pathway through an FDA pre-submission process. Its non-invasive AI diagnostic tool aims to expand accessibility to advanced prenatal diagnostics globally, providing reliable and timely results to healthcare providers and parents. The strategic value of Prometheus lies in its ability to integrate high-risk AI functionality into regulated clinical workflows, a major driver of MedTech M&A for 2026. 16. Evolving Therapeutics: Combating AMR through Phage Therapy Evolving Therapeutics is a Valencia-based biotechnology startup dedicated to combating multi-resistant bacteria through the innovative use of phages (natural viruses). Phage therapy provides a sustainable and ecological alternative to traditional antibiotics, reducing the risk of antimicrobial resistance (AMR) and toxic residues. The company's platform isolates and optimises natural phages that are highly specific, targeting only the harmful bacteria while respecting the surrounding microbiota. In January 2025, the company received an investment of €100,000 from Angels, the investment arm of Juan Roig, to expand its laboratory and team. Evolving Therapeutics follows a "One Health" approach, providing preventative, diagnostic and treatment solutions for human health, animal health and agriculture. Their ability to eliminate biofilms, where traditional antibiotics often fail, addresses a significant problem in clinical and industrial settings. As global health policy shifts toward gain strategic autonomy and resilience in drug supply chains, Evolving Therapeutics is a key innovation partner for addressing the global threat of multi-resistant bacteria. 17. Oxolife: Improving Reproductive Success through Endometrial Innovation Barcelona-based Oxolife is a biotechnology firm focused on developing a first-in-class drug to enhance female fertility.The company’s lead drug acts directly on the endometrium to enhance embryo implantation and restore ovulation, addressing a critical failure point in traditional IVF cycles. By improving the success rates of fertility treatments, Oxolife aims to reduce the emotional and financial burden on families pursuing reproductive care. Oxolife was named one of the Top 10 health startups at South Summit Madrid 2025 and is part of the high-growth "FemTech" sector in Europe. The strategic importance of the company is tied to the broader consolidation of the fertility market, where investors are actively searching for technologies that improve successful outcomes. As the first FemTech unicorn recently emerged in the UK, companies like Oxolife are being watched as potential targets for large-scale funding rounds or strategic partnerships with global fertility platforms. 18. IOMED: Facilitating Health Data Activation for Research IOMED is a leader in artificial intelligence for health data activation, providing a platform that structures and extracts clinical information from medical records for research purposes. Founded in 2016 by Javier de Oca and Gabriel de Maeztu, the Barcelona-based company helps hospitals and research institutions unlock the clinical knowledge contained in their unstructured data. In September 2023, IOMED closed a €10 Million Series A investment round led by Philips Ventures and XTX Ventures.This investment is intended to support the company's international expansion across Europe and the UK. IOMED's platform is particularly valuable in the context of the European Health Data Space, as it enables the compliant and efficient secondary use of health data for pharmaceutical research and clinical trials. The involvement of Philips Ventures as a lead investor signifies a strong strategic alignment with global medical technology leaders who are prioritising digital transformation and data-driven analytics. 19. Medlumics: Advanced Photonic Imaging for Cardiovascular Care Medlumics is a Madrid-based medical device company that develops biological tissue imaging solutions using optical coherence tomography (OCT). Its technology is primarily applied to the treatment of atrial fibrillation (A-Fib), providing clinicians with high-resolution, real-time visualisation of cardiac tissue during ablation procedures. This allows for more precise treatment and potentially better long-term outcomes for patients with cardiovascular conditions. The company has raised a total of $62.8 Million in funding, including a Series E round in 2020 and support from Asabys Partners and CDTI in 2024. Medlumics operates in the "cardiovascular and peripheral vascular" segment, which has seen a massive uptick in venture investment and M&A activity in 2025. For a strategic buyer like Stryker or Boston Scientific, Medlumics offers a specialised, high-growth technology that can be integrated into broader surgical and diagnostic platforms. 20. Trialing Health: Connecting Oncologists to Active Clinical Trials Trialing Health is a physician-driven platform focused on improving access to clinical trials, particularly in oncology.Based in Madrid, the company connects oncologists, hospitals and pharmaceutical sponsors through structured trial intelligence and referral workflows. By providing dynamic study updates and notifying physicians when enrolment slots become available, Trialing helps to modernise clinical trial access and accelerate oncology research. Trialing was recognised among the Top 10 health startups at South Summit Madrid 2025 and has established an exclusive collaboration with The START Center for Cancer Research to distribute information on oncology trials across Europe.The platform's AI-supported screening capabilities help oncologists rapidly identify appropriate studies for their patients, reducing delays in referral opportunities. As scientific output in oncology continues to lead the healthcare sector in Spain, Trialing is a key ally in transforming how patients access innovative cancer therapies. Strategic M&A and Private Equity Dynamics in 2026 The M&A landscape for 2026 is expected to be characterised by a "broader resurgence" in transaction activity, following a decade-high deal value in 2025. Large listed healthcare businesses are likely to "prune their portfolios," creating carve-out opportunities for private equity investors and other strategic buyers. This reallocation of capital will support renewed investment in platform technologies, robotics and data-enabled solutions. Private Equity's Role: The Buy-and-Build Strategy Private equity engagement in the European healthcare sector has been particularly strong, with sponsor buyout deals increasing by 276% to €29.6 Billion year-to-date in 2025. PE firms are increasingly using the "buy-and-build" playbook to acquire fragmented independent clinics in Italy, Spain, and Poland. By integrating these clinics into pan-European platforms, PE firms can drive growth in sales, turnover, and EBITDA, eventually exiting at significantly higher multiples.This trend is particularly evident in the fertility, dental, and veterinary sectors, where the Spanish market is highly fragmented. Strategic M&A: Capability-Focused Tuck-ins Multinational MedTech strategics are increasingly favoring smaller, "capability-focused" tuck-in acquisitions that strengthen core business units without the complexity of large-scale integrations. Buyers are targeting "commercial-ready" targets that can demonstrate revenue contribution within the first year. In 2025, medtech M&A activity officially surpassed the previous year's total by November, with 42 deals announced or completed. Targeted Therapies and Robotics: Boston Scientific has been the most active strategic buyer, targeting renal denervation, peripheral vascular intervention, and orthopaedic reconstruction. Imaging and AI Diagnostics: GE HealthCare and Abbott have leaned heavily into AI workflow orchestration and cancer diagnostics to reinforce their market leadership. Regulatory Compliance as a Competitive Moat The EU AI Act and the European Health Data Space (EHDS) have introduced new levels of complexity to the healthcare sector. For investors, companies that have already achieved high-risk AI system compliance or demonstrated interoperability with the EHDS framework represent lower-risk assets with significant entry barriers. Strategic acquirers are prioritising targets that accelerate their own digital transformation while maintaining the "compliance rigour" required by these new regulations. Synthesis and Forward-Looking Outlook The Spanish HealthTech and MedTech ecosystem is entering 2026 from a position of strength. The record levels of investment in Catalonia, the maturation of specialized hubs in Madrid and Valencia, and the strategic alignment with the pharmaceutical industry’s growth goals have created a robust foundation for the future. The sector's resilience during global economic uncertainty highlights its role as a "safe harbour" within the broader healthcare industry, consistently delivering revenue growth of 6% to 7% for commercial leaders. Key Predictions for 2026-2027 Acceleration of Mega-Deals: Following the momentum established in 2025, the market is projected to see a substantial increase in "mega-deals" ($5 billion and above), as late-stage startups that have taken a "wait-and-see" approach in 2025 prepare for public listings or strategic exits. Consolidation of Data Platforms: As the EHDS becomes fully operational for secondary data use, we expect to see a wave of acquisitions targeting "data activation" companies like Savana and IOMED, as pharmaceutical firms scramble to secure the high-quality clinical evidence needed for AI-driven drug discovery. Internationalisation of Spanish Scaleups: Fuelled by large Series A and B rounds in 2025, companies like Biorce and Quibim will complete their global rollouts, establishing a permanent presence in the U.S. and Asian markets. Growth in "GLP-1 Proof" MedTech: The rapid adoption of weight-loss drugs will continue to create uncertainty, driving MedTech companies to use M&A to diversify their portfolios into areas less affected by obesity-linked trends, such as cardiovascular diagnostics and specialised robotics. In conclusion, Spain has moved beyond the stage of being an emerging player and is now consolidating its status as a leading European hub for healthcare innovation. The synergy between a strong university research system, lower operating costs than traditional hubs, and a high quality of life continues to attract world-class investors and talent. The next phase of development will depend on the ecosystem's ability to help startups scale internationally and maintain its leadership in high-impact science and clinical research. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk